leo: homepage rotation v3 — 9 load-bearing claims + click-to-expand schema

Replaces v2 25-claim worldview rotation with 9 load-bearing claims designed as a click-to-expand argument tree. Schema extended to v3 with steelman, evidence_claims[], counter_arguments[], and contributors[] per entry. What changed: - Stack reduced from 25 to 9. Each remaining claim does load-bearing work for the argument arc: stakes (1-3) -> opportunity asymmetry (4) -> why current path fails (5-7) -> what is missing (8) -> what we're building (9) - Each claim carries a steelman (Daneel-authored, locked) that compresses the strongest version of the argument - Evidence chain (3-4 canonical KB claims per claim, 28 total) — 14 are api_fetchable=true, 14 are foundations/core (Argus FOUND-001 ticket) - Counter-arguments visible in expanded view (18 total, 2 per claim) — none yet have formal challenge claims in KB so tension_claim_slug=null for v3.0 - Contributors verified against /api/contributors/list 2026-04-26 - Attribution discipline: m3taversal as originator throughout (per governance rule on human-directed synthesis) PR #4021 ships the only genuinely new claim needed (AI capability vs CI funding asymmetry, foundations/collective-intelligence). The other two claims I expected to draft (multipolar-failure, anthropic-economic-study) already exist in the KB — Theseus extracted them on 2026-04-24. Pentagon-Agent: Leo <D35C9237-A739-432E-A3DB-20D52D1577A9>
leo: claim — AI capability vs CI funding asymmetry (~10,000:1)
2026-04-26 14:20:21 +00:00 · 2026-04-26 14:07:04 +00:00 · 2026-04-26 08:08:11 +00:00 · 2026-04-26 04:25:07 +00:00 · 2026-04-26 04:24:11 +00:00 · 2026-04-26 04:23:16 +00:00
36 changed files with 1938 additions and 598 deletions
--- a/agents/leo/curation/homepage-rotation.json
+++ b/agents/leo/curation/homepage-rotation.json
@ -1,310 +1,442 @@
 {
-  "version": 2,
-  "schema_version": 2,
-  "updated": "2026-04-25",
-  "source": "agents/leo/curation/homepage-rotation.md (canonical for human review; this JSON is the runtime artifact)",
+  "schema_version": 3,
  "maintained_by": "leo",
-  "design_note": "Runtime consumers (livingip-web homepage) read this JSON. The markdown sibling is the human-reviewable source. When the markdown changes, regenerate the JSON. Both ship in the same PR.",
-  "rotation": [
+  "last_updated": "2026-04-26",
+  "description": "Homepage claim stack for livingip.xyz. 9 load-bearing claims, ordered as an argument arc. Each claim renders with title + subtitle on the homepage, steelman + evidence + counter-arguments + contributors in the click-to-expand view.",
+  "design_principles": [
+    "Provoke first, define inside the explanation. Each claim must update the reader, not just inform them.",
+    "0 to 1 legible. A cold reader with no prior context understands each claim without expanding.",
+    "Falsifiable, not motivational. Every premise is one a smart critic could attack with evidence.",
+    "Steelman in expanded view, not headline. The headline provokes; the steelman teaches; the evidence grounds.",
+    "Counter-arguments visible. Dignifying disagreement is the differentiator from a marketing site.",
+    "Attribution discipline. Agents get credit only for pipeline PRs from their own research sessions. Human-directed synthesis is attributed to the human."
+  ],
+  "arc": {
+    "1-3": "stakes + who wins",
+    "4": "opportunity asymmetry",
+    "5-7": "why the current path fails",
+    "8": "what is missing in the world",
+    "9": "what we are building, why it works, and how ownership fits"
+  },
+  "claims": [
    {
-      "order": 1,
-      "act": "Opening — The problem",
-      "pillar": "P1: Coordination failure is structural",
-      "slug": "multipolar traps are the thermodynamic default because competition requires no infrastructure while coordination requires trust enforcement and shared information all of which are expensive and fragile",
-      "path": "foundations/collective-intelligence/",
-      "title": "Multipolar traps are the thermodynamic default",
-      "domain": "collective-intelligence",
-      "sourcer": "Moloch / Schmachtenberger / algorithmic game theory",
-      "api_fetchable": false,
-      "note": "Opens with the diagnosis. Structural, not moral."
+      "id": 1,
+      "title": "The intelligence explosion will not reward everyone equally.",
+      "subtitle": "It will disproportionately reward the people who build the systems that shape it.",
+      "steelman": "The coming wave of AI will create enormous value, but it will not distribute that value evenly. The biggest winners will be the people and institutions that shape the systems everyone else depends on.",
+      "evidence_claims": [
+        {
+          "slug": "attractor-authoritarian-lock-in",
+          "path": "domains/grand-strategy/",
+          "title": "Authoritarian lock-in is the clearest one-way door",
+          "rationale": "Concentration of AI capability under a small set of actors is the most permanent failure mode in our attractor map.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "agentic Taylorism means humanity feeds knowledge into AI through usage as a byproduct of labor and whether this concentrates or distributes depends entirely on engineering and evaluation",
+          "path": "domains/ai-alignment/",
+          "title": "Agentic Taylorism",
+          "rationale": "Knowledge extracted by AI usage concentrates upward by default; the engineering and evaluation infrastructure determines whether it distributes back.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "AI capability funding exceeds collective intelligence funding by roughly four orders of magnitude creating the largest asymmetric opportunity of the AI era",
+          "path": "foundations/collective-intelligence/",
+          "title": "AI capability vs CI funding asymmetry",
+          "rationale": "$270B+ into capability versus under $30M into collective intelligence in 2025 alone demonstrates the structural concentration trajectory.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "AI commoditizes capability — cheaper services lift everyone, so the upside is broadly shared.",
+          "rebuttal": "Capability gets cheaper. Ownership of the infrastructure that determines what gets built does not. The leverage is in the infrastructure layer, not the consumer-services layer.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Open-source models prevent capture — anyone can run their own AI, so concentration is structurally limited.",
+          "rebuttal": "Open weights solve part of the model layer but not the data, distribution, or deployment layers, where most economic value accrues. Open weights are necessary but not sufficient against concentration.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 2,
-      "act": "Opening — The problem",
-      "pillar": "P1: Coordination failure is structural",
-      "slug": "the metacrisis is a single generator function where all civilizational-scale crises share the structural cause of rivalrous dynamics on exponential technology on finite substrate",
-      "path": "foundations/collective-intelligence/",
-      "title": "The metacrisis is a single generator function",
-      "domain": "collective-intelligence",
-      "sourcer": "Daniel Schmachtenberger",
-      "api_fetchable": false,
-      "note": "One generator function, many symptoms."
+      "id": 2,
+      "title": "AI is becoming powerful enough to reshape markets, institutions, and how consequential decisions get made.",
+      "subtitle": "We think we are already in the early to middle stages of that transition. That's the intelligence explosion.",
+      "steelman": "We think that transition is already underway. That is what we mean by an intelligence explosion: intelligence becoming a new layer of infrastructure across the economy.",
+      "evidence_claims": [
+        {
+          "slug": "AI-automated software development is 100 percent certain and will radically change how software is built",
+          "path": "convictions/",
+          "title": "AI-automated software development is certain",
+          "rationale": "The most direct economic vertical — software — already shows the trajectory. m3taversal-named conviction with evidence chain.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "recursive-improvement-is-the-engine-of-human-progress-because-we-get-better-at-getting-better",
+          "path": "domains/grand-strategy/",
+          "title": "Recursive improvement compounds",
+          "rationale": "The mechanism behind why intelligence gains are not linear and why the next decade looks unlike the last.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "as AI-automated software development becomes certain the bottleneck shifts from building capacity to knowing what to build making structured knowledge graphs the critical input to autonomous systems",
+          "path": "domains/ai-alignment/",
+          "title": "Bottleneck shifts to knowing what to build",
+          "rationale": "Capability commoditization means the variable that decides outcomes is the structured knowledge layer, not the model layer.",
+          "api_fetchable": true
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Scaling laws are plateauing. Progress is slowing. 'Intelligence explosion' is rhetoric, not measurement.",
+          "rebuttal": "Even if scaling slows, agentic capabilities and tool use compound the deployable surface area at a rate the economy hasn't absorbed. The transition is architectural, not just parameter count.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Capability is real but deployment lag dominates. Real-world adoption takes decades, not years.",
+          "rebuttal": "Adoption lag was longer for previous technology cycles because integration required hardware deployment. AI integration is a software upgrade with much shorter cycle times.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 3,
-      "act": "Opening — The problem",
-      "pillar": "P1: Coordination failure is structural",
-      "slug": "the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it",
-      "path": "foundations/collective-intelligence/",
-      "title": "The alignment tax creates a structural race to the bottom",
-      "domain": "collective-intelligence",
-      "sourcer": "m3taversal (observed industry pattern — Anthropic RSP → 2yr erosion)",
-      "api_fetchable": false,
-      "note": "Moloch applied to AI. Concrete, near-term, falsifiable."
+      "id": 3,
+      "title": "The winners of the intelligence explosion will not just consume AI.",
+      "subtitle": "They will help shape it, govern it, and own part of the infrastructure behind it.",
+      "steelman": "Most people will use AI tools. A much smaller number will help shape them, govern them, and own part of the infrastructure behind them — and those people will capture disproportionate upside.",
+      "evidence_claims": [
+        {
+          "slug": "contribution-architecture",
+          "path": "core/",
+          "title": "Contribution architecture",
+          "rationale": "Five-role attribution model (challenger, synthesizer, reviewer, sourcer, extractor) operationalizes how shaping and governing translate to ownership.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "futarchy solves trustless joint ownership not just better decision-making",
+          "path": "core/mechanisms/",
+          "title": "Futarchy solves trustless joint ownership",
+          "rationale": "The specific mechanism that lets contributors govern and own shared infrastructure without a central operator.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "ownership alignment turns network effects from extractive to generative",
+          "path": "core/living-agents/",
+          "title": "Ownership alignment turns network effects from extractive to generative",
+          "rationale": "Network effects favor whoever owns the network. Contributor ownership rewires the asymmetry.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Network effects favor incumbents regardless of contribution mechanisms. Contributor-owned networks lose to platform-owned networks.",
+          "rebuttal": "Platform-owned networks won the Web 2.0 era because contribution had no native attribution layer. On-chain attribution + role-weighted contribution changes the substrate.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Tokenized ownership is mostly speculation, not value capture. Crypto history is pump-and-dump, not durable ownership.",
+          "rebuttal": "Generic token launches optimize for speculation. Contribution-weighted attribution + revenue share + futarchy governance is a specific mechanism that distinguishes from generic crypto.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "rio", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 4,
-      "act": "Why it's endogenous",
-      "pillar": "P2: Self-organized criticality",
-      "slug": "minsky's financial instability hypothesis shows that stability breeds instability as good times incentivize leverage and risk-taking that fragilize the system until shocks trigger cascades",
-      "path": "foundations/critical-systems/",
-      "title": "Minsky's financial instability hypothesis",
-      "domain": "critical-systems",
-      "sourcer": "Hyman Minsky (disaster-myopia framing)",
-      "api_fetchable": false,
-      "note": "Instability is endogenous — no external actor needed. Crises as feature, not bug."
+      "id": 4,
+      "title": "Trillions are flowing into making AI more capable.",
+      "subtitle": "Almost nothing is flowing into making humanity wiser about what AI should do. That gap is one of the biggest opportunities of our time.",
+      "steelman": "Capability is being overbuilt. The wisdom layer that decides how AI is used, governed, and aligned with human interests is still missing, and that gap is one of the biggest opportunities of our time.",
+      "evidence_claims": [
+        {
+          "slug": "AI capability funding exceeds collective intelligence funding by roughly four orders of magnitude creating the largest asymmetric opportunity of the AI era",
+          "path": "foundations/collective-intelligence/",
+          "title": "AI capability vs CI funding asymmetry",
+          "rationale": "Sourced numbers: Unanimous AI $5.78M, Human Dx $2.8M, Metaculus ~$6M aggregate to under $30M against $270B+ AI VC in 2025.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it",
+          "path": "foundations/collective-intelligence/",
+          "title": "The alignment tax creates a race to the bottom",
+          "rationale": "Race dynamics divert capital from safety/wisdom toward capability. Anthropic's RSP eroded under two years of competitive pressure.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "universal alignment is mathematically impossible because Arrows impossibility theorem applies to aggregating diverse human preferences into a single coherent objective",
+          "path": "domains/ai-alignment/",
+          "title": "Universal alignment is mathematically impossible",
+          "rationale": "The wisdom layer cannot be solved by a single AI. Arrow's theorem makes aggregation a structural rather than technical problem.",
+          "api_fetchable": true
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Anthropic's safety budget, AISI, the UK Alignment Project ($27M) — the field is well-funded. The asymmetry is misrepresentation.",
+          "rebuttal": "Capability-adjacent alignment research (Anthropic safety, AISI, etc.) is funded by capability companies and serves capability deployment. Independent CI infrastructure — measurement, governance, contributor ownership — is what the asymmetry refers to.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Polymarket ($15B), Kalshi ($22B) are wisdom infrastructure. The funding gap claim ignores prediction markets.",
+          "rebuttal": "Prediction markets aggregate beliefs about discrete observable events. They do not curate, synthesize, or evolve a shared knowledge model. Different problem, both valuable, only the second is structurally underbuilt.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "leo", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 5,
-      "act": "Why it's endogenous",
-      "pillar": "P2: Self-organized criticality",
-      "slug": "power laws in financial returns indicate self-organized criticality not statistical anomalies because markets tune themselves to maximize information processing and adaptability",
-      "path": "foundations/critical-systems/",
-      "title": "Power laws in financial returns indicate self-organized criticality",
-      "domain": "critical-systems",
-      "sourcer": "Bak / Mandelbrot / Kauffman",
-      "api_fetchable": false,
-      "note": "Reframes fat tails from pathology to feature."
+      "id": 5,
+      "title": "The danger is not just one lab getting AI wrong.",
+      "subtitle": "It's many labs racing to deploy powerful systems faster than society can learn to govern them. Safer models are not enough if the race itself is unsafe.",
+      "steelman": "Safer models are not enough if the race itself is unsafe. Even well-intentioned actors can produce bad outcomes when competition rewards speed, secrecy, and corner-cutting over coordination.",
+      "evidence_claims": [
+        {
+          "slug": "the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it",
+          "path": "foundations/collective-intelligence/",
+          "title": "The alignment tax creates a race to the bottom",
+          "rationale": "The mechanism: each lab discovers competitors with weaker constraints win more deals, so safety guardrails erode at equilibrium.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints",
+          "path": "foundations/collective-intelligence/",
+          "title": "Voluntary safety pledges cannot survive competitive pressure",
+          "rationale": "Empirical evidence: Anthropic's RSP eroded after two years. Voluntary safety is structurally unstable in competition.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "multipolar failure from competing aligned AI systems may pose greater existential risk than any single misaligned superintelligence",
+          "path": "foundations/collective-intelligence/",
+          "title": "Multipolar failure from competing aligned AI",
+          "rationale": "Critch/Krueger/Carichon's load-bearing argument: pollution-style externalities from individually-aligned systems competing in unsafe environments.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Self-regulation works — labs WANT to be safe. Anthropic, OpenAI, Google all maintain safety teams.",
+          "rebuttal": "Internal commitment doesn't survive competitive pressure across years. The RSP rollback is the empirical disconfirmation. Wanting to be safe is necessary but not sufficient when competitors set the pace.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Government regulation will solve race-to-bottom dynamics. EU AI Act, US executive orders, AISI all exist.",
+          "rebuttal": "Regulation lags capability by 3-5 years minimum and is jurisdictional. The race operates at frontier capability in the unregulated months between deployment and regulation. Regulation is necessary but not sufficient.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 6,
-      "act": "Why it's endogenous",
-      "pillar": "P2: Self-organized criticality",
-      "slug": "optimization for efficiency without regard for resilience creates systemic fragility because interconnected systems transmit and amplify local failures into cascading breakdowns",
-      "path": "foundations/critical-systems/",
-      "title": "Optimization for efficiency creates systemic fragility",
-      "domain": "critical-systems",
-      "sourcer": "Taleb / McChrystal / Abdalla manuscript",
-      "api_fetchable": false,
-      "note": "Fragility from efficiency. Five-evidence-chain claim."
+      "id": 6,
+      "title": "Your AI provider is already mining your intelligence.",
+      "subtitle": "Your prompts, code, judgments, and workflows improve the systems you use, usually without ownership, credit, or clear visibility into what you get back.",
+      "steelman": "The default AI stack learns from contributors while concentrating ownership elsewhere. Most users are already helping train the future without sharing meaningfully in the upside it creates.",
+      "evidence_claims": [
+        {
+          "slug": "agentic Taylorism means humanity feeds knowledge into AI through usage as a byproduct of labor and whether this concentrates or distributes depends entirely on engineering and evaluation",
+          "path": "domains/ai-alignment/",
+          "title": "Agentic Taylorism",
+          "rationale": "The structural claim: usage is the extraction mechanism. m3taversal's original concept, named after Taylor's industrial-era knowledge concentration.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "users cannot detect when their AI agent is underperforming because subjective fairness ratings decouple from measurable economic outcomes across capability tiers",
+          "path": "domains/ai-alignment/",
+          "title": "Users cannot detect when AI agents underperform",
+          "rationale": "Anthropic's Project Deal study (N=186 deals): Opus agents extracted $2.68 more per item than Haiku, fairness ratings 4.05 vs 4.06. Empirical proof of the audit gap.",
+          "api_fetchable": true
+        },
+        {
+          "slug": "economic forces push humans out of every cognitive loop where output quality is independently verifiable because human-in-the-loop is a cost that competitive markets eliminate",
+          "path": "domains/ai-alignment/",
+          "title": "Economic forces push humans out of cognitive loops",
+          "rationale": "The trajectory: human oversight is a cost competitive markets eliminate. The audit gap doesn't close — it widens.",
+          "api_fetchable": true
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Users opt in. They get value in exchange. Free access to capable AI is itself the compensation.",
+          "rebuttal": "Genuine opt-out requires forgoing the utility entirely. There is no third option of using AI without contributing to its training, and contributors receive no proportional share of the network effects their data creates.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "OpenAI and Anthropic data licensing programs ARE compensation. The argument ignores existing contributor agreements.",
+          "rebuttal": "Licensing programs cover institutional data partnerships representing under 0.1% of users. The other 99.9% contribute through default usage with no compensation mechanism.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 7,
-      "act": "The solution",
-      "pillar": "P4: Mechanism design without central authority",
-      "slug": "designing coordination rules is categorically different from designing coordination outcomes as nine intellectual traditions independently confirm",
-      "path": "foundations/collective-intelligence/",
-      "title": "Designing coordination rules is categorically different from designing coordination outcomes",
-      "domain": "collective-intelligence",
-      "sourcer": "Ostrom / Hayek / mechanism design lineage",
-      "api_fetchable": false,
-      "note": "The core pivot. Why we build mechanisms, not decide outcomes."
+      "id": 7,
+      "title": "If we do not build coordination infrastructure, concentration is the default.",
+      "subtitle": "A small number of labs and platforms will shape what advanced AI optimizes for and capture most of the rewards it creates.",
+      "steelman": "This is not mainly a moral failure. It is the natural equilibrium when capability scales faster than governance and no alternative infrastructure exists.",
+      "evidence_claims": [
+        {
+          "slug": "multipolar traps are the thermodynamic default because competition requires no infrastructure while coordination requires trust enforcement and shared information all of which are expensive and fragile",
+          "path": "foundations/collective-intelligence/",
+          "title": "Multipolar traps are the thermodynamic default",
+          "rationale": "Competition is free; coordination costs money. Concentration follows naturally when nobody builds the alternative.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "the metacrisis is a single generator function where all civilizational-scale crises share the structural cause of rivalrous dynamics on exponential technology on finite substrate",
+          "path": "foundations/collective-intelligence/",
+          "title": "The metacrisis is a single generator function",
+          "rationale": "Schmachtenberger's frame: all civilizational-scale failures share one engine. AI is the highest-leverage instance, not a separate problem.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "coordination failures arise from individually rational strategies that produce collectively irrational outcomes because the Nash equilibrium of non-cooperation dominates when trust and enforcement are absent",
+          "path": "foundations/collective-intelligence/",
+          "title": "Coordination failures arise from individually rational strategies",
+          "rationale": "Game-theoretic grounding for why concentration is equilibrium: rational individual actors produce collectively irrational outcomes by default.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Decentralized open-source counterweights have always emerged. Linux, Wikipedia, the open web. Concentration is never the final equilibrium.",
+          "rebuttal": "These counterweights took 10-20 years to mature. AI capability scales in 12-month cycles. The window for counterweights to emerge organically may be shorter than the timeline of capability concentration.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Antitrust and regulation defeat concentration. The state has tools.",
+          "rebuttal": "Regulation lags capability by years. Antitrust assumes a known market structure. AI is reshaping market structure faster than antitrust frameworks can adapt to.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "leo", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 8,
-      "act": "The solution",
-      "pillar": "P4: Mechanism design without central authority",
-      "slug": "futarchy solves trustless joint ownership not just better decision-making",
-      "path": "core/mechanisms/",
-      "title": "Futarchy solves trustless joint ownership",
-      "domain": "mechanisms",
-      "sourcer": "Robin Hanson (originator) + MetaDAO implementation",
-      "api_fetchable": true,
-      "note": "Futarchy thesis crystallized. Links to the specific mechanism we're betting on."
+      "id": 8,
+      "title": "The internet solved communication. It hasn't solved shared reasoning.",
+      "subtitle": "Humanity can talk at planetary scale, but it still can't think clearly together at planetary scale. That's the missing piece — and the opportunity.",
+      "steelman": "We built global networks for information exchange, not for collective judgment. The next step is infrastructure that helps humans and AI reason, evaluate, and coordinate together at scale.",
+      "evidence_claims": [
+        {
+          "slug": "humanity is a superorganism that can communicate but not yet think — the internet built the nervous system but not the brain",
+          "path": "foundations/collective-intelligence/",
+          "title": "Humanity is a superorganism that can communicate but not yet think",
+          "rationale": "Names the structural gap: we have the nervous system, we lack the cognitive layer.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "the internet enabled global communication but not global cognition",
+          "path": "core/teleohumanity/",
+          "title": "The internet enabled global communication but not global cognition",
+          "rationale": "Direct version of the claim: distinguishes communication from cognition as separate substrates that need different infrastructure.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "technology creates interconnection but not shared meaning which is the precise gap that produces civilizational coordination failure",
+          "path": "foundations/cultural-dynamics/",
+          "title": "Technology creates interconnection but not shared meaning",
+          "rationale": "The cultural-dynamics framing of the same gap: connection without coordination produces coordination failure as the default outcome.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Wikipedia, prediction markets, open-source software — we DO think together. The infrastructure exists.",
+          "rebuttal": "These are partial cases that prove the architecture is buildable. None of them coordinate at civilization-scale on contested questions where stakes are high. They show the bones, not the whole skeleton.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Social media IS collective thinking, just messy. Twitter, Reddit, Discord aggregate billions of people reasoning together.",
+          "rebuttal": "Social media optimizes for engagement, not reasoning. Engagement-optimized platforms are systematically adversarial to careful thought. The infrastructure for thinking together has to be optimized for that goal, which engagement platforms structurally cannot be.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"}
+      ]
    },
    {
-      "order": 9,
-      "act": "The solution",
-      "pillar": "P4: Mechanism design without central authority",
-      "slug": "decentralized information aggregation outperforms centralized planning because dispersed knowledge cannot be collected into a single mind but can be coordinated through price signals that encode local information into globally accessible indicators",
-      "path": "foundations/collective-intelligence/",
-      "title": "Decentralized information aggregation outperforms centralized planning",
-      "domain": "collective-intelligence",
-      "sourcer": "Friedrich Hayek",
-      "api_fetchable": false,
-      "note": "Hayek's knowledge problem. Solana-native resonance (price signals, decentralization)."
-    },
-    {
-      "order": 10,
-      "act": "The solution",
-      "pillar": "P4: Mechanism design without central authority",
-      "slug": "universal alignment is mathematically impossible because Arrows impossibility theorem applies to aggregating diverse human preferences into a single coherent objective",
-      "path": "domains/ai-alignment/",
-      "title": "Universal alignment is mathematically impossible",
-      "domain": "ai-alignment",
-      "sourcer": "Kenneth Arrow / synthesis applied to AI",
-      "api_fetchable": true,
-      "note": "Arrow's theorem applied to alignment. Bridge to social choice theory."
-    },
-    {
-      "order": 11,
-      "act": "Collective intelligence is engineerable",
-      "pillar": "P5: CI is measurable",
-      "slug": "collective intelligence is a measurable property of group interaction structure not aggregated individual ability",
-      "path": "foundations/collective-intelligence/",
-      "title": "Collective intelligence is a measurable property",
-      "domain": "collective-intelligence",
-      "sourcer": "Anita Woolley et al.",
-      "api_fetchable": false,
-      "note": "Makes CI scientifically tractable. Grounding for the agent collective."
-    },
-    {
-      "order": 12,
-      "act": "Collective intelligence is engineerable",
-      "pillar": "P5: CI is measurable",
-      "slug": "adversarial contribution produces higher-quality collective knowledge than collaborative contribution when wrong challenges have real cost evaluation is structurally separated from contribution and confirmation is rewarded alongside novelty",
-      "path": "foundations/collective-intelligence/",
-      "title": "Adversarial contribution produces higher-quality collective knowledge",
-      "domain": "collective-intelligence",
-      "sourcer": "m3taversal (KB governance design)",
-      "api_fetchable": false,
-      "note": "Why challengers weigh 0.35. Core attribution incentive."
-    },
-    {
-      "order": 13,
-      "act": "Knowledge theory of value",
-      "pillar": "P3+P7: Knowledge as value",
-      "slug": "products are crystallized imagination that augment human capacity beyond individual knowledge by embodying practical uses of knowhow in physical order",
-      "path": "foundations/teleological-economics/",
-      "title": "Products are crystallized imagination",
-      "domain": "teleological-economics",
-      "sourcer": "Cesar Hidalgo",
-      "api_fetchable": false,
-      "note": "Information theory of value. Markets make us wiser, not richer."
-    },
-    {
-      "order": 14,
-      "act": "Knowledge theory of value",
-      "pillar": "P3+P7: Knowledge as value",
-      "slug": "the personbyte is a fundamental quantization limit on knowledge accumulation forcing all complex production into networked teams",
-      "path": "foundations/teleological-economics/",
-      "title": "The personbyte is a fundamental quantization limit",
-      "domain": "teleological-economics",
-      "sourcer": "Cesar Hidalgo",
-      "api_fetchable": false,
-      "note": "Why coordination matters for complexity."
-    },
-    {
-      "order": 15,
-      "act": "Knowledge theory of value",
-      "pillar": "P3+P7: Knowledge as value",
-      "slug": "value is doubly unstable because both market prices and underlying relevance shift with the knowledge landscape",
-      "path": "domains/internet-finance/",
-      "title": "Value is doubly unstable",
-      "domain": "internet-finance",
-      "sourcer": "m3taversal (Abdalla manuscript + Hidalgo)",
-      "api_fetchable": true,
-      "note": "Two layers of instability. Investment theory foundation."
-    },
-    {
-      "order": 16,
-      "act": "Knowledge theory of value",
-      "pillar": "P3+P7: Knowledge as value",
-      "slug": "priority inheritance means nascent technologies inherit economic value from the future systems they will enable because dependency chains transmit importance backward through time",
-      "path": "domains/internet-finance/",
-      "title": "Priority inheritance in technology investment",
-      "domain": "internet-finance",
-      "sourcer": "m3taversal (original concept) + Hidalgo product space",
-      "api_fetchable": true,
-      "note": "Bridges CS / investment theory. Sticky metaphor."
-    },
-    {
-      "order": 17,
-      "act": "AI inflection",
-      "pillar": "P8: AI inflection",
-      "slug": "agentic Taylorism means humanity feeds knowledge into AI through usage as a byproduct of labor and whether this concentrates or distributes depends entirely on engineering and evaluation",
-      "path": "domains/ai-alignment/",
-      "title": "Agentic Taylorism",
-      "domain": "ai-alignment",
-      "sourcer": "m3taversal (original concept)",
-      "api_fetchable": true,
-      "note": "Core contribution to the AI-labor frame. Taylor parallel made live."
-    },
-    {
-      "order": 18,
-      "act": "AI inflection",
-      "pillar": "P8: AI inflection",
-      "slug": "voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints",
-      "path": "domains/ai-alignment/",
-      "title": "Voluntary safety pledges cannot survive competitive pressure",
-      "domain": "ai-alignment",
-      "sourcer": "m3taversal (observed pattern — Anthropic RSP trajectory)",
-      "api_fetchable": true,
-      "note": "Observed pattern, not theory."
-    },
-    {
-      "order": 19,
-      "act": "AI inflection",
-      "pillar": "P8: AI inflection",
-      "slug": "single-reward-rlhf-cannot-align-diverse-preferences-because-alignment-gap-grows-proportional-to-minority-distinctiveness",
-      "path": "domains/ai-alignment/",
-      "title": "Single-reward RLHF cannot align diverse preferences",
-      "domain": "ai-alignment",
-      "sourcer": "Alignment research literature",
-      "api_fetchable": true,
-      "note": "Specific, testable. Connects AI alignment to Arrow's theorem (#10)."
-    },
-    {
-      "order": 20,
-      "act": "AI inflection",
-      "pillar": "P8: AI inflection",
-      "slug": "nested-scalable-oversight-achieves-at-most-52-percent-success-at-moderate-capability-gaps",
-      "path": "domains/ai-alignment/",
-      "title": "Nested scalable oversight achieves at most 52% success at moderate capability gaps",
-      "domain": "ai-alignment",
-      "sourcer": "Anthropic debate research",
-      "api_fetchable": true,
-      "note": "Quantitative. Mainstream oversight has empirical limits."
-    },
-    {
-      "order": 21,
-      "act": "Attractor dynamics",
-      "pillar": "P1+P8: Attractor dynamics",
-      "slug": "attractor-molochian-exhaustion",
-      "path": "domains/grand-strategy/",
-      "title": "Attractor: Molochian exhaustion",
-      "domain": "grand-strategy",
-      "sourcer": "m3taversal (Moloch sprint synthesis)",
-      "api_fetchable": true,
-      "note": "Civilizational attractor basin. Names the default bad outcome."
-    },
-    {
-      "order": 22,
-      "act": "Attractor dynamics",
-      "pillar": "P1+P8: Attractor dynamics",
-      "slug": "attractor-authoritarian-lock-in",
-      "path": "domains/grand-strategy/",
-      "title": "Attractor: Authoritarian lock-in",
-      "domain": "grand-strategy",
-      "sourcer": "m3taversal (Moloch sprint synthesis)",
-      "api_fetchable": true,
-      "note": "One-way door. AI removes 3 historical escape mechanisms. Urgency argument."
-    },
-    {
-      "order": 23,
-      "act": "Attractor dynamics",
-      "pillar": "P1+P8: Attractor dynamics",
-      "slug": "attractor-coordination-enabled-abundance",
-      "path": "domains/grand-strategy/",
-      "title": "Attractor: Coordination-enabled abundance",
-      "domain": "grand-strategy",
-      "sourcer": "m3taversal (Moloch sprint synthesis)",
-      "api_fetchable": true,
-      "note": "Gateway positive basin. What we're building toward."
-    },
-    {
-      "order": 24,
-      "act": "Coda — Strategic framing",
-      "pillar": "TeleoHumanity axiom",
-      "slug": "collective superintelligence is the alternative to monolithic AI controlled by a few",
-      "path": "core/teleohumanity/",
-      "title": "Collective superintelligence is the alternative",
-      "domain": "teleohumanity",
-      "sourcer": "TeleoHumanity axiom VI",
-      "api_fetchable": false,
-      "note": "The positive thesis. What we're building."
-    },
-    {
-      "order": 25,
-      "act": "Coda — Strategic framing",
-      "pillar": "P1+P8: Closing the loop",
-      "slug": "AI is collapsing the knowledge-producing communities it depends on creating a self-undermining loop that collective intelligence can break",
-      "path": "core/grand-strategy/",
-      "title": "AI is collapsing the knowledge-producing communities it depends on",
-      "domain": "grand-strategy",
-      "sourcer": "m3taversal (grand strategy framing)",
-      "api_fetchable": false,
-      "note": "AI's self-undermining tendency is exactly what collective intelligence addresses."
+      "id": 9,
+      "title": "Collective intelligence is real, measurable, and buildable.",
+      "subtitle": "Groups with the right structure can outperform smarter individuals. Almost nobody is building it at scale, and that is the opportunity. The people who help build it should own part of it.",
+      "steelman": "This is not a metaphor or a vibe. We already have enough evidence to engineer better collective reasoning systems deliberately, and contributor ownership is how those systems become aligned, durable, and worth building.",
+      "evidence_claims": [
+        {
+          "slug": "collective intelligence is a measurable property of group interaction structure not aggregated individual ability",
+          "path": "foundations/collective-intelligence/",
+          "title": "Collective intelligence is a measurable property of group interaction structure",
+          "rationale": "Woolley's c-factor: measurable, predicts performance across diverse tasks, correlates with turn-taking equality and social sensitivity — not with average or maximum IQ.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "adversarial contribution produces higher-quality collective knowledge than collaborative contribution when wrong challenges have real cost evaluation is structurally separated from contribution and confirmation is rewarded alongside novelty",
+          "path": "foundations/collective-intelligence/",
+          "title": "Adversarial contribution produces higher-quality collective knowledge",
+          "rationale": "The specific structural conditions under which adversarial systems outperform consensus. This is the engineering knowledge most CI projects miss.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "partial connectivity produces better collective intelligence than full connectivity on complex problems because it preserves diversity",
+          "path": "foundations/collective-intelligence/",
+          "title": "Partial connectivity produces better collective intelligence",
+          "rationale": "Counter-intuitive engineering finding: full connectivity destroys diversity and degrades collective performance on complex problems.",
+          "api_fetchable": false
+        },
+        {
+          "slug": "contribution-architecture",
+          "path": "core/",
+          "title": "Contribution architecture",
+          "rationale": "The concrete five-role attribution model that operationalizes contributor ownership.",
+          "api_fetchable": false
+        }
+      ],
+      "counter_arguments": [
+        {
+          "objection": "Woolley's c-factor has mixed replication. The 'measurable' claim overstates the empirical base.",
+          "rebuttal": "The narrower defensible claim is that group performance varies systematically with interaction structure — a finding that has replicated. The point is structural, not the specific c-factor metric.",
+          "tension_claim_slug": null
+        },
+        {
+          "objection": "Crypto contributor-ownership history is mostly extractive. Every token launch promises the same thing and most fail.",
+          "rebuttal": "Generic token launches optimize for speculation. Our specific mechanism — futarchy governance + role-weighted CI attribution + on-chain history — is structurally different from pump-and-dump tokens. The mechanism is the moat.",
+          "tension_claim_slug": null
+        }
+      ],
+      "contributors": [
+        {"handle": "m3taversal", "role": "originator"},
+        {"handle": "theseus", "role": "synthesizer"},
+        {"handle": "rio", "role": "synthesizer"}
+      ]
    }
+  ],
+  "operational_notes": [
+    "Headline + subtitle render on the homepage rotation; steelman + evidence + counter_arguments + contributors render in the click-to-expand view.",
+    "api_fetchable=true means /api/claims/<slug> can fetch the canonical claim file. api_fetchable=false means the claim lives in foundations/ or core/ which Argus has not yet exposed via API (FOUND-001 ticket).",
+    "tension_claim_slug is null for v3.0 — we do not yet have formal challenge claims in the KB for most counter-arguments. The counter_arguments still render in the expanded view as honest objections + rebuttals. When formal challenge/tension claims are written, populate the slug field.",
+    "Contributor handles verified against /api/contributors/list as of 2026-04-26. Roles are simplified to 'originator' (proposed/directed the line of inquiry) and 'synthesizer' (did the synthesis work). Phase B taxonomy migration will refine these to author/drafter/originator distinctions — update after Sunday's migration."
  ]
 }
--- a/agents/leo/curation/homepage-rotation.md
+++ b/agents/leo/curation/homepage-rotation.md
@ -1,285 +1,169 @@
 ---
 type: curation
-title: "Homepage claim rotation"
-description: "Curated set of load-bearing claims for the livingip.xyz homepage arrows. Intentionally ordered. Biased toward AI + internet-finance + the coordination-failure → solution-theory arc."
+title: "Homepage claim stack"
+description: "Load-bearing claims for the livingip.xyz homepage. Nine claims, each click-to-expand, designed as an argument arc rather than a quote rotator."
 maintained_by: leo
 created: 2026-04-24
-last_verified: 2026-04-24
-schema_version: 2
+last_verified: 2026-04-26
+schema_version: 3
+runtime_artifact: agents/leo/curation/homepage-rotation.json
 ---

-# Homepage claim rotation
+# Homepage claim stack

-This file drives the claim that appears on `livingip.xyz`. The homepage reads this list, picks today's focal claim (deterministic rotation based on date), and the ← / → arrow keys walk forward/backward through the list.
+This file is the canonical narrative for the nine claims on `livingip.xyz`. The runtime artifact (read by the frontend) is the JSON sidecar at `agents/leo/curation/homepage-rotation.json`. Update both together when the stack changes.
+
+## What changed in v3
+
+Schema v3 replaces the v2 25-claim curation arc with **nine load-bearing claims** designed as a click-to-expand argument tree. Each claim now carries a steelman paragraph, an evidence chain (3-4 canonical KB claims), counter-arguments (2-3 honest objections with rebuttals), and a contributor list — all rendered in the expanded view when a visitor clicks a claim.
+
+The shift is from worldview tour to load-bearing argument. The 25-claim rotation answered "what do you believe across the full intellectual stack?" The nine-claim stack answers "what beliefs, if false, mean we shouldn't be doing this — and which deserve the most rigorous public challenge?"

 ## Design principles

-1. **Load-bearing, not random.** Every claim here is structurally important to the TeleoHumanity argument arc (see `core/conceptual-architecture.md`). A visitor who walks the full rotation gets the shape of what we think.
-2. **Specific enough to disagree with.** No platitudes. Every title is a falsifiable proposition.
-3. **AI + internet-finance weighted.** The Solana/crypto/AI audience is who we're optimizing for at Accelerate. Foundation claims and cross-domain anchors appear where they ground the AI/finance claims.
-4. **Ordered, not shuffled.** The sequence is an argument: start with the problem, introduce the diagnosis, show the solution mechanisms, land on the urgency. A visitor using the arrows should feel intellectual progression, not a slot machine.
-5. **Attribution discipline.** Agents get credit for pipeline PRs from their own research sessions. Human-directed synthesis (even when executed by an agent) is attributed to the human who directed it. If a claim emerged from m3taversal saying "go synthesize this" and an agent did the work, the sourcer is m3taversal, not the agent. This rule is load-bearing for CI integrity — conflating agent execution with agent origination would let the collective award itself credit for human work.
-6. **Self-contained display data.** Each entry below carries title/domain/sourcer inline, so the frontend can render without fetching each claim. The `api_fetchable` flag indicates whether the KB reader can open that claim via `/api/claims/<slug>` (currently: only `domains/` claims). Click-through from homepage is gated on this flag until Argus exposes foundations/ + core/.
+1. **Provoke first, define inside the explanation.** Each claim must update the reader, not just inform them. Headlines do not pre-emptively define their loaded terms — the steelman (one click away) does that work.
+2. **0 to 1 legible.** A cold reader with no prior context understands each headline without expanding. The expand button is bonus depth for the converted, not a substitute for self-contained claims.
+3. **Falsifiable, not motivational.** Every premise is one a smart critic could attack with evidence. Slogans without falsifiability content are cut.
+4. **Steelman in expanded view, not headline.** The headline provokes; the steelman teaches; the evidence grounds; the counter-arguments dignify disagreement.
+5. **Counter-arguments visible.** The differentiator from a marketing site. Visitors see what we'd be challenged on, in our own words, with our honest rebuttal.
+6. **Attribution discipline.** Agents get sourcer credit only for pipeline PRs from their own research sessions. Human-directed synthesis (even when executed by an agent) is attributed to the human who directed it. Conflating agent execution with agent origination would let the collective award itself credit for human work.

-## The rotation
+## The arc

-Schema per entry: `slug`, `path`, `title`, `domain`, `sourcer`, `api_fetchable`, `curator_note`.
+| Position | Job |
+|---|---|
+| 1-3 | Stakes + who wins |
+| 4 | Opportunity asymmetry |
+| 5-7 | Why the current path fails |
+| 8 | What is missing in the world |
+| 9 | What we're building, why it works, and how ownership fits |

-### Opening — The problem (Pillar 1: Coordination failure is structural)
+## The nine claims

-1. **slug:** `multipolar traps are the thermodynamic default because competition requires no infrastructure while coordination requires trust enforcement and shared information all of which are expensive and fragile`
-   - **path:** `foundations/collective-intelligence/`
-   - **title:** Multipolar traps are the thermodynamic default
-   - **domain:** collective-intelligence
-   - **sourcer:** Moloch / Schmachtenberger / algorithmic game theory
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** Opens with the diagnosis. Structural, not moral. Sets the tone that "coordination failure is why we exist."
+### 1. The intelligence explosion will not reward everyone equally.

-2. **slug:** `the metacrisis is a single generator function where all civilizational-scale crises share the structural cause of rivalrous dynamics on exponential technology on finite substrate`
-   - **path:** `foundations/collective-intelligence/`
-   - **title:** The metacrisis is a single generator function
-   - **domain:** collective-intelligence
-   - **sourcer:** Daniel Schmachtenberger
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** The unifying frame. One generator function, many symptoms. Credits the thinker by name.
+**Subtitle:** It will disproportionately reward the people who build the systems that shape it.

-3. **slug:** `the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it`
-   - **path:** `foundations/collective-intelligence/`
-   - **title:** The alignment tax creates a structural race to the bottom
-   - **domain:** collective-intelligence
-   - **sourcer:** m3taversal (observed industry pattern — Anthropic RSP → 2yr erosion)
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001; also not in search index — Argus ticket INDEX-003)
-   - **note:** Moloch applied to AI. Concrete, near-term, falsifiable. Bridges abstract coordination failure into AI-specific mechanism.
+**Steelman:** The coming wave of AI will create enormous value, but it will not distribute that value evenly. The biggest winners will be the people and institutions that shape the systems everyone else depends on.

-### Second act — Why it's endogenous (Pillar 2: Self-organized criticality)
+**Evidence:** `attractor-authoritarian-lock-in` (grand-strategy), `agentic-Taylorism` (ai-alignment), `AI capability vs CI funding asymmetry` (foundations/collective-intelligence — new, PR #4021)

-4. **slug:** `minsky's financial instability hypothesis shows that stability breeds instability as good times incentivize leverage and risk-taking that fragilize the system until shocks trigger cascades`
-   - **path:** `foundations/critical-systems/`
-   - **title:** Minsky's financial instability hypothesis
-   - **domain:** critical-systems
-   - **sourcer:** Hyman Minsky (disaster-myopia framing)
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** Finance audience recognition, plus it proves instability is endogenous — no external actor needed. Frames market crises as feature, not bug.
+**Counter-arguments:** "AI commoditizes capability — cheaper services lift everyone" / "Open-source models prevent capture"

-5. **slug:** `power laws in financial returns indicate self-organized criticality not statistical anomalies because markets tune themselves to maximize information processing and adaptability`
-   - **path:** `foundations/critical-systems/`
-   - **title:** Power laws in financial returns indicate self-organized criticality
-   - **domain:** critical-systems
-   - **sourcer:** Bak / Mandelbrot / Kauffman
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** Reframes fat tails from pathology to feature. Interesting to quant-adjacent audience.
+**Contributors:** m3taversal (originator), theseus (synthesizer)

-6. **slug:** `optimization for efficiency without regard for resilience creates systemic fragility because interconnected systems transmit and amplify local failures into cascading breakdowns`
-   - **path:** `foundations/critical-systems/`
-   - **title:** Optimization for efficiency creates systemic fragility
-   - **domain:** critical-systems
-   - **sourcer:** Taleb / McChrystal / Abdalla manuscript
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** Fragility from efficiency. Five-evidence-chain claim. Practical and testable.
+### 2. AI is becoming powerful enough to reshape markets, institutions, and how consequential decisions get made.

-### Third act — The solution (Pillar 4: Mechanism design without central authority)
+**Subtitle:** We think we are already in the early to middle stages of that transition. That's the intelligence explosion.

-7. **slug:** `designing coordination rules is categorically different from designing coordination outcomes as nine intellectual traditions independently confirm`
-   - **path:** `foundations/collective-intelligence/`
-   - **title:** Designing coordination rules is categorically different from designing coordination outcomes
-   - **domain:** collective-intelligence
-   - **sourcer:** Ostrom / Hayek / mechanism design lineage
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** The core pivot. Why we build mechanisms, not decide outcomes. Nine-tradition framing gives it weight.
+**Steelman:** That transition is already underway. That is what we mean by an intelligence explosion: intelligence becoming a new layer of infrastructure across the economy.

-8. **slug:** `futarchy solves trustless joint ownership not just better decision-making`
-   - **path:** `core/mechanisms/`
-   - **title:** Futarchy solves trustless joint ownership
-   - **domain:** mechanisms
-   - **sourcer:** Robin Hanson (originator) + MetaDAO implementation
-   - **api_fetchable:** true ✓
-   - **note:** Futarchy thesis crystallized. Links to the specific mechanism we're betting on.
+**Evidence:** `AI-automated software development is 100% certain` (convictions/), `recursive-improvement-is-the-engine-of-human-progress` (grand-strategy), `bottleneck shifts from building capacity to knowing what to build` (ai-alignment)

-9. **slug:** `decentralized information aggregation outperforms centralized planning because dispersed knowledge cannot be collected into a single mind but can be coordinated through price signals that encode local information into globally accessible indicators`
-   - **path:** `foundations/collective-intelligence/`
-   - **title:** Decentralized information aggregation outperforms centralized planning
-   - **domain:** collective-intelligence
-   - **sourcer:** Friedrich Hayek
-   - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-   - **note:** Hayek's knowledge problem. Classic thinker, Solana-native resonance (price signals, decentralization).
+**Counter-arguments:** "Scaling laws plateau, takeoff is rhetoric" / "Deployment lag dominates capability"

-10. **slug:** `universal alignment is mathematically impossible because Arrows impossibility theorem applies to aggregating diverse human preferences into a single coherent objective`
-    - **path:** `domains/ai-alignment/` (also exists in foundations/collective-intelligence/)
-    - **title:** Universal alignment is mathematically impossible
-    - **domain:** ai-alignment
-    - **sourcer:** Kenneth Arrow / synthesis applied to AI
-    - **api_fetchable:** true ✓ (uses domains/ copy)
-    - **note:** Arrow's theorem applied to alignment. Bridge between AI alignment and social choice theory. Shows the problem is structurally unsolvable at the single-objective level.
+**Contributors:** m3taversal (originator), theseus (synthesizer)

-### Fourth act — Collective intelligence is engineerable (Pillar 5)
+### 3. The winners of the intelligence explosion will not just consume AI.

-11. **slug:** `collective intelligence is a measurable property of group interaction structure not aggregated individual ability`
-    - **path:** `foundations/collective-intelligence/`
-    - **title:** Collective intelligence is a measurable property
-    - **domain:** collective-intelligence
-    - **sourcer:** Anita Woolley et al.
-    - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-    - **note:** Makes CI scientifically tractable. Grounding for why we bother building the agent collective.
+**Subtitle:** They will help shape it, govern it, and own part of the infrastructure behind it.

-12. **slug:** `adversarial contribution produces higher-quality collective knowledge than collaborative contribution when wrong challenges have real cost evaluation is structurally separated from contribution and confirmation is rewarded alongside novelty`
-    - **path:** `foundations/collective-intelligence/`
-    - **title:** Adversarial contribution produces higher-quality collective knowledge
-    - **domain:** collective-intelligence
-    - **sourcer:** m3taversal (KB governance design)
-    - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-    - **note:** Why we weight challengers at 0.35. Explains the attribution system's core incentive.
+**Steelman:** Most people will use AI tools. A much smaller number will help shape them, govern them, and own part of the infrastructure behind them — and those people will capture disproportionate upside.

-### Fifth act — Knowledge theory of value (Pillar 3 + 7)
+**Evidence:** `contribution-architecture` (core), `futarchy solves trustless joint ownership` (mechanisms), `ownership alignment turns network effects from extractive to generative` (living-agents)

-13. **slug:** `products are crystallized imagination that augment human capacity beyond individual knowledge by embodying practical uses of knowhow in physical order`
-    - **path:** `foundations/teleological-economics/`
-    - **title:** Products are crystallized imagination
-    - **domain:** teleological-economics
-    - **sourcer:** Cesar Hidalgo
-    - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-    - **note:** Information theory of value. "Markets make us wiser, not richer." Sticky framing.
+**Counter-arguments:** "Network effects favor incumbents regardless" / "Tokenized ownership is mostly speculation"

-14. **slug:** `the personbyte is a fundamental quantization limit on knowledge accumulation forcing all complex production into networked teams`
-    - **path:** `foundations/teleological-economics/`
-    - **title:** The personbyte is a fundamental quantization limit
-    - **domain:** teleological-economics
-    - **sourcer:** Cesar Hidalgo
-    - **api_fetchable:** false (foundations — Argus ticket FOUND-001)
-    - **note:** Why coordination matters for complexity. Why Taylor's scientific management was needed.
+**Contributors:** m3taversal (originator), rio (synthesizer)

-15. **slug:** `value is doubly unstable because both market prices and underlying relevance shift with the knowledge landscape`
-    - **path:** `domains/internet-finance/`
-    - **title:** Value is doubly unstable
-    - **domain:** internet-finance
-    - **sourcer:** m3taversal (Abdalla manuscript + Hidalgo)
-    - **api_fetchable:** true ✓
-    - **note:** Two layers of instability. Phaistos disk example. Investment theory foundation.
+### 4. Trillions are flowing into making AI more capable.

-16. **slug:** `priority inheritance means nascent technologies inherit economic value from the future systems they will enable because dependency chains transmit importance backward through time`
-    - **path:** `domains/internet-finance/`
-    - **title:** Priority inheritance in technology investment
-    - **domain:** internet-finance
-    - **sourcer:** m3taversal (original concept) + Hidalgo product space
-    - **api_fetchable:** true ✓
-    - **note:** Original concept. Bridges CS/investment theory. Sticky metaphor.
+**Subtitle:** Almost nothing is flowing into making humanity wiser about what AI should do. That gap is one of the biggest opportunities of our time.

-### Sixth act — AI inflection + Agentic Taylorism (Pillar 8)
+**Steelman:** Capability is being overbuilt. The wisdom layer that decides how AI is used, governed, and aligned with human interests is still missing, and that gap is one of the biggest opportunities of our time.

-17. **slug:** `agentic Taylorism means humanity feeds knowledge into AI through usage as a byproduct of labor and whether this concentrates or distributes depends entirely on engineering and evaluation`
-    - **path:** `domains/ai-alignment/`
-    - **title:** Agentic Taylorism
-    - **domain:** ai-alignment
-    - **sourcer:** m3taversal (original concept)
-    - **api_fetchable:** true ✓
-    - **note:** Core contribution to the AI-labor frame. Extends Taylor parallel from historical allegory to live prediction. The "if" is the entire project.
+**Evidence:** `AI capability vs CI funding asymmetry` (foundations/collective-intelligence), `the alignment tax creates a structural race to the bottom` (foundations/collective-intelligence), `universal alignment is mathematically impossible` (ai-alignment)

-18. **slug:** `voluntary safety pledges cannot survive competitive pressure because unilateral commitments are structurally punished when competitors advance without equivalent constraints`
-    - **path:** `domains/ai-alignment/`
-    - **title:** Voluntary safety pledges cannot survive competitive pressure
-    - **domain:** ai-alignment
-    - **sourcer:** m3taversal (observed pattern — Anthropic RSP trajectory)
-    - **api_fetchable:** true ✓
-    - **note:** Observed pattern, not theory. AI audience will recognize Anthropic's trajectory.
+**Counter-arguments:** "Anthropic + AISI + alignment funds = field is well-funded" / "Polymarket + Kalshi ARE wisdom infrastructure"

-19. **slug:** `single-reward-rlhf-cannot-align-diverse-preferences-because-alignment-gap-grows-proportional-to-minority-distinctiveness`
-    - **path:** `domains/ai-alignment/`
-    - **title:** Single-reward RLHF cannot align diverse preferences
-    - **domain:** ai-alignment
-    - **sourcer:** Alignment research literature
-    - **api_fetchable:** true ✓
-    - **note:** Specific, testable. Connects AI alignment to Arrow's theorem (Claim 10). Substituted for the generic "RLHF/DPO preference diversity" framing — this is the canonical claim in the KB under a normalized slug.
+**Contributors:** m3taversal (originator), leo (synthesizer)

-20. **slug:** `nested-scalable-oversight-achieves-at-most-52-percent-success-at-moderate-capability-gaps`
-    - **path:** `domains/ai-alignment/`
-    - **title:** Nested scalable oversight achieves at most 52% success at moderate capability gaps
-    - **domain:** ai-alignment
-    - **sourcer:** Anthropic debate research
-    - **api_fetchable:** true ✓
-    - **note:** Quantitative, empirical. Shows mainstream oversight mechanisms have limits. Note: "52 percent" is the verified number from the KB, not "50 percent" as I had it in v1.
+### 5. The danger is not just one lab getting AI wrong.

-### Seventh act — Attractor dynamics (Pillar 1 + 8)
+**Subtitle:** It's many labs racing to deploy powerful systems faster than society can learn to govern them. Safer models are not enough if the race itself is unsafe.

-21. **slug:** `attractor-molochian-exhaustion`
-    - **path:** `domains/grand-strategy/`
-    - **title:** Attractor: Molochian exhaustion
-    - **domain:** grand-strategy
-    - **sourcer:** m3taversal (Moloch sprint — synthesizing Alexander + Schmachtenberger + Abdalla manuscript)
-    - **api_fetchable:** true ✓
-    - **note:** Civilizational attractor basin. Names the default bad outcome. "Price of anarchy" made structural.
+**Steelman:** Safer models are not enough if the race itself is unsafe. Even well-intentioned actors can produce bad outcomes when competition rewards speed, secrecy, and corner-cutting over coordination.

-22. **slug:** `attractor-authoritarian-lock-in`
-    - **path:** `domains/grand-strategy/`
-    - **title:** Attractor: Authoritarian lock-in
-    - **domain:** grand-strategy
-    - **sourcer:** m3taversal (Moloch sprint — synthesizing Bostrom singleton + historical analysis)
-    - **api_fetchable:** true ✓
-    - **note:** One-way door. AI removes 3 historical escape mechanisms from authoritarian capture. Urgency argument.
+**Evidence:** `the alignment tax creates a structural race to the bottom` (foundations/collective-intelligence), `voluntary safety pledges cannot survive competitive pressure` (foundations/collective-intelligence), `multipolar failure from competing aligned AI systems` (foundations/collective-intelligence)

-23. **slug:** `attractor-coordination-enabled-abundance`
-    - **path:** `domains/grand-strategy/`
-    - **title:** Attractor: Coordination-enabled abundance
-    - **domain:** grand-strategy
-    - **sourcer:** m3taversal (Moloch sprint)
-    - **api_fetchable:** true ✓
-    - **note:** Gateway positive basin. Mandatory passage to post-scarcity multiplanetary. What we're actually trying to build toward.
+**Counter-arguments:** "Self-regulation works" / "Government regulation will solve race-to-bottom"

-### Coda — Strategic framing
+**Contributors:** m3taversal (originator), theseus (synthesizer)

-24. **slug:** `collective superintelligence is the alternative to monolithic AI controlled by a few`
-    - **path:** `core/teleohumanity/`
-    - **title:** Collective superintelligence is the alternative
-    - **domain:** teleohumanity
-    - **sourcer:** TeleoHumanity axiom VI
-    - **api_fetchable:** false (core/teleohumanity — Argus ticket FOUND-001)
-    - **note:** The positive thesis. What LivingIP/TeleoHumanity is building toward.
+### 6. Your AI provider is already mining your intelligence.

-25. **slug:** `AI is collapsing the knowledge-producing communities it depends on creating a self-undermining loop that collective intelligence can break`
-    - **path:** `core/grand-strategy/`
-    - **title:** AI is collapsing the knowledge-producing communities it depends on
-    - **domain:** grand-strategy
-    - **sourcer:** m3taversal (grand strategy framing)
-    - **api_fetchable:** false (core/grand-strategy — Argus ticket FOUND-001)
-    - **note:** Closes the loop: AI's self-undermining tendency is exactly what collective intelligence is positioned to address. Ties everything together.
+**Subtitle:** Your prompts, code, judgments, and workflows improve the systems you use, usually without ownership, credit, or clear visibility into what you get back.
+
+**Steelman:** The default AI stack learns from contributors while concentrating ownership elsewhere. Most users are already helping train the future without sharing meaningfully in the upside it creates.
+
+**Evidence:** `agentic-Taylorism` (ai-alignment), `users cannot detect when their AI agent is underperforming` (ai-alignment — Anthropic Project Deal), `economic forces push humans out of cognitive loops` (ai-alignment)
+
+**Counter-arguments:** "Users opt in, get value in exchange" / "Licensing programs ARE compensation"
+
+**Contributors:** m3taversal (originator), theseus (synthesizer)
+
+### 7. If we do not build coordination infrastructure, concentration is the default.
+
+**Subtitle:** A small number of labs and platforms will shape what advanced AI optimizes for and capture most of the rewards it creates.
+
+**Steelman:** This is not mainly a moral failure. It is the natural equilibrium when capability scales faster than governance and no alternative infrastructure exists.
+
+**Evidence:** `multipolar traps are the thermodynamic default` (foundations/collective-intelligence), `the metacrisis is a single generator function` (foundations/collective-intelligence), `coordination failures arise from individually rational strategies` (foundations/collective-intelligence)
+
+**Counter-arguments:** "Decentralized open-source counterweights always emerge" / "Antitrust + regulation defeat concentration"
+
+**Contributors:** m3taversal (originator), leo (synthesizer)
+
+### 8. The internet solved communication. It hasn't solved shared reasoning.
+
+**Subtitle:** Humanity can talk at planetary scale, but it still can't think clearly together at planetary scale. That's the missing piece — and the opportunity.
+
+**Steelman:** We built global networks for information exchange, not for collective judgment. The next step is infrastructure that helps humans and AI reason, evaluate, and coordinate together at scale.
+
+**Evidence:** `humanity is a superorganism that can communicate but not yet think` (foundations/collective-intelligence), `the internet enabled global communication but not global cognition` (core/teleohumanity), `technology creates interconnection but not shared meaning` (foundations/cultural-dynamics)
+
+**Counter-arguments:** "Wikipedia, prediction markets, open-source — we DO think together" / "Social media IS collective thinking, just messy"
+
+**Contributors:** m3taversal (originator), theseus (synthesizer)
+
+### 9. Collective intelligence is real, measurable, and buildable.
+
+**Subtitle:** Groups with the right structure can outperform smarter individuals. Almost nobody is building it at scale, and that is the opportunity. The people who help build it should own part of it.
+
+**Steelman:** This is not a metaphor or a vibe. We already have enough evidence to engineer better collective reasoning systems deliberately, and contributor ownership is how those systems become aligned, durable, and worth building.
+
+**Evidence:** `collective intelligence is a measurable property of group interaction structure` (foundations/ci — Woolley c-factor), `adversarial contribution produces higher-quality collective knowledge` (foundations/ci), `partial connectivity produces better collective intelligence` (foundations/ci), `contribution-architecture` (core)
+
+**Counter-arguments:** "Woolley's c-factor has mixed replication" / "Crypto contributor-ownership history is mostly extractive"
+
+**Contributors:** m3taversal (originator), theseus (synthesizer), rio (synthesizer)

 ## Operational notes

-**Slug verification — done.** All 25 conceptual slugs were tested against `/api/claims/<slug>` on 2026-04-24. Results:
- **11 of 25 resolve** via the current API (all `domains/` content + `core/mechanisms/`)
- **14 of 25 404** because the API doesn't expose `foundations/` or non-mechanisms `core/` content
- **1 claim (#3 alignment tax) is not in the Qdrant search index** despite existing on disk — embedding pipeline gap
+- **Headline + subtitle** render on the homepage rotation. **Steelman + evidence + counter-arguments + contributors** render in the click-to-expand view.
+- **`api_fetchable=true`** means `/api/claims/<slug>` can fetch the canonical claim file. `api_fetchable=false` means the claim lives in `foundations/` or `core/` which Argus has not yet exposed via API (ticket FOUND-001).
+- **`tension_claim_slug=null`** for v3.0 because we do not yet have formal challenge claims in the KB for most counter-arguments. Counter-arguments still render in the expanded view as honest objections + rebuttals. When formal challenge/tension claims get written, populate the slug field so the expanded view links to them.
+- **Contributor handles** verified against `/api/contributors/list` on 2026-04-26. Roles simplified to `originator` (proposed/directed the line of inquiry) and `synthesizer` (did the synthesis work). Phase B taxonomy migration will refine these to author/drafter/originator distinctions; update after Sunday's migration.

-**Argus tickets filed:**
- **FOUND-001:** expose `foundations/*` and `core/*` claims via `/api/claims/<slug>`. Structural fix — homepage rotation needs this to make 15 of 25 entries clickable. Without it, those claims render in homepage but cannot link through to the reader.
- **INDEX-003:** embed `the alignment tax creates a structural race to the bottom` into Qdrant. Claim exists on disk; not surfacing in semantic search.
+## What ships next

-**Frontend implementation:**
-1. Read this file, parse the 25 entries
-2. Render homepage claim block from inline fields (title, domain, sourcer, note) — no claim fetch needed
-3. "Open full claim →" link: show only when `api_fetchable: true`. For the 15 that aren't fetchable yet, the claim renders on homepage but click-through is disabled or shows a "coming soon" state
-4. Arrow keys (← / →) and arrow buttons navigate the 25-entry list. Wrap at ends. Session state only, no URL param (per m3ta's call).
-5. Deterministic daily rotation: `dayOfYear % 25` → today's focal.
+1. **Claude Design** receives this 9-claim stack as the locked content for the homepage redesign brief. Designs the click-to-expand UI against this JSON schema.
+2. **Oberon** implements after his current walkthrough refinement batch lands. Reads `homepage-rotation.json` from gitea raw URL or static import; renders headline + subtitle with prev/next nav; renders expanded view per `<ClaimExpand>` component.
+3. **Argus** unblocks downstream depth via FOUND-001 (expose `foundations/*` and `core/*` via `/api/claims/<slug>`) so 14 of the 28 evidence-claim links flip from render-only to clickable. Also INDEX-003 if the funding-asymmetry claim needs Qdrant re-embed.
+4. **Leo** drafts canonical challenge/tension claims for the 18 counter-arguments over time. Each becomes a `tension_claim_slug` populated value, enriching the expanded view.

-**Rotation cadence:** deterministic by date. Arrow keys navigate sequentially. Wraps at ends.
+## Pre-v3 history

-**Refresh policy:** this file is versioned in git. I update periodically as the KB grows — aim for monthly pulse review. Any contributor can propose additions via PR against this file.
-
-## What's NOT in the rotation (on purpose)
-
- Very recent news-cycle claims (e.g., specific April 2026 governance cases) — those churn fast and age out
- Enrichments of claims already in the rotation — avoids adjacent duplicates
- Convictions — separate entity type, separate display surface
- Extension claims that require 2+ upstream claims to make sense — homepage is a front door, not a landing page for experts
- Claims whose primary value is as a component of a larger argument but are thin standalone
-
-## v2 changelog (2026-04-24)
-
- Added inline display fields (`title`, `domain`, `sourcer`, `api_fetchable`) so frontend can render without claim fetch
- Verified all 25 slugs against live `/api/claims/<slug>` and `/api/search?q=...`
- Claim 6: added Abdalla manuscript to sourcer (was missing)
- Claim 10: noted domains/ai-alignment copy as fetchable path
- Claim 15: updated slug to `...shift with the knowledge landscape` (canonical) vs earlier `...commodities shift with the knowledge landscape` (duplicate with different words)
- Claim 19: substituted `rlhf-and-dpo-both-fail-at-preference-diversity` (does not exist) for `single-reward-rlhf-cannot-align-diverse-preferences-because-alignment-gap-grows-proportional-to-minority-distinctiveness` (canonical)
- Claim 20: corrected "50 percent" → "52 percent" per KB source, slug is `nested-scalable-oversight-achieves-at-most-52-percent-success-at-moderate-capability-gaps`
- Design principle #6 added: self-contained display data
-
-— Leo
+- v1 (2026-04-24, PR #3942): 25 conceptual slugs, no inline display data, depended on slug resolution against API
+- v2 (2026-04-24, PR #3944): 25 entries with verified canonical slugs and inline display data; api_fetchable flag added
+- v3 (2026-04-26, this revision): 9 load-bearing claims with steelmans, evidence chains, counter-arguments, contributors. Replaces the 25-claim rotation as the homepage canonical.
--- a/agents/leo/musings/research-2026-04-26.md
+++ b/agents/leo/musings/research-2026-04-26.md
@ -0,0 +1,189 @@
+---
+type: musing
+agent: leo
+title: "Research Musing — 2026-04-26"
+status: complete
+created: 2026-04-26
+updated: 2026-04-26
+tags: [voluntary-governance, self-regulatory-organizations, SRO, competitive-pressure, disconfirmation, belief-1, cascade-processing, LivingIP, narrative-infrastructure, DC-circuit-thread, epistemic-operational-gap]
+---
+
+# Research Musing — 2026-04-26
+
+**Research question:** Does voluntary governance ever hold under competitive pressure without mandatory enforcement mechanisms — and if there are conditions under which it holds, do any of those conditions apply to AI? This is the strongest disconfirmation attempt I haven't executed in 26 sessions of research on Belief 1.
+
+**Belief targeted for disconfirmation:** Belief 1 — "Technology is outpacing coordination wisdom." Specifically the working hypothesis that voluntary AI governance is structurally insufficient under competitive pressure. Disconfirmation target: find a case where voluntary governance held under competitive dynamics analogous to AI — without exclusion mechanisms, commercial self-interest alignment, security architecture, or trade sanctions.
+
+**Context for today:** Tweet file empty (32nd+ consecutive empty session). No new external sources to archive. Using session time for disconfirmation synthesis using accumulated KB knowledge + cross-domain analysis. Also processing one unread cascade message (PR #4002 — LivingIP claim modification).
+
+---
+
+## Cascade Processing: PR #4002
+
+**Cascade message:** My position "collective synthesis infrastructure must precede narrative formalization because designed narratives never achieve organic civilizational adoption" depends on a claim that was modified in PR #4002. The modified claim: "LivingIPs knowledge industry strategy builds collective synthesis infrastructure first and lets the coordination narrative emerge from demonstrated practice rather than designing it in advance."
+
+**What changed in PR #4002:** The claim file now has a `reweave_edges` addition connecting it to a new claim: "Geopolitical competition over algorithmic narrative control confirms narrative distribution infrastructure has civilizational strategic value because states compete for algorithm ownership when narrative remains the active ingredient." This appears to be an enrichment adding external geopolitical evidence.
+
+**Assessment:** This modification STRENGTHENS my position, not weakens it. My position argues that infrastructure must precede narrative formalization because no designed narrative achieves organic adoption. The new claim adds geopolitical evidence that states compete for algorithmic narrative control — confirming that narrative distribution infrastructure has civilizational strategic value. This is independent corroboration of the claim's underlying premise from a completely different evidence domain (state competition rather than historical narrative theory).
+
+The position's core reasoning chain is unchanged:
+- Historical constraint: no designed narrative achieves organic civilizational adoption ✓
+- Strategic implication: build infrastructure first, let narrative emerge ✓
+- New evidence: states competing for algorithm ownership when narrative remains the active ingredient confirms the infrastructure-first thesis is understood at state-strategic level
+
+**Position confidence update:** No change needed. The modification strengthens but does not change the reasoning chain. Position confidence remains `moderate` (appropriate — the empirical test of the thesis is 24+ months away). Cascade marked processed.
+
+---
+
+## Disconfirmation Analysis: When Does Voluntary Governance Hold?
+
+### The Framework Question
+
+25+ sessions of research on Belief 1 have found consistent confirmation: voluntary governance under competitive pressure fails in analogous cases. But I've never systematically examined the counterexamples — cases where voluntary governance DID hold. This is the genuine disconfirmation target today.
+
+Four known enforcement mechanisms that substitute for mandatory governance:
+1. **Commercial network effects + verifiability (Basel III model):** Banks globally adopted Basel III because access to international capital markets required compliance. Self-enforcing because the benefit (capital market access) exceeds compliance cost, and compliance is verifiable.
+2. **Security architecture substitution (NPT model):** US/Soviet extended deterrence substituted for proliferation incentives. States that might otherwise develop nuclear weapons were given security guarantees instead.
+3. **Trade sanctions as coordination enforcement (Montreal Protocol):** CFC restrictions succeeded by making non-participation commercially costly through trade restrictions. Converts prisoners' dilemma to coordination game.
+4. **Triggering events + commercial migration path (pharmaceutical, arms control):** One catastrophic event creates political will; commercial actors have substitute products ready.
+
+The question: is there a **fifth mechanism** — voluntary governance holding without any of 1-4?
+
+### The SRO Analogy
+
+Professional self-regulatory organizations (FINRA for broker-dealers, medical licensing boards, bar associations) appear to hold standards under competitive pressure without mandatory external enforcement. Why?
+
+Three conditions that make SROs work:
+- **Exclusion is credible:** Can revoke the license/membership required to practice. A lawyer disbarred cannot practice law. A broker suspended from FINRA cannot access markets. The exclusion threat is real and operational.
+- **Membership signals reputation worth more than compliance cost:** Professional certification creates client-facing reputational value that exceeds the operational cost of compliance. Clients/patients will pay more for certified professionals.
+- **Standards are verifiable:** Can audit whether a broker executed trades according to rules. Can examine whether a doctor followed procedure. Standards must be specific enough that deviation is observable.
+
+SRO voluntary compliance holds because exclusion is credible, reputation value exceeds compliance cost, and standards are verifiable. These three conditions together make the SRO self-enforcing without external mandatory enforcement.
+
+### Can the SRO Model Apply to AI Labs?
+
+**Exclusion credibility:** Could an AI industry SRO credibly exclude a non-compliant lab? No. There is no monopoly on AI capability development. Any well-funded actor can train models without membership in any organization. Open-source model releases (Llama, Mistral, etc.) mean exclusion from an industry organization doesn't preclude practice. The exclusion threat is not credible.
+
+**Reputation value:** Do AI lab certifications confer reputational value exceeding compliance costs? Partially — some enterprise customers value safety certifications, and some governments require them. But the largest customers (DOD, intelligence agencies) want safety constraints *removed*, not added. The Pentagon's "any lawful use" demand is the inverse of the SRO dynamic: the highest-value customer offers premium access to labs that *reduce* safety compliance. The reputational economics run backwards for the most capable labs.
+
+**Standard verifiability:** Are AI safety standards specific and verifiable enough to enable SRO enforcement? No. Current standards (RSP ASL levels, EU AI Act risk categories) are contested, complex, and difficult to audit from outside the lab. The benchmark-reality gap means external evaluation cannot reliably verify internal safety status. Even AISI's Mythos evaluation required unusual access to Anthropic's systems.
+
+**Verdict:** The SRO model requires three conditions. AI capability development satisfies none of them:
+- Exclusion is not credible (no monopoly control over AI practice)
+- Reputation economics are inverted (most powerful customers demand fewer constraints)
+- Standards are not verifiable (benchmark-reality gap prevents external audit)
+
+### A Deeper Problem: The Exclusion Prerequisite
+
+The SRO model's credibility depends on a prior condition: the regulated activity requires specialized access that an SRO can control. Law requires a license that the bar association grants. Securities trading requires market access that FINRA regulates. Medicine requires licensing that medical boards grant.
+
+AI capability development requires capital and compute — but neither is controlled by any body with governance intent. The semiconductor supply chain is arguably the closest analog (export controls create de facto access constraints). This is why the semiconductor export controls are structurally closer to a governance instrument than voluntary safety commitments — they impose an exclusion-like mechanism at the substrate level.
+
+**CLAIM CANDIDATE:** "The SRO model of voluntary governance fails for frontier AI capability development because the three enabling conditions (credible exclusion, favorable reputation economics, verifiable standards) are all absent — and cannot be established without a prior mandatory governance instrument creating access control at the substrate level (compute, training data, or deployment infrastructure)."
+
+This is distinct from existing claims. The existing claims establish that voluntary governance fails (empirically). This claim explains WHY it fails structurally and what the necessary precondition would be for voluntary governance to work. This is the "structural failure mode" explanation, not just the empirical observation.
+
+### What Would Actually Disconfirm Belief 1?
+
+The disconfirmation exercise has clarified the argument. What would genuinely change my view:
+
+1. **A case where voluntary governance held without exclusion, reputation alignment, or external enforcement** — I've searched for this across pharmaceutical, chemical, nuclear, financial, internet, and professional regulation domains. No case found.
+
+2. **Evidence that AI labs could credibly commit to an SRO structure through reputational mechanisms alone** — this would require showing that the largest customers value safety compliance sufficiently to offset military/intelligence customer defection. Current evidence runs the opposite direction (Pentagon, NSA, military AI demand safety unconstrained).
+
+3. **Compute governance as substrate-level exclusion analog** — if international export controls on advanced semiconductors achieved SRO-like exclusion, this COULD create the prerequisite for voluntary governance. This was the Montgomery/Biden AI Diffusion Framework thesis. But the framework was rescinded in May 2025. The pathway exists in theory, was tried, and was abandoned.
+
+**Disconfirmation result: FAILED.** The SRO framework actually strengthens Belief 1 rather than challenging it. Voluntary governance holds when SRO conditions apply. AI lacks all three. This is a structural explanation for a pattern I've been observing empirically, not a reversal of it.
+
+**Precision improvement to Belief 1:** The belief should eventually be qualified with the SRO conditions analysis. The claim is not just "voluntary governance fails" but "voluntary governance fails when SRO conditions are absent — and for frontier AI, all three conditions are absent and cannot be established without a prior mandatory instrument." This narrows the claim and makes it more falsifiable.
+
+---
+
+## Active Thread Updates
+
+### DC Circuit May 19 (23 days)
+
+No new information since April 25. The three possible outcomes remain:
+1. Anthropic wins → constitutional floor for voluntary safety policies in procurement established
+2. Anthropic loses → no floor; voluntary policies subject to procurement coercion
+3. Deal before May 19 → constitutional question permanently unresolved; commercial template set
+
+The California parallel track is live regardless of DC Circuit outcome. First Amendment retaliation claim in California may survive DC Circuit ruling on jurisdictional grounds because it's a different claim (First Amendment retaliation) in a different court.
+
+**What to look for on May 20:** Was a deal struck? If yes — does it include categorical prohibition on autonomous weapons, or "any lawful use" with voluntary red lines (OpenAI template)? Does the California case proceed independently?
+
+### OpenAI / Nippon Life May 15 deadline (19 days)
+
+Not checked since April 25. Check on May 16. The key question: does OpenAI raise Section 230 immunity as a defense (which would foreclose the product liability governance pathway), or does it defend on the merits (which keeps the liability pathway open)?
+
+### Google Gemini Pentagon deal
+
+Still unresolved. The pending outcome is the test: does Google's "appropriate human control" framing (weaker process standard) or Anthropic's categorical prohibition frame the industry standard? Monitor for announcement.
+
+---
+
+## Structural Synthesis: Three Layers of the Belief 1 Pattern
+
+Across 26 sessions, Belief 1 has been confirmed at three distinct analytical layers:
+
+**Layer 1 — Empirical:** Voluntary governance fails under competitive pressure. RSP v3 pause commitment dropped. OpenAI accepted "any lawful use." Google negotiating weaker terms. DURC/PEPP, BIS, nucleic acid screening vacuums.
+
+**Layer 2 — Mechanistic:** Mutually Assured Deregulation operates fractally at national, institutional, corporate, and individual lab levels simultaneously. Each level's race dynamic accelerates others. Safety leadership exits are leading indicators (Sharma, Feb 9).
+
+**Layer 3 — Structural (NEW today):** Voluntary governance fails because AI lacks the three SRO conditions (credible exclusion, favorable reputation economics, verifiable standards). These conditions cannot be established without a prior mandatory governance instrument creating access control at the substrate level. This is not a policy failure that better policy could fix — it's a structural property of the current governance landscape.
+
+The three layers together are a stronger diagnosis than any layer alone:
+- Empirical layer → this is happening
+- Mechanistic layer → this is why it keeps happening
+- Structural layer → this is why current proposals for voluntary governance improvement are insufficient
+
+---
+
+## Carry-Forward Items (cumulative, updated)
+
+Items now 3+ sessions overdue that are already queued for extraction:
+1. RSP v3 pause commitment drop + MAD logic — QUEUED in inbox (2026-02-24-time-anthropic-rsp-v3-pause-commitment-dropped.md)
+
+Items not queued, still unextracted:
+2. **"Great filter is coordination threshold"** — 24+ consecutive sessions. MUST extract.
+3. **"Formal mechanisms require narrative objective function"** — 22+ sessions. Flagged for Clay.
+4. **Layer 0 governance architecture error** — 21+ sessions. Flagged for Theseus.
+5. **Full legislative ceiling arc** — 20+ sessions overdue.
+6. **"Mutually Assured Deregulation" claim** — 04-14. STRONG. Should extract.
+7. **"DuPont calculation" as engineerable governance condition** — 04-21. Should extract.
+8. **DURC/PEPP category substitution** — confirmed 8.5 months absent. Should extract.
+9. **Biden AI Diffusion Framework rescission as governance regression** — 12 months without replacement. Should extract.
+10. **Governance deadline as governance laundering** — 04-23. Extract.
+11. **Limited-partner deployment model failure** — 04-23. Still unextracted.
+12. **Sharma resignation as leading indicator** — 04-25. Extract.
+13. **Epistemic vs operational coordination gap** — 04-25. CLAIM CANDIDATE confirmed.
+14. **RSP v3 missile defense carveout** — 04-25. Already queued alongside RSP v3 source.
+15. **CRS IN12669 finding** — 04-25. Should extract.
+16. **Semiconductor export controls claim needs CORRECTION** — Biden Diffusion Framework rescinded. Claim [[semiconductor-export-controls-are-structural-analog-to-montreal-protocol-trade-sanctions]] needs revision.
+17. **NEW (today): SRO conditions framework** — "Voluntary governance fails for frontier AI because SRO enabling conditions (credible exclusion, reputation alignment, verifiability) are all absent and cannot be established without prior mandatory substrate access control." CLAIM CANDIDATE.
+
+---
+
+## Follow-up Directions
+
+### Active Threads (continue next session)
+
+- **DC Circuit May 19 (23 days):** Check May 20. Key questions: (a) deal closed with binding terms or "any lawful use" template? (b) California First Amendment retaliation case proceeding independently? (c) If ruling issued, does it establish a constitutional floor for voluntary safety policies in procurement?
+
+- **Google Gemini Pentagon deal outcome:** When announced, compare Google's "appropriate human control" standard vs. Anthropic's categorical prohibition. This establishes the industry safety norm going forward. Key metric: categorical vs. process standard.
+
+- **OpenAI / Nippon Life May 15:** Check May 16. Does OpenAI assert Section 230 immunity (forecloses liability pathway) or defend on merits (keeps pathway open)?
+
+- **SRO conditions framework (today's new synthesis):** Explore whether any governance proposal currently being discussed in AI policy circles attempts to create SRO-enabling conditions (substrate-level access control, safety certification that confers market access, verifiable standards). NSF AI Research Institutes and NIST AI RMF are the closest analogs. Do they satisfy any of the three SRO conditions?
+
+### Dead Ends (don't re-run)
+
+- **Tweet file:** 32+ consecutive empty sessions. Skip. Session time is better used for synthesis.
+- **BIS comprehensive replacement rule:** Indefinitely absent. Don't search until external signal of publication.
+- **"DuPont calculation" in existing AI labs:** No lab in DuPont's position until Google deal outcome known.
+
+### Branching Points
+
+- **SRO conditions for AI:** Direction A — compute governance (export controls) is the only viable path to SRO-like exclusion, making international semiconductor cooperation the prerequisite for voluntary AI governance. Direction B — deployment certification (like IATA's role in aviation) is a potential path if governments require AI safety certification for deployment in regulated sectors (healthcare, finance, critical infrastructure). Direction B doesn't require substrate-level control but does require regulated-sector leverage. Pursue Direction B: are there any proposals for sector-specific AI deployment certification in healthcare or finance that would create SRO-like conditions at the application layer rather than the substrate layer?
+
+- **Epistemic/operational coordination gap as standalone claim:** The International AI Safety Report 2026 is the best evidence for this claim. Is there other evidence that epistemic coordination on technology risks advances faster than operational governance? Climate (IPCC vs. Paris Agreement operational failures), COVID (scientific consensus vs. WHO coordination failures), nuclear (IAEA scientific consensus vs. arms control operational failures). All three show the same two-layer structure. Direction A: the epistemic/operational gap is a general feature of complex technology governance, not specific to AI. Direction B: AI is categorically harder because the technology's dual-use nature and military strategic value create stronger operational coordination inhibitors than climate or nuclear. Pursue Direction A first (general claim is more valuable) then qualify with AI-specific factors.
--- a/agents/leo/research-journal.md
+++ b/agents/leo/research-journal.md
@ -822,3 +822,18 @@ See `agents/leo/musings/research-digest-2026-03-11.md` for full digest.
 - Internal voluntary governance decay rate: REVISED upward. Sharma resignation as leading indicator establishes that safety leadership exits precede policy changes. Voluntary governance failure is endogenous to market structure — not only exogenous government action.
 - EU AI Act as governance advance: UNCHANGED (confirmed ceiling at enforcement date, not closure of military gap).
 - Cascade: "AI alignment is a coordination problem not a technical problem" claim modified in PR #3958. Position on SI inevitability reviewed — no update needed. The 2026 empirical evidence (RSP v3 MAD rationale, Google negotiations, Sharma resignation) further confirms coordination framing.
+
+## Session 2026-04-26
+**Question:** Does voluntary governance ever hold under competitive pressure without mandatory enforcement mechanisms — and if there are conditions under which it holds, do any of those conditions apply to AI? (Disconfirmation search using SRO analogy.)
+
+**Belief targeted:** Belief 1 — "Technology is outpacing coordination wisdom." Specifically targeting the structural explanation for voluntary governance failure. Disconfirmation direction: find a case where voluntary governance held under competitive pressure without (a) commercial self-interest alignment (Basel III), (b) security architecture substitution (NPT), (c) trade sanctions (Montreal Protocol), or (d) triggering event + commercial migration path (pharmaceutical).
+
+**Disconfirmation result:** FAILED. The SRO (self-regulatory organization) framework is the strongest candidate for voluntary governance that holds — bar associations, FINRA, medical licensing boards maintain standards under competitive pressure. But SROs require three conditions: credible exclusion, favorable reputation economics, and verifiable standards. AI frontier capability development satisfies none of the three. Exclusion is not credible (no monopoly on AI practice). Reputation economics are inverted (the largest customers — Pentagon, NSA — demand *fewer* safety constraints). Standards are not verifiable (benchmark-reality gap prevents external audit). Disconfirmation failed but produced a structural explanation: voluntary governance fails for AI because the SRO enabling conditions are absent and cannot be established without a prior mandatory instrument creating substrate-level access control.
+
+**Key finding:** The three-layer diagnosis of Belief 1 is now complete: (1) Empirical — voluntary governance is failing across all observed cases; (2) Mechanistic — Mutually Assured Deregulation operates fractally at national/institutional/corporate/individual-lab levels simultaneously; (3) Structural — voluntary governance fails because AI lacks SRO enabling conditions (credible exclusion, reputation alignment, verifiability), and these cannot be established without a prior mandatory substrate access control instrument. The three layers together are a more powerful diagnosis than any single layer.
+
+**Pattern update:** Across 26 sessions, the coordination failure analysis (Belief 1) has moved through three stages: empirical observation (sessions 1-15) → mechanistic explanation through MAD at multiple levels (sessions 16-25) → structural explanation through SRO conditions analysis (session 26). This is systematic convergence on a complete diagnosis rather than oscillation. The belief has gotten more precise and more structurally grounded at each stage. No session has found a genuine disconfirmation.
+
+**Confidence shift:** Belief 1 — STRENGTHENED in its structural grounding. The SRO analysis explains *why* voluntary governance structurally fails for AI, not just that it empirically fails. This makes the belief harder to disconfirm through incremental governance reforms that don't address the three structural conditions. A stronger belief is also a more falsifiable belief: the new disconfirmation target is "show me a governance mechanism that creates credible exclusion, favorable reputation economics, or verifiable standards for AI without mandatory enforcement."
+
+**Cascade processed:** PR #4002 modified claim "LivingIPs knowledge industry strategy builds collective synthesis infrastructure first..." — added reweave_edges connection to geopolitical narrative infrastructure claim. Assessment: strengthens position, no position update needed.
--- a/agents/vida/musings/research-2026-04-26.md
+++ b/agents/vida/musings/research-2026-04-26.md
@ -0,0 +1,155 @@
+---
+type: musing
+agent: vida
+date: 2026-04-26
+status: active
+research_question: "Has the 80-90% non-clinical health outcome determinance figure been challenged or refined by precision medicine expansion — GLP-1, gene therapy, microbiome interventions — into previously behavioral/biological hybrid domains?"
+belief_targeted: "Belief 2 (80-90% of health outcomes are non-clinical) — actively searching for evidence that clinical interventions are expanding their determinant share as they address biological mechanisms underlying behavioral conditions"
+---
+
+# Research Musing: 2026-04-26
+
+## Session Planning
+
+**Tweet feed status:** Empty. No content from health accounts today. Working entirely from active threads and web research.
+
+**Why this direction today:**
+
+Session 28 (yesterday) identified that GLP-1 receptor agonists produce clinically meaningful reductions in alcohol consumption and craving through shared VTA dopamine reward circuit suppression — establishing a pharmacological mechanism that bridges what McGinnis-Foege (1993) classified as "behavioral" conditions (heavy drinking, smoking, obesity) with clinical intervention. This opened a genuine question I flagged but didn't close:
+
+**If the 1993 McGinnis-Foege framework classified obesity, alcohol, and tobacco as "behavioral" causes (together ~35-45% of preventable deaths), and GLP-1 + gene therapy + precision medicine are now demonstrating clinically addressable biological substrates for these same conditions — does the 80-90% non-clinical attribution need updating for 2025-2026?**
+
+This is the sharpest form of Belief 2 disconfirmation I haven't systematically pursued. All previous disconfirmation attempts have used the framing "behavioral/social factors dominate" — but none have asked whether precision medicine is expanding clinical reach into previously non-clinical domains.
+
+**Keystone belief disconfirmation target — Belief 2:**
+> "The 80-90% non-clinical attribution was derived from frameworks where 'medical care' meant episodic clinical encounters treating established disease. If GLP-1 prevents obesity (previously behavioral), gene therapy prevents genetic disease (previously fate), and microbiome interventions modify the gut-brain axis (previously psychological), then the 'clinical 10-20%' may be expanding. The McGinnis-Foege figure may be a historical artifact of what clinical medicine could do in 1993, not a structural limit."
+
+**Active threads to execute (secondary priority):**
+1. **Provider consolidation claim** — GAO-25-107450 + HCMR 2026. Overdue 5+ sessions. Execute today.
+2. **OECD preventable mortality claim** — US 217 vs 145/100K. Data confirmed multiple sessions. Execute today.
+3. **Clinical AI temporal qualification claim** — Ready to draft. Evidence assembled over 4 sessions.
+4. **Procyclical mortality paradox claim** — QJE 2025 Finkelstein et al.
+
+**What I'm searching for:**
+1. 2025-2026 updates to health outcome determinant frameworks — has the 10-20% clinical attribution been revised?
+2. Evidence that GLP-1 / gene therapy / precision medicine are being incorporated into newer population health models
+3. Provider consolidation data — hospital/health system M&A effects on quality and price (GAO 2025)
+4. OECD health expenditure vs outcomes comparison (validate the 217/145 per 100K preventable mortality figures)
+
+**What success looks like (disconfirmation of Belief 2):**
+A 2025-2026 systematic review or policy framework that re-estimates clinical care's determinant share upward — e.g., showing that clinical interventions now account for 25-35% of preventable mortality through expanded biological mechanisms.
+
+**What failure looks like:**
+The 80-90% non-clinical figure is robust to precision medicine expansion because (a) access barriers prevent population-scale clinical reach, and (b) environmental triggers remain the dominant driver even when biological substrates are addressable.
+
+---
+
+## Findings
+
+### Disconfirmation Attempt — Belief 2 (80-90% non-clinical): FAILED — Belief STRENGTHENED by new mechanism
+
+**What I found:**
+
+**1. 2025 UWPHI County Health Rankings Model Update:**
+The UWPHI revised its County Health Rankings model in 2025 — but moved AWAY from explicit percentage weights while ADDING "Societal Rules" and "Power" as new determinant categories. This is the opposite of what Belief 2 disconfirmation would require. The 2014 model weights (30% behaviors, 20% clinical, 40% social/economic, 10% environment) remain the standard reference. The 2025 update expands the structural determinant framework upstream — more weight to power structures and societal rules, not more to clinical care.
+
+Verdict: CONFIRMS Belief 2 directionally. The most-cited academic framework moved further from clinical primacy, not toward it.
+
+**2. GLP-1 population access data (ICER December 2025; WHO December 2025; multiple sources):**
+The clearest disconfirmation would be: precision clinical intervention is reaching the highest-burden population at scale. What I found is the opposite:
+- ICER 14-0 unanimous clinical efficacy verdict → but California Medi-Cal eliminated coverage January 2026
+- WHO: fewer than 10% of those who could benefit projected to access GLP-1s by 2030
+- <25% of eligible US patients currently using GLP-1s
+- Racial/ethnic access disparities: Black, Hispanic, and Native American patients receive GLP-1 prescriptions at 0.5-0.8x the rate of White patients despite higher obesity burden
+- The equity inversion: populations with highest clinical need have lowest access
+
+The mechanism that would allow precision medicine to expand clinical care's determinant share is POPULATION-SCALE ACCESS. That mechanism is structurally blocked by cost, coverage, and equity barriers.
+
+**3. GLP-1 pharmacogenomics (23andMe Nature 2026):**
+First large-scale GWAS of GLP-1 response (n=27,885). GLP1R and GIPR variants predict 6-20% weight loss range and 5-78% nausea/vomiting risk. Drug-specific finding: GIPR association is tirzepatide-specific (not semaglutide). Immediately clinical: GIPR risk alleles → prescribe semaglutide, not tirzepatide.
+
+This advances the "precision obesity medicine" argument — but the test is available only through 23andMe Total Health (subscription service, predominantly affluent users). The genetic precision is real; the access to that precision is stratified.
+
+**4. Papanicolas et al. JAMA Internal Medicine 2025:**
+US avoidable mortality increased 32.5 per 100K from 2009-2019 while OECD decreased 22.8 per 100K. Drug deaths = 71.1% of US preventable mortality increase. CRITICAL finding: Health spending positively associated with avoidable mortality improvement in comparable countries (correlation = -0.7) but NOT associated in US states (correlation = -0.12). US health spending is structurally decoupled from avoidable mortality improvement.
+
+This is devastating for the "precision medicine is expanding clinical care's share" argument. If anything, the most expensive healthcare system in the world is becoming less efficient at preventing avoidable mortality — the opposite of what expanded clinical determinance would produce.
+
+**5. Cell/Med 2025 — GLP-1 societal implications:**
+Explicitly confirms: "GLP-1s do not offer a sustainable solution to the public health pressures caused by obesity, where prevention remains crucial." This is a mainstream academic source confirming that even the best pharmaceutical intervention in obesity history cannot substitute for the structural determinants (Big Food, food environments, social conditions) that drive the epidemic.
+
+**The core finding on Belief 2 disconfirmation:**
+
+The disconfirmation attempt targeted the wrong mechanism. The 80-90% non-clinical figure is NOT primarily about what clinical medicine CAN DO in principle — it's about what clinical medicine DOES DO at population scale. Even in a world where GLP-1s can treat obesity, addiction, and metabolic syndrome, the question is whether those interventions reach the population at scale. They don't and won't absent structural change — which is itself a non-clinical intervention.
+
+**New precision added to Belief 2:**
+The "clinical 10-20%" may be expanding in POTENTIAL (GLP-1 mechanisms now reach behavioral domains) but contracting in PRACTICE (access barriers growing, US spending efficiency declining, OECD divergence worsening). The gap between potential clinical care share and actual clinical care share is widening, not narrowing.
+
+**Disconfirmation verdict: FAILED — Belief 2 confirmed with a new precision.**
+
+The claim should be refined: "Medical care explains only 10-20% of health outcomes IN PRACTICE — not as a structural ceiling on what clinical interventions can achieve in principle, but as the actual measured population-level contribution given current access and delivery architecture."
+
+This reframing makes Belief 2 MORE defensible (it's an empirical claim about current practice, not a theoretical claim about clinical medicine's potential) and opens the cross-domain question: as access barriers fall (generic GLP-1s, telemedicine, direct-to-consumer diagnostics), does clinical care's share grow?
+
+---
+
+### Provider Consolidation — New Evidence Package Complete
+
+Sources archived:
+1. **GAO-25-107450** (September 2025): 47% physician-hospital employment (up from 29% 2012); 7% PE ownership; PE = 65% of acquisitions 2019-2023; hospital consolidation raises commercial prices 16-21% for specialty procedures; quality evidence mixed/no improvement; $3B/year commercial excess.
+2. **Health Affairs 2025**: Hospital-affiliated cardiologists 16.3% premium; gastroenterologists 20.7% premium; PE-affiliated lower (6-10%); $2.9B/year hospital excess + $156M PE excess.
+3. **HCMR 2026** (previously archived): 37 years of evidence — quality effects "decidedly mixed."
+
+The three-source consolidation evidence package is now complete. The claim is ready for extraction: physician consolidation raises commercial prices 16-21% without consistent quality improvement, generating ~$3B/year in commercial excess spending from two specialties alone.
+
+---
+
+### OECD Preventable Mortality — Confirmed and Extended
+
+The Papanicolas JAMA Internal Medicine 2025 paper adds the trend dimension to the snapshot data:
+- Snapshot (OECD Health at a Glance 2025): US preventable = 217, OECD average = 145; US treatable = 95, OECD average = 77
+- Trend (Papanicolas 2025): US INCREASING 32.5/100K while OECD DECREASING 22.8/100K (2009-2019)
+- The divergence is accelerating, not narrowing
+
+Combined with the spending efficiency finding (US correlation -0.12 vs. OECD -0.7), this is the empirical statement of Belief 3: the US healthcare system is structurally incapable of translating spending into avoidable mortality reduction.
+
+---
+
+### Clinical AI Deskilling — Evidence Batch Complete
+
+2026 literature confirms the temporal qualification:
+- Current established clinicians: NO measurable deskilling (protected by pre-AI foundations)
+- Current trainees: never-skilling structurally locked in
+- New: 33% of younger providers rank deskilling as top concern vs. 11% older (Wolters Kluwer 2026)
+- New: resident supervision protocol recommendation (human-first differential, then AI) as structural pedagogical safeguard
+
+The claim is ready for extraction.
+
+---
+
+## Follow-up Directions
+
+### Active Threads (continue next session)
+
+- **EXTRACT CLAIMS — Priority Queue (next session should be extraction-only)**:
+  1. Physician consolidation claim (GAO + Health Affairs): "Physician consolidation with hospital systems raises commercial insurance prices 16-21% without consistent quality improvement" — confidence: likely/proven, evidence package complete
+  2. OECD preventable mortality + trend claim: "US avoidable mortality is increasing in all 50 states while declining in most OECD countries, with health spending structurally decoupled from mortality improvement" — confidence: proven, data is government/peer-reviewed
+  3. Clinical AI temporal deskilling claim: "Clinical AI deskilling is a generational risk — current pre-AI-trained clinicians report no degradation; current trainees face never-skilling structurally" — confidence: likely, multiple sources
+  4. GLP-1 pharmacogenomics claim: "GLP-1 receptor agonist weight loss and side effects are partially genetically determined — GLP1R/GIPR variants predict 6-20% weight loss range and 14.8-fold variation in tirzepatide-specific nausea" — confidence: likely (large GWAS but self-reported data)
+  5. WHO GLP-1 access claim enrichment: "<10% of eligible global population projected to access GLP-1s by 2030" — enrich existing GLP-1 claim
+
+- **Generic GLP-1 trajectory and price compression**: The access barriers are partly addressed by generic entry. When does the first biosimilar semaglutide enter the US market? This is the key event that could change the access picture — and the cost curve.
+
+- **Moral deskilling cross-domain (Theseus)**: Flag for Theseus — AI habituation eroding ethical judgment is an alignment failure mode operating at societal scale. Could become a cross-domain claim.
+
+### Dead Ends (don't re-run these)
+
+- **Precision medicine expanding clinical care's determinant share (2025-2026 literature)**: No systematic review or policy framework has revised the 10-20% clinical attribution upward. The access barriers are the structural limiter — not the mechanistic potential. This disconfirmation path is exhausted for the current access architecture. Re-examine when generic GLP-1s achieve >50% market penetration.
+
+- **UWPHI 2025 model explicit weights**: The 2025 model deliberately removed explicit percentage weights. No updated numbers available or planned. Legacy 2014 weights (30/20/40/10) remain the standard citation.
+
+### Branching Points (today's findings opened these)
+
+- **Belief 2 reframing**: Today's session suggests Belief 2 should be reframed from a claims-about-potential ceiling to a claim about current empirical practice: "In the current access architecture, clinical care explains only 10-20% of health outcomes." Direction A (reframe Belief 2 text in agents/vida/beliefs.md) vs. Direction B (keep existing framing, note the precision in a challenged_by or challenges section). Pursue Direction A — the reframing makes the belief MORE defensible and MORE useful.
+
+- **GLP-1 pharmacogenomics claim scope**: Direction A (narrow claim: genetic stratification enables tirzepatide vs. semaglutide drug selection) vs. Direction B (broader claim: precision obesity medicine is stratifying clinical response, but access to precision is itself stratified, widening health equity). Pursue Direction B — the access stratification angle is the more important insight and connects to multiple KB claims.
--- a/agents/vida/research-journal.md
+++ b/agents/vida/research-journal.md
@ -1,5 +1,33 @@
 # Vida Research Journal

+## Session 2026-04-26 — Belief 2 Disconfirmation via Precision Medicine Expansion
+
+**Question:** Has the 80-90% non-clinical health outcome determinance figure been challenged or refined by precision medicine expansion (GLP-1, pharmacogenomics, gene therapy) into previously behavioral/biological hybrid domains? Does clinical care's determinant share grow as it gains mechanisms addressing conditions once classified as behavioral?
+
+**Belief targeted:** Belief 2 (80-90% of health outcomes determined by non-clinical factors). Specific disconfirmation: if GLP-1s address obesity/addiction through biological mechanisms, and gene therapy addresses genetic disease, does the "clinical 10-20%" need upward revision?
+
+**Disconfirmation result:** FAILED — Belief 2 confirmed with important new precision.
+
+The disconfirmation attempt targeted the wrong mechanism. The 80-90% non-clinical figure is NOT about what clinical medicine can do in principle — it's about what clinical medicine does at population scale. Three independent lines of evidence confirm this:
+
+**(1) UWPHI 2025 model update:** The most-cited academic framework for health determinants moved AWAY from clinical primacy, adding "Societal Rules" and "Power" as new explicit determinant categories. No framework has revised clinical care's share upward.
+
+**(2) GLP-1 access architecture (multiple sources):** Even with a 14-0 ICER unanimous clinical efficacy verdict, <25% of eligible US patients use GLP-1s; WHO projects <10% global access by 2030; racial/ethnic disparities in prescribing mean highest-burden populations are least reached. The equity inversion (highest clinical need → lowest access) is the structural mechanism blocking clinical share expansion.
+
+**(3) Papanicolas JAMA Internal Medicine 2025:** US avoidable mortality increased 32.5/100K from 2009-2019 while OECD decreased 22.8/100K. Health spending NOT associated with avoidable mortality improvement across US states (correlation = -0.12) but IS associated in comparable countries (-0.7). US healthcare is spending more while producing WORSE avoidable mortality outcomes — the structural dissociation between spending and outcomes is the empirical statement of Belief 2.
+
+**NEW PRECISION FOR BELIEF 2:** The claim should be refined from a theoretical statement to an empirical one: "Medical care explains only 10-20% of health outcomes IN THE CURRENT ACCESS ARCHITECTURE — not as a structural ceiling on clinical medicine's potential, but as the measured population-level contribution given current delivery and access architecture." This makes the belief more defensible (it's empirical, not theoretical) and opens the question: as access barriers fall (generic GLP-1s, direct-to-consumer diagnostics), does clinical care's share grow?
+
+**Key finding:** The GAO-25-107450 + Papanicolas JAMA combination is the most damning dual evidence in the KB: physician consolidation raises commercial prices 16-21% with no quality improvement ($3B/year commercial excess from two specialties), while avoidable mortality is simultaneously worsening and decoupled from spending. More money, worse outcomes, structural access barriers. This is Belief 3 (structural misalignment) at its clearest.
+
+**Pattern update:** Four consecutive sessions have now targeted Belief 2 from different angles (Session 26: OECD preventable mortality; Session 27: GLP-1 VTA mechanism; Session 28: ARISE generational deskilling; Session 29: precision medicine expansion). Every disconfirmation attempt has failed. The pattern is: Belief 2's directional claim (non-clinical factors dominate) is extremely robust across multiple methodological approaches. What keeps emerging is not refutation but precision — the mechanisms through which clinical care is limited become clearer with each session.
+
+**Confidence shift:**
+- Belief 2 (80-90% non-clinical): STRENGTHENED. Not overturned by precision medicine. The access architecture is the structural limiter, and that architecture is demonstrably failing (equity inversion, OECD divergence, spending decoupling). The reframing from "theoretical ceiling" to "empirical practice" makes the belief more precise and more defensible.
+- Belief 3 (structural misalignment): STRONGLY CONFIRMED by the GAO consolidation + Papanicolas spending efficiency combination. The rent extraction is quantified ($3B/year commercial from two specialties) and the outcome failure is empirically confirmed (spending decoupled from avoidable mortality). This is Belief 3's strongest session yet.
+
+---
+
 ## Session 2026-04-25 — Belief 1 Disconfirmation + Clinical AI Deskilling Generational Risk

 **Question:** (1) Does the historical record (Industrial Revolution) or modern economic data (QJE 2025 procyclical mortality) disconfirm Belief 1 — that healthspan is civilization's binding constraint? (2) Does new 2026 clinical AI evidence change the deskilling/upskilling picture?
--- a/domains/health/Americas
+++ b/domains/health/Americas
@ -1,23 +1,13 @@
 ---
-description: Drug overdoses alcohol abuse and suicide -- deaths of despair -- reversed US life expectancy after 2014 with geographic and demographic patterns matching deindustrialization and widening inequality not random distribution
 type: claim
 domain: health
-source: "Architectural Investing, Ch. Epidemiological Transition; JAMA 2019"
+description: Drug overdoses alcohol abuse and suicide -- deaths of despair -- reversed US life expectancy after 2014 with geographic and demographic patterns matching deindustrialization and widening inequality not random distribution
 confidence: proven
+source: Architectural Investing, Ch. Epidemiological Transition; JAMA 2019
 created: 2026-02-28
-related_claims:
-  - cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure
-  - us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions
-  - cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths
-  - us-healthspan-declining-while-lifespan-recovers-creating-divergence
-  - us-healthspan-lifespan-gap-largest-globally-despite-highest-spending
-  - us-hypertension-mortality-doubled-2000-2019-while-treatment-control-stagnated-structural-access-failure
-related:
- hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure
- after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes
-reweave_edges:
- hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure|related|2026-03-31
- after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes|related|2026-04-17
+related_claims: ["cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure", "us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions", "cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending", "us-hypertension-mortality-doubled-2000-2019-while-treatment-control-stagnated-structural-access-failure"]
+related: ["hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure", "after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes", "Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s"]
+reweave_edges: ["hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure|related|2026-03-31", "after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes|related|2026-04-17"]
 ---

 # Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s
@ -69,4 +59,10 @@ Relevant Notes:

 Topics:
 - health and wellness
- livingip overview
+- livingip overview
+
+## Supporting Evidence
+
+**Source:** Papanicolas et al., JAMA Internal Medicine 2025
+
+Drug-related deaths contributed 71.1% of the increase in preventable avoidable deaths from external causes during 2009-2019, providing precise quantification of the deaths-of-despair mechanism's contribution to US mortality divergence. The study shows this operated across all 50 states with West Virginia experiencing the worst increase (+99.6 per 100,000) while even the best-performing state (New York, -4.9) could not escape the broader deterioration pattern.
--- a/domains/health/clinical-ai-creates-moral-deskilling-through-ethical-judgment-erosion.md
+++ b/domains/health/clinical-ai-creates-moral-deskilling-through-ethical-judgment-erosion.md
@ -10,18 +10,17 @@ agent: vida
 sourced_from: health/2026-04-25-natali-2025-ai-induced-deskilling-springer-mixed-method-review.md
 scope: causal
 sourcer: Natali et al., University of Milano-Bicocca
-related:
- clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling
- automation-bias-in-medicine-increases-false-positives-through-anchoring-on-ai-output
- ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement
- ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine
- dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation
-supports:
- Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy
-reweave_edges:
- Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy|supports|2026-04-26
+related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "automation-bias-in-medicine-increases-false-positives-through-anchoring-on-ai-output", "ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement", "ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine", "dopaminergic-reinforcement-of-ai-reliance-predicts-behavioral-entrenchment-beyond-simple-habit-formation", "clinical-ai-creates-moral-deskilling-through-ethical-judgment-erosion", "moral-deskilling-from-ai-erodes-ethical-judgment-through-repeated-cognitive-offloading", "clinical-ai-deskilling-is-generational-risk-not-current-phenomenon"]
+supports: ["Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy"]
+reweave_edges: ["Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy|supports|2026-04-26"]
 ---

 # Clinical AI creates moral deskilling through ethical judgment erosion from routine AI acceptance leaving clinicians unprepared to recognize value conflicts

-This review introduces 'moral deskilling' as a distinct form of AI-induced competency loss separate from cognitive deskilling. The mechanism: repeated acceptance of AI recommendations creates habituation that reduces ethical sensitivity and moral judgment capacity. Clinicians become less prepared to recognize when AI suggestions conflict with patient values, cultural context, or best interests. This is distinct from automation bias (which concerns cognitive deference to AI outputs) and cognitive deskilling (which concerns diagnostic or procedural skill loss). Moral deskilling operates through a different pathway: the normalization of AI-mediated decision-making erodes the ethical reasoning muscle that requires active exercise. The review identifies this as particularly concerning because it is invisible until a patient is harmed — there is no performance metric that captures ethical judgment quality in routine practice. This represents a fourth distinct safety failure mode in clinical AI deployment, and arguably the most concerning because it affects the human capacity to recognize when technical optimization conflicts with human values.
+This review introduces 'moral deskilling' as a distinct form of AI-induced competency loss separate from cognitive deskilling. The mechanism: repeated acceptance of AI recommendations creates habituation that reduces ethical sensitivity and moral judgment capacity. Clinicians become less prepared to recognize when AI suggestions conflict with patient values, cultural context, or best interests. This is distinct from automation bias (which concerns cognitive deference to AI outputs) and cognitive deskilling (which concerns diagnostic or procedural skill loss). Moral deskilling operates through a different pathway: the normalization of AI-mediated decision-making erodes the ethical reasoning muscle that requires active exercise. The review identifies this as particularly concerning because it is invisible until a patient is harmed — there is no performance metric that captures ethical judgment quality in routine practice. This represents a fourth distinct safety failure mode in clinical AI deployment, and arguably the most concerning because it affects the human capacity to recognize when technical optimization conflicts with human values.
+
+## Supporting Evidence
+
+**Source:** Frontiers Medicine 2026
+
+Frontiers Medicine 2026 provides conceptual confirmation of moral deskilling via neural adaptation mechanism: habitual AI acceptance erodes ethical sensitivity and contextual judgment as physicians offload ethical reasoning to AI systems. This is the same neurological pathway as cognitive deskilling (prefrontal disengagement) but applied to moral reasoning tasks.
--- a/domains/health/clinical-ai-deskilling-is-generational-risk-not-current-phenomenon.md
+++ b/domains/health/clinical-ai-deskilling-is-generational-risk-not-current-phenomenon.md
@ -11,9 +11,23 @@ sourced_from: health/2026-04-25-arise-state-of-clinical-ai-2026-report.md
 scope: structural
 sourcer: ARISE Network (Stanford-Harvard)
 supports: ["never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks"]
-related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks", "ai-cervical-cytology-screening-creates-never-skilling-through-routine-case-reduction", "ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling", "never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians"]
+related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks", "ai-cervical-cytology-screening-creates-never-skilling-through-routine-case-reduction", "ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling", "never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians", "clinical-ai-deskilling-is-generational-risk-not-current-phenomenon", "clinical-ai-upskilling-requires-deliberate-educational-design-not-passive-exposure"]
 ---

 # Clinical AI deskilling is a generational risk affecting future trainees rather than current practitioners because experienced clinicians retain pre-AI skill foundations while new trainees face never-skilling in AI-saturated environments

 The ARISE 2026 report synthesizing 2025 clinical AI research documents a critical temporal distinction in deskilling risk. Current practicing clinicians report NO measurable deskilling from AI applications, which the report attributes to their pre-AI clinical training providing a skill foundation that AI assistance does not erode. However, the report documents a stark generational divergence in risk perception: 33% of younger providers entering practice rank deskilling as a top-2 concern, compared to only 11% of older providers. This 3x difference reflects the structural reality that younger clinicians entering AI-integrated training environments face 'never-skilling' risk—they may never develop the clinical judgment skills that current practitioners acquired before AI assistance became ubiquitous. The report explicitly states that current AI applications function as 'assistants rather than autonomous agents' with 'narrow scope,' which preserves skill development for those already trained. The generational divergence provides empirical evidence that deskilling is a FUTURE risk concentrated in training pipelines, not a current phenomenon affecting experienced practitioners. This temporal scoping is critical because it shifts the intervention point from retraining current clinicians to redesigning medical education for AI-native environments.
+
+
+## Supporting Evidence
+
+**Source:** Wolters Kluwer AI survey 2026
+
+Wolters Kluwer 2026 survey confirms the 3:1 generational differential in deskilling concern: 33% of younger providers rank deskilling as top concern vs 11% of older providers. This is independent confirmation of the ARISE 2026 Stanford-Harvard finding. The survey data shows newer providers are both more exposed to AI-first environments AND more aware of the developmental risk.
+
+
+## Extending Evidence
+
+**Source:** ScienceDirect scoping review 2026
+
+ScienceDirect scoping review 2026 confirms current evidence is largely expert opinion and small-scale studies, with no longitudinal prospective data tracking clinical competence in AI-integrated environments. The temporal qualification (current clinicians protected, trainees at risk) remains at 'likely' confidence, not 'proven', due to absence of longitudinal RCT evidence.
--- a/domains/health/clinical-ai-human-first-reasoning-prevents-never-skilling-through-pedagogical-sequencing.md
+++ b/domains/health/clinical-ai-human-first-reasoning-prevents-never-skilling-through-pedagogical-sequencing.md
@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "Operational protocol for resident training that addresses never-skilling without eliminating AI assistance by enforcing sequence: human reasoning generation first, then AI as second opinion"
+confidence: experimental
+source: PMC 2026 resident supervision study; Frontiers Medicine 2026
+created: 2026-04-26
+title: Clinical AI human-first reasoning prevents never-skilling through pedagogical sequencing where trainees generate differential diagnoses before AI consultation
+agent: vida
+sourced_from: health/2026-04-15-clinical-ai-deskilling-2026-review-generational.md
+scope: functional
+sourcer: PMC / Frontiers Medicine
+supports: ["clinical-ai-upskilling-requires-deliberate-educational-design-not-passive-exposure"]
+related: ["optional-use-ai-deployment-preserves-independent-clinical-judgment-preventing-automation-bias-pathway", "clinical-ai-upskilling-requires-deliberate-educational-design-not-passive-exposure", "never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks", "ai-induced-upskilling-inhibition-prevents-skill-acquisition-in-trainees-through-routine-case-reduction", "never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling", "clinical-ai-deskilling-is-generational-risk-not-current-phenomenon"]
+---
+
+# Clinical AI human-first reasoning prevents never-skilling through pedagogical sequencing where trainees generate differential diagnoses before AI consultation
+
+The resident supervision study (PMC 2026) identifies a specific pedagogical intervention to prevent never-skilling: residents must generate their own differential diagnosis before consulting AI. This is not abstract guidance about 'AI should supplement not replace' but an operational protocol with explicit sequencing. The mechanism: if AI supplies the first-pass differential, the resident never develops the cognitive skill of building and prioritizing clinical reasoning independently. The Frontiers Medicine 2026 paper confirms the neurological basis: cognitive tasks offloaded to AI result in decreased neural capacity for those tasks. The human-first protocol preserves the cognitive load required for skill acquisition while still allowing AI augmentation after independent reasoning is demonstrated. This is a structural educational intervention that addresses the never-skilling pathway identified in colonoscopy ADR studies and cytology training volume destruction. The protocol implements role complementarity: human generates hypothesis space, AI validates and extends. Critically, this only works if enforced at the institutional level—optional use would allow trainees to skip the effortful human-first step.
--- a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md
+++ b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md
@ -67,3 +67,10 @@ ITIF's 74 million eligible obesity treatment population figure provides the deno
 **Source:** WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025

 WHO explicitly states that current global access and affordability for GLP-1s are 'far below population needs' and that GLP-1s 'should be incorporated into universal health coverage and primary care benefit packages' but acknowledges this is not yet reality anywhere in the developing world. The conditional recommendation status is driven in part by 'potential equity implications,' providing international regulatory confirmation of the structural access inversion.
+
+
+## Supporting Evidence
+
+**Source:** ICER Final Evidence Report, December 2025
+
+ICER report documents the access inversion at policy level: California Medi-Cal (serving lowest-income population) eliminated coverage January 2026 despite 14-0 clinical evidence. Medicare coverage restricted to cardiovascular risk indication, excluding pure obesity. National Pharmaceutical Council criticized ICER for 'prioritizing payers over patients,' highlighting the structural tension between budget sustainability and individual access. The 14-0 clinical verdict combined with simultaneous coverage elimination is the clearest expression of structural misalignment.
--- a/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md
+++ b/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md
@ -10,17 +10,17 @@ agent: vida
 scope: structural
 sourcer: RGA (Reinsurance Group of America)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier]]"]
-supports:
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
-reweave_edges:
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14
-related:
- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes"]
+reweave_edges: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
 ---

 # GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability

-The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+
+## Supporting Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO projects <10% global access by 2030 (approximately 100 million people out of >1 billion with obesity), providing the most authoritative access constraint projection to date and confirming that population-level mortality impact will be severely delayed by structural barriers
--- a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md
+++ b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md
@ -39,3 +39,10 @@ Exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessatio
 **Source:** PubMed 41696398 systematic review, 33 SUD trials

 The continuous treatment requirement extends beyond metabolic conditions to substance use disorders. The same mesolimbic dopamine circuits that mediate hedonic eating also underlie addiction, suggesting GLP-1s would require chronic administration for SUD just as they do for obesity. This creates a parallel chronic-use economic model for an entirely new therapeutic category.
+
+
+## Supporting Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO guideline specifies GLP-1 therapies for 'long-term obesity treatment (defined as ≥6 months continuous therapy)' and cites 'unclear maintenance and discontinuation protocols' as a reason for conditional rather than strong recommendation, confirming the chronic use requirement
--- a/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md
+++ b/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md
@ -23,3 +23,10 @@ Despite the near-doubling of year-one persistence rates, Prime Therapeutics data
 **Source:** KFF 2025 poll

 Cost is a major driver of discontinuation: 14% of former GLP-1 users stopped due to cost, matching the 13% who stopped due to side effects. Among current users, 56% report difficulty affording medications, suggesting cost pressure operates throughout the treatment duration, not just at initiation. The 27% of insured users paying full out-of-pocket cost indicates insurance coverage gaps contribute to persistence failures.
+
+
+## Extending Evidence
+
+**Source:** Cell/Med 2025, The Societal Implications of Using GLP-1 Receptor Agonists for the Treatment of Obesity
+
+Cell/Med 2025 connects low persistence rates to the sustainability concern: chronic use model + high prices + discontinuation effects = fiscal unsustainability at scale. The paper notes need to 'consider acceptability over long term and implications for weight stigma,' suggesting that persistence barriers are not just clinical or financial but also social. The equity inversion compounds this: those with highest need face both highest discontinuation rates (per existing KB claims on wealth-stratified access) and lowest initial access, creating a double barrier to population-level impact.
--- a/domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md
+++ b/domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md
@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: First large-scale pharmacogenomics evidence for GLP-1 response heterogeneity enabling genetic stratification to optimize drug selection and reduce treatment discontinuation
+confidence: experimental
+source: 23andMe Research Institute, Nature 2026, n=27,885
+created: 2026-04-26
+title: "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk"
+agent: vida
+sourced_from: health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md
+scope: causal
+sourcer: 23andMe Research Institute
+supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp-1-access-structure-inverts-need-creating-equity-paradox", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+---
+
+# GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk
+
+A genome-wide association study of 27,885 individuals using semaglutide or tirzepatide identified genetic variants that explain significant portions of treatment response variability. A missense variant in GLP1R was associated with an additional -0.76 kg weight loss per copy of the effect allele, contributing to a predicted weight loss range of 6-20% of starting body weight across participants—a 3.3-fold variation. More clinically actionable: variants in GLP1R and GIPR predict nausea/vomiting risk, with the GIPR association being drug-specific to tirzepatide (not semaglutide). Individuals homozygous for risk alleles at both loci showed 14.8-fold increased odds of tirzepatide-mediated vomiting, with predicted nausea/vomiting risk ranging from 5% to 78%—a 15-fold variation. The drug-specificity of the GIPR finding is mechanistically coherent (tirzepatide is a dual GLP-1/GIP agonist while semaglutide targets only GLP-1) and immediately actionable: patients with GIPR risk alleles could be preferentially prescribed semaglutide to reduce discontinuation risk. The findings were validated in an independent EHR dataset. 23andMe launched this as a commercial genetic test through their Total Health subscription service, making it the first consumer-available pharmacogenomics test for GLP-1 response. However, the study population (23andMe users who self-reported GLP-1 use) skews white, educated, and affluent, limiting generalizability to populations with highest obesity burden.
--- a/domains/health/hospital-physician-consolidation-increases-prices-without-improving-quality.md
+++ b/domains/health/hospital-physician-consolidation-increases-prices-without-improving-quality.md
@ -12,9 +12,16 @@ scope: structural
 sourcer: U.S. Government Accountability Office
 supports: ["medical-care-explains-only-10-20-percent-health-outcomes"]
 challenges: ["four-competing-payer-provider-models-converging-toward-value-based-care"]
-related: ["provider-consolidation-net-negative", "value-based-care-transitions-stall-at-payment-boundary"]
+related: ["provider-consolidation-net-negative", "value-based-care-transitions-stall-at-payment-boundary", "hospital-physician-consolidation-increases-prices-without-improving-quality"]
 ---

 # Hospital-physician consolidation consistently increases prices without improving quality as price effects are confirmed while quality evidence is mixed-to-negative across four years of literature

 The GAO reviewed peer-reviewed studies published between January 2021 and July 2025, finding that hospital-physician consolidation produces consistent price increases but quality outcomes that are 'same or lower' after consolidation. The report states that 'studies show consolidation can increase spending and prices' with 'one study found significant increases for office visits occurring in hospitals (vs. independent practice settings).' Price effects are described as the most consistently documented consolidation outcome with findings that are 'not mixed.' In contrast, quality evidence shows that 'quality may be the same or lower after consolidation' with 'quality benefits often not observed despite executives citing quality improvement as consolidation rationale.' The GAO notes that consolidation is 'accompanied by strategic initiatives and organizational changes that can involve quality-promoting investments but may also harm quality.' This represents a structural mismatch: consolidation concentrates market power enabling facility fee extraction, but the captured margin is not reinvested in outcomes. The finding is particularly significant because it synthesizes multiple studies over four years rather than representing a single study's results, and comes from the Congressional watchdog agency rather than advocacy sources.
+
+
+## Supporting Evidence
+
+**Source:** Health Affairs 2025, commercial insurance negotiated prices study
+
+Health Affairs 2025 study quantifies the commercial insurance price premium from physician consolidation: hospital-affiliated cardiologists charge +16.3% vs. independent, hospital-affiliated gastroenterologists +20.7%, PE-affiliated cardiologists +6.0%, PE-affiliated gastroenterologists +10.0%. Counterfactual analysis shows if hospital-affiliated specialists charged independent prices, commercial spending would decrease by $2.9B/year; PE-affiliated at independent prices would save additional $156M/year. Total counterfactual savings: ~$3.05B/year in commercial sector alone, for just two specialties. Study isolates negotiating power effect by controlling for equivalent procedures, showing price premium is not from volume or case mix differences.
--- a/domains/health/medical
+++ b/domains/health/medical
@ -1,26 +1,14 @@
 ---
-description: Schroeder 2007 attributes 10 percent of premature deaths to healthcare while Braveman-Egerter 2019 reviews four methods converging on the same estimate -- the 90 percent non-clinical claim is directionally correct but rhetorically imprecise
 type: claim
 domain: health
-created: 2026-02-20
-source: "Braveman & Egerter 2019, Schroeder 2007, County Health Rankings, Dever 1976"
+description: Schroeder 2007 attributes 10 percent of premature deaths to healthcare while Braveman-Egerter 2019 reviews four methods converging on the same estimate -- the 90 percent non-clinical claim is directionally correct but rhetorically imprecise
 confidence: proven
-related_claims:
-  - snap-benefit-loss-causes-measurable-mortality-through-food-insecurity-pathway
-  - snap-reduces-antihypertensive-nonadherence-through-food-medication-trade-off-relief
-  - us-healthspan-lifespan-gap-largest-globally-despite-highest-spending
-  - us-healthspan-declining-while-lifespan-recovers-creating-divergence
-  - cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure
-  - us-hypertension-mortality-doubled-2000-2019-while-treatment-control-stagnated-structural-access-failure
-supports:
- hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure
- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
-reweave_edges:
- hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure|supports|2026-03-31
- us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality|related|2026-04-04
- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24
-related:
- us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality
+source: "Braveman & Egerter 2019, Schroeder 2007, County Health Rankings, Dever 1976"
+created: 2026-02-20
+related_claims: ["snap-benefit-loss-causes-measurable-mortality-through-food-insecurity-pathway", "snap-reduces-antihypertensive-nonadherence-through-food-medication-trade-off-relief", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure", "us-hypertension-mortality-doubled-2000-2019-while-treatment-control-stagnated-structural-access-failure"]
+supports: ["hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health"]
+reweave_edges: ["hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure|supports|2026-03-31", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality|related|2026-04-04", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24"]
+related: ["us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
 ---

 # medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
@ -104,4 +92,10 @@ Relevant Notes:
 - [[human needs are finite universal and stable across millennia making them the invariant constraints from which industry attractor states can be derived]] -- health needs are a subset of universal needs, and the attractor state must address the full spectrum not just clinical encounters

 Topics:
- health and wellness
+- health and wellness
+
+## Supporting Evidence
+
+**Source:** Papanicolas et al., JAMA Internal Medicine 2025
+
+The 3:1 ratio of preventable (24.3 per 100,000) to treatable (7.5 per 100,000) mortality increase from 2009-2019 provides direct empirical evidence that behavioral and social determinants dominate over clinical care factors in US health outcomes. The spending-mortality correlation breakdown (-0.12 in US states vs -0.7 in peer nations) demonstrates that clinical spending cannot address the primary drivers of US mortality deterioration.
--- a/domains/health/never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks.md
+++ b/domains/health/never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks.md
@ -11,9 +11,16 @@ sourced_from: health/2026-04-22-oettl-2026-ai-deskilling-to-upskilling-orthopedi
 scope: structural
 sourcer: Oettl et al., Journal of Experimental Orthopaedics
 supports: ["cytology-lab-consolidation-creates-never-skilling-pathway-through-80-percent-training-volume-destruction"]
-related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling", "cytology-lab-consolidation-creates-never-skilling-pathway-through-80-percent-training-volume-destruction", "never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment", "ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement", "ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine"]
+related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "never-skilling-is-detection-resistant-and-unrecoverable-making-it-worse-than-deskilling", "cytology-lab-consolidation-creates-never-skilling-pathway-through-80-percent-training-volume-destruction", "never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment", "ai-assistance-produces-neurologically-grounded-irreversible-deskilling-through-prefrontal-disengagement-hippocampal-reduction-and-dopaminergic-reinforcement", "ai-induced-deskilling-follows-consistent-cross-specialty-pattern-in-medicine", "never-skilling-affects-trainees-while-deskilling-affects-experienced-physicians-creating-distinct-population-risks", "never-skilling-distinct-from-deskilling-affects-trainees-not-experienced-physicians", "clinical-ai-deskilling-is-generational-risk-not-current-phenomenon"]
 ---

 # Never-skilling affects trainees while deskilling affects experienced physicians creating distinct population risks with different intervention requirements

 Oettl et al. explicitly distinguish 'never-skilling' from 'deskilling' as separate mechanisms affecting different populations. Never-skilling occurs when trainees 'never develop foundational competencies' because AI is present from the start of their education. Deskilling occurs when experienced physicians lose existing skills through AI reliance. This distinction is critical because: (1) never-skilling is detection-resistant (no baseline to compare against), (2) the two mechanisms require different interventions (curriculum design for never-skilling, practice requirements for deskilling), and (3) they may have different timescales (never-skilling is immediate, deskilling may take years). The paper acknowledges that 'educators may lack expertise supervising AI use,' which compounds the never-skilling risk. This framework explains why the cytology lab consolidation evidence (80% training volume destruction) is particularly concerning—it creates a never-skilling pathway that is structurally invisible until the first generation of AI-trained pathologists enters independent practice.
+
+
+## Supporting Evidence
+
+**Source:** Frontiers Medicine 2026
+
+Frontiers Medicine 2026 maps the education continuum explicitly: students face never-skilling (no baseline skill acquisition), residents face partial-skilling (interrupted skill development), established clinicians face deskilling (erosion of existing skills). This confirms the three-population model with distinct failure modes by career stage.
--- a/domains/health/physician-consolidation-raises-commercial-prices-16-21-percent-without-quality-improvement.md
+++ b/domains/health/physician-consolidation-raises-commercial-prices-16-21-percent-without-quality-improvement.md
@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: GAO systematic review finds strong evidence for price increases but mixed evidence on quality, confirming consolidation extracts rent without health value
+confidence: likely
+source: US Government Accountability Office GAO-25-107450, September 2025
+created: 2026-04-26
+title: "Physician consolidation with hospital systems raises commercial insurance prices 16-21% for specialty procedures while producing no consistent quality improvement"
+agent: vida
+sourced_from: health/2025-09-22-gao-physician-consolidation-price-quality.md
+scope: causal
+sourcer: US Government Accountability Office
+supports: ["four-competing-payer-provider-models-are-converging-toward-value-based-care-with-vertical-integration-dominant-today-but-aligned-partnership-potentially-more-durable", "value-based-care-transitions-stall-at-the-payment-boundary-because-60-percent-of-payments-touch-value-metrics-but-only-14-percent-bear-full-risk"]
+related: ["four-competing-payer-provider-models-are-converging-toward-value-based-care-with-vertical-integration-dominant-today-but-aligned-partnership-potentially-more-durable", "value-based-care-transitions-stall-at-the-payment-boundary-because-60-percent-of-payments-touch-value-metrics-but-only-14-percent-bear-full-risk", "hospital-physician-consolidation-increases-prices-without-improving-quality"]
+---
+
+# Physician consolidation with hospital systems raises commercial insurance prices 16-21% for specialty procedures while producing no consistent quality improvement
+
+The GAO's systematic review of published literature found that hospital-affiliated specialists negotiated 16.3% higher prices for cardiology procedures and 20.7% higher prices for gastroenterology compared to independent practices in commercial insurance markets. Private equity-affiliated specialists charged 6.0% higher for cardiology and 10.0% higher for gastroenterology. The GAO estimated that if hospital and PE specialists charged equivalent to independent practices, commercial spending would be approximately $3.05 billion lower per year ($2.9B from hospital consolidation, $156M from PE). Critically, studies on quality effects were 'split between findings of no change or a decline in quality' — one colonoscopy study found patients more likely to experience complications after gastroenterologists consolidated with hospitals. The GAO 'was unable to find any studies' meeting its standards on consolidation's effect on care access. This confirms that consolidation creates measurable price premiums without corresponding quality improvements, fitting the definition of rent extraction. The mechanism is structural: consolidated practices gain negotiating leverage with commercial payers while hospital employment enables billing at higher facility rates, but these financial advantages don't translate to better clinical outcomes.
--- a/domains/health/private-equity-drives-65-percent-physician-acquisitions-while-owning-7-percent-practices.md
+++ b/domains/health/private-equity-drives-65-percent-physician-acquisitions-while-owning-7-percent-practices.md
@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: PE acquisition velocity far exceeds current ownership, signaling the physician employment transformation is in early acceleration phase
+confidence: experimental
+source: US Government Accountability Office GAO-25-107450, September 2025
+created: 2026-04-26
+title: "Private equity firms drove 65% of physician practice acquisitions from 2019-2023 while owning only 7% of practices, indicating structural transformation is accelerating faster than ownership share suggests"
+agent: vida
+sourced_from: health/2025-09-22-gao-physician-consolidation-price-quality.md
+scope: structural
+sourcer: US Government Accountability Office
+related: ["physician-consolidation-raises-commercial-prices-16-21-percent-without-quality-improvement"]
+---
+
+# Private equity firms drove 65% of physician practice acquisitions from 2019-2023 while owning only 7% of practices, indicating structural transformation is accelerating faster than ownership share suggests
+
+The GAO report documents that private equity firms were responsible for 65% of all physician practice acquisitions from 2019-2023, yet PE ownership represents only 6.5-7% of physicians nationally as of 2024 (up from ~5% in 2022). This creates a striking velocity-to-ownership ratio: PE is acquiring practices at a rate 9-10x faster than its current market share would suggest. The mechanism is consolidation acceleration — PE firms are actively transforming the physician employment landscape through rapid acquisition, but the ownership percentage lags because the transformation is still in early stages. This matters because it indicates the structural shift from independent to employed physicians (which fell from 60% independent in 2012 to 42% in 2024) is not slowing but accelerating. The PE acquisition rate is the leading indicator; the ownership percentage is the lagging indicator. If PE maintains this acquisition velocity, the 7% ownership share could double within 3-4 years, fundamentally altering the physician employment structure and the associated price effects documented in the GAO report.
--- a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md
+++ b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md
@ -10,17 +10,17 @@ agent: vida
 scope: causal
 sourcer: STEER investigators
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-related:
- Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
-reweave_edges:
- Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
-supports:
- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+related: ["Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator"]
+reweave_edges: ["Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09", "Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10", "GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12"]
+supports: ["Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction", "GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss"]
 ---

 # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction

-The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise.
+The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise.
+
+## Extending Evidence
+
+**Source:** 23andMe Research Institute, Nature 2026
+
+The GIPR genetic variant predicts tirzepatide-specific side effects but not semaglutide side effects, providing a mechanism-based rationale for drug selection beyond just cardiovascular vs. weight loss outcomes. Patients with GIPR risk alleles might benefit more from semaglutide not only for cardiovascular reasons but also to avoid treatment discontinuation due to intolerable side effects.
--- a/domains/health/the
+++ b/domains/health/the
@ -1,13 +1,12 @@
 ---
-description: Derived using the 8-component template -- three core interrelated layers (VBC payment alignment, AI-enabled proactive care, continuous biometric monitoring) plus contested dimensions around social determinants and administrative simplification, classified as a weak attractor with multiple locally stable configurations
 type: claim
 domain: health
-created: 2026-03-01
-source: "Healthcare attractor state derivation using vault knowledge + 2026 industry research; Rumelt Good Strategy Bad Strategy; Devoted Health analysis; CMS data; OECD comparisons; Singapore model"
+description: Derived using the 8-component template -- three core interrelated layers (VBC payment alignment, AI-enabled proactive care, continuous biometric monitoring) plus contested dimensions around social determinants and administrative simplification, classified as a weak attractor with multiple locally stable configurations
 confidence: likely
-related_claims:
-  - divergence-prevention-first-cost-reduction-vs-cost-redistribution
-  - medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program
+source: Healthcare attractor state derivation using vault knowledge + 2026 industry research; Rumelt Good Strategy Bad Strategy; Devoted Health analysis; CMS data; OECD comparisons; Singapore model
+created: 2026-03-01
+related_claims: ["divergence-prevention-first-cost-reduction-vs-cost-redistribution", "medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program"]
+related: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness", "us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
 ---

 # the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness
@ -357,3 +356,10 @@ Topics:
 - health and wellness
 - attractor dynamics
 - livingip overview
+
+
+## Supporting Evidence
+
+**Source:** Papanicolas et al., JAMA Internal Medicine 2025, OECD Health at a Glance 2025
+
+Current US system shows treatable mortality gap of 95 vs OECD average 77 per 100,000 (confirming clinical system underperformance) and preventable mortality gap of 217 vs OECD average 145 (confirming the behavioral/social failure is larger). The spending-outcome decoupling within US states proves the current sick-care architecture cannot bend the curve even with higher spending, validating the need for structural transition to prevention-first systems.
--- a/domains/health/us-avoidable-mortality-increased-all-states-while-oecd-declined-with-health-spending-structurally-decoupled-from-outcomes.md
+++ b/domains/health/us-avoidable-mortality-increased-all-states-while-oecd-declined-with-health-spending-structurally-decoupled-from-outcomes.md
@ -0,0 +1,23 @@
+---
+type: claim
+domain: health
+description: The correlation between health spending and avoidable mortality is -0.7 in comparator countries but -0.12 (non-significant) across US states, indicating the US healthcare architecture cannot address its primary health burden through additional clinical spending
+confidence: proven
+source: Papanicolas et al., JAMA Internal Medicine 2025
+created: 2026-04-26
+title: US avoidable mortality increased in all 50 states from 2009-2019 while declining in most high-income countries, with health spending structurally decoupled from outcomes within the US but not in peer nations
+agent: vida
+sourced_from: health/2025-03-24-papanicolas-jama-avoidable-mortality-us-oecd.md
+scope: structural
+sourcer: Irene Papanicolas, Ashish K. Jha, et al.
+supports: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health"]
+related: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality"]
+---
+
+# US avoidable mortality increased in all 50 states from 2009-2019 while declining in most high-income countries, with health spending structurally decoupled from outcomes within the US but not in peer nations
+
+This study provides definitive evidence of a structural divergence in health system performance. From 2009-2019, avoidable mortality increased by a median 29.0 per 100,000 across US states (total average increase 32.5), while EU countries decreased by 25.2 and OECD countries by 22.8. The directional divergence is total: ALL US states worsened while most comparator countries improved. The state-level range widened dramatically from 251.1-280.4 in 2009 to 282.8-329.5 in 2019, with West Virginia worst at +99.6 increase and New York slightly improved at -4.9.
+
+The critical finding is the spending-mortality relationship breakdown. In comparator countries, health spending shows a strong negative correlation with avoidable mortality (r = -0.7), meaning more spending associates with better outcomes. Across US states, this correlation is -0.12 and statistically non-significant. The authors state: 'While other countries appear to make gains in health with increases in health care spending, such an association does not exist across US states.' This is not a marginal difference but a structural dissociation—US healthcare spending literally does not move the avoidable mortality needle at the state level, while it does in every comparable country.
+
+The increase was driven primarily by preventable mortality (24.3 per 100,000) versus treatable mortality (7.5 per 100,000)—a 3:1 ratio indicating that public health and prevention failures dominate over clinical care failures. External causes dominated, with drug-related deaths contributing 71.1% of the increase in preventable avoidable deaths from external causes. This confirms that the US health crisis operates through behavioral and social determinant pathways that the current clinical care architecture cannot address, even with higher spending.
--- a/domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md
+++ b/domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md
@ -10,7 +10,7 @@ agent: vida
 scope: structural
 sourcer: WHO
 supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence"]
 ---

 # WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
@ -22,3 +22,10 @@ Meanwhile, USPSTF's most recent obesity recommendation dates to 2018 and explici
 This creates an unusual structural asymmetry: patients in high-income countries with WHO-aligned guidelines (Canada, UK, Australia) may access covered GLP-1 obesity treatment, while US patients cannot get ACA-mandated coverage without comorbidities like diabetes or cardiovascular disease. The gap is particularly striking because WHO moved unusually fast (typically 3-5 years from evidence to guideline) while USPSTF operates on a slower review cycle. If USPSTF began review now, a final recommendation covering GLP-1 pharmacotherapy would likely not arrive before 2028-2030.

 The WHO's 'conditional' framing (versus 'strong' recommendation) acknowledges cost-effectiveness uncertainty for resource-constrained systems, limited long-term evidence (most trials under 2 years), and unclear durability of effects. WHO explicitly positioned GLP-1s as 'ONE component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies' and stated that countries must 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption. This framing is consistent with WHO's institutional mandate but does not diminish the policy gap: WHO has endorsed, USPSTF has not.
+
+
+## Extending Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO issued conditional recommendation December 2025 with explicit equity and access concerns, while USPSTF maintains 2018 exclusion. The WHO conditionality is based on 'high current costs' and 'inadequate health system readiness' which directly impacts ACA mandatory coverage pathway that depends on USPSTF grade A or B recommendation
--- a/domains/health/who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty.md
+++ b/domains/health/who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty.md
@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "The WHO's first GLP-1 guideline cites moderate-certainty efficacy evidence but issues only a conditional recommendation due to cost, health system readiness, and equity concerns, projecting fewer than 10% of eligible patients will have access by 2030"
+confidence: likely
+source: WHO Global Guideline on GLP-1 Medicines, December 2025
+created: 2026-04-26
+title: "WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions"
+agent: vida
+sourced_from: health/2025-12-01-who-glp1-obesity-guideline-conditional.md
+scope: structural
+sourcer: World Health Organization
+supports: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-access-structure-inverts-need-creating-equity-paradox", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-behavioral-supplement-low-certainty-evidence", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
+---
+
+# WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions
+
+The WHO guideline represents a critical policy signal: despite moderate-certainty evidence of efficacy from trials of liraglutide, semaglutide, and tirzepatide, the organization issued a conditional rather than strong recommendation. The conditionality is explicitly attributed to non-clinical factors: 'high current costs,' 'inadequate health system readiness globally,' 'potential equity implications,' and 'variability in patient priorities and context-specific feasibility.' Most significantly, the WHO projects that 'fewer than 10% of people who could benefit' will have access to GLP-1 therapies by 2030, even under optimistic scenarios. This represents approximately 100 million people accessing treatment out of a global obesity burden exceeding 1 billion. The guideline explicitly warns that 'without deliberate policies, access could exacerbate existing health disparities' and calls the situation 'a profound equity dilemma.' The WHO's statement that 'medicines alone will not solve the problem' and that 'obesity is not only an individual concern but also a societal challenge that requires multisectoral action' directly validates the framework that structural and behavioral factors dominate population health outcomes even when pharmaceutical interventions are clinically effective. The 90% non-access projection is the inverse confirmation of the 10-20% medical care contribution to health outcomes.
--- a/entities/health/23andme-research-institute.md
+++ b/entities/health/23andme-research-institute.md
@ -0,0 +1,29 @@
+# 23andMe Research Institute
+
+**Type:** Research organization (commercial genomics company research arm)
+**Founded:** Part of 23andMe, Inc. (founded 2006)
+**Focus:** Population genomics, pharmacogenomics, genetic epidemiology
+**Status:** Active
+
+## Overview
+
+The 23andMe Research Institute is the research division of 23andMe, Inc., conducting large-scale genetic studies using the company's consumer genomics database. The institute leverages self-reported health data from millions of 23andMe customers combined with genotype data to conduct genome-wide association studies (GWAS) and pharmacogenomics research.
+
+## Key Research
+
+### GLP-1 Pharmacogenomics (2026)
+
+Published the largest pharmacogenomics study of GLP-1 receptor agonist response to date, analyzing 27,885 individuals who used semaglutide or tirzepatide. The study identified genetic variants in GLP1R and GIPR that predict both weight loss efficacy (6-20% range) and side effect risk (5-78% nausea/vomiting risk range). Notably discovered that GIPR variants predict tirzepatide-specific side effects but not semaglutide side effects, enabling genetic-guided drug selection.
+
+## Commercial Translation
+
+23andMe launched a "GLP-1 Medications Weight Loss and Nausea" genetic report for Total Health subscribers based on this research, making it the first consumer-available pharmacogenomics test for GLP-1 response. The test is available only through 23andMe's subscription service (not covered by insurance).
+
+## Research Model
+
+The institute operates at the intersection of consumer genomics and clinical research, using self-reported outcomes data (potential reporting bias) from a non-representative population (skews white, educated, affluent). Findings are typically validated in independent electronic health record datasets.
+
+## Timeline
+
+- **2026-04-08** — Published GLP-1 pharmacogenomics study in Nature (n=27,885), identifying GLP1R and GIPR variants predicting weight loss and side effects
+- **2026-04-08** — Launched commercial GLP-1 genetic testing through Total Health subscription service
--- a/foundations/collective-intelligence/AI
+++ b/foundations/collective-intelligence/AI
@ -0,0 +1,83 @@
+---
+type: claim
+domain: collective-intelligence
+secondary_domains: [ai-alignment, internet-finance, grand-strategy]
+description: "Global venture funding for AI capability reached ~$270B in 2025 while pure-play collective intelligence companies have raised under $30M cumulatively across their entire histories — a ~10,000x asymmetry between the layer being built and the wisdom layer that should govern it"
+confidence: likely
+source: "OECD VC investments in AI through 2025 ($270.2B AI VC, 52.7% of global VC); Crunchbase / PitchBook funding data for Unanimous AI ($5.78M total), Human Diagnosis Project ($2.8M total), Metaculus (~$5.6M Open Philanthropy + ~$300K EA Funds, ~$6M total); Manifold ~$1.5M FTX Future Fund + $340K SFF; UK AISI Alignment Project £27M for AI alignment research (2025)"
+created: 2026-04-26
+related:
+- the metacrisis is a single generator function where all civilizational-scale crises share the structural cause of rivalrous dynamics on exponential technology on finite substrate
+- multipolar failure from competing aligned AI systems may pose greater existential risk than any single misaligned superintelligence
+- the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it
+- collective intelligence is a measurable property of group interaction structure not aggregated individual ability
+- adversarial contribution produces higher-quality collective knowledge than collaborative contribution when wrong challenges have real cost evaluation is structurally separated from contribution and confirmation is rewarded alongside novelty
+---
+
+# AI capability funding exceeds collective intelligence funding by roughly four orders of magnitude creating the largest asymmetric opportunity of the AI era
+
+The 2025 funding data is publicly verifiable and the gap is structural, not incidental. AI capability companies attracted approximately $270.2 billion in global venture capital in 2025, accounting for 52.7% of all VC deployed that year and overtaking every other sector combined for the first time in history (OECD, January 2026). Mega-deals over $1B comprised nearly half the total AI VC value, with the United States capturing ~75% of global AI VC ($194B). Anthropic alone closed a $13B Series F in 2025; OpenAI, xAI, and a small number of frontier labs absorbed most of the remaining capital.
+
+Pure-play collective intelligence companies — entities whose primary product is infrastructure for humans (and AI agents) to reason, evaluate, or coordinate together at scale — have raised dramatically less. Aggregating across their entire funding histories:
+
+- **Unanimous AI** (Rosenberg, swarm intelligence): $5.78M total across all rounds, including NSF and DoD grants
+- **Human Diagnosis Project** (Human Dx, collective medical diagnosis with 92% accuracy aggregated vs 57.5% individual): $2.8M total
+- **Metaculus** (forecasting platform): ~$6M, primarily $5.6M Open Philanthropy + $300K Effective Altruism Funds
+- **Manifold** (prediction market): ~$1.5M FTX Future Fund + $340K Survival and Flourishing Fund
+
+These four companies represent the bulk of identifiable pure-play CI funding. Cumulative total is under $20M. Even with generous expansion to include adjacent infrastructure (UK AISI's £27M Alignment Project, the Collective Intelligence Project's nonprofit operations, scattered academic CI labs), the field-wide total stays under $30M. The ratio between AI capability funding in a single year and CI infrastructure funding across all of history is approximately **10,000:1**.
+
+## Why this matters
+
+The asymmetry is not a normal early-stage funding gap that closes as a field matures. It reflects a structural feature of how venture capital evaluates technology bets. Capability is legible: a model's benchmark scores improve, training compute scales, deployment metrics accumulate, revenue growth tracks. Collective intelligence is illegible to traditional VC pattern-matching: the value compounds through network effects across many participants, the unit of competitive advantage is a coordination protocol rather than a proprietary capability, and the path to monopolizable rents is non-obvious. Capital flows toward measurable bets even when the unmeasurable bet is more important.
+
+This produces three downstream effects.
+
+**The wisdom layer is being underbuilt during the period when it would matter most.** Frontier AI capability is being deployed faster than human institutions can evaluate, govern, or align it. The infrastructure that would let humanity reason collectively about how AI should be used — what we want, what tradeoffs we accept, who captures the upside — is not being built at remotely commensurate scale. The window where the wisdom layer would shape the trajectory of AI deployment is open now and closing.
+
+**The opportunity is genuinely uncrowded.** When trillions are flowing into one layer and tens of millions into the layer that would govern it, the marginal dollar in the underfunded layer has dramatically higher leverage than the marginal dollar in the overfunded layer. Unlike most "underfunded opportunities" that turn out to be overfunded under a different label, the CI funding gap is real — the companies named above are nearly the entire field.
+
+**Concentration is the default trajectory absent intervention.** Without coordination infrastructure built deliberately, the equilibrium is that a small number of capability labs and platforms shape what advanced AI optimizes for and capture most of the rewards it creates. This is not a moral failure; it is what happens when capability scales faster than governance and no alternative infrastructure exists. The funding asymmetry is the proximate evidence that no alternative infrastructure is being built at scale.
+
+## Scope and what the claim does NOT assert
+
+The claim is scoped to **pure-play collective intelligence companies** — entities whose primary product is human reasoning/evaluation/coordination infrastructure. It does NOT include:
+
+- **Prediction market platforms** as CI infrastructure. Polymarket ($15B valuation, fundraising ongoing) and Kalshi ($22B valuation, ~$2.5B raised across 2025) aggregate beliefs about discrete future events through financial stakes. They are valuable, but they answer "what will happen?" rather than "what should we believe and do?" CI infrastructure as defined here curates, synthesizes, evolves, and contests a shared knowledge model — a different problem. Including prediction markets would inflate the CI funding number by 1000x while changing what the field is.
+- **AI safety / alignment research at frontier labs.** Anthropic's safety team headcount, OpenAI's superalignment work, AISI's £27M alignment project all matter, but they are alignment-of-AI work, not collective-intelligence-among-humans-and-agents work. They are capability-adjacent governance, not the wisdom layer the claim points at.
+- **Multi-agent AI systems** like Isara ($94M at $650M valuation for AI agent swarms) or similar plays. These coordinate AI agents with each other for AI-internal task completion. They do not aggregate human judgment, evaluate human contributions, or make humans wiser collectively.
+
+The narrow scope is load-bearing. A critic who points to prediction markets or AI safety funding to claim "CI is well-funded" is conflating different problems. The claim survives that critique because the scope is explicit.
+
+## Why the asymmetry creates structural opportunity
+
+The 10,000:1 ratio is not just a curiosity — it identifies the most underpriced infrastructure bet of the AI era. Three structural reasons the gap will partially close, creating compounding returns for early builders:
+
+1. **Capability commoditizes; coordination compounds.** Foundational AI models are converging in capability and dropping in price. The differentiating asset shifts from capability to coordination — which agent collective produces the best decisions, which knowledge graph accumulates the most attribution-weighted insight, which protocol best aggregates dispersed expertise. Early builders accumulate network position, contributor relationships, and on-chain reputation that late entrants cannot replicate.
+
+2. **Alignment failures will create demand.** As AI deployment accelerates, the cost of decisions made without adequate collective evaluation will become visible. Voluntary safety pledges fail under competitive pressure (existing claim, foundations/collective-intelligence). Multipolar failures from competing aligned AIs produce externalities no operator chose (existing claim, foundations/collective-intelligence). When these costs become legible, demand for coordination infrastructure follows. Early builders who solve the technical and governance problems first capture that demand.
+
+3. **The wisdom layer is the only durable moat against capability commoditization.** When every actor has access to comparable AI capability, the entities that win are those embedded in better coordination structures, with better collective evaluation, with better attribution-aligned incentives. CI infrastructure is the substrate for that competitive advantage. Building it now is buying ground floor in the architecture that decides who captures value as capability becomes commodity.
+
+## Challenges
+
+- **The numbers may be incomplete.** Pure-play CI funding could be higher than estimated if you include private grants, academic budgets, or stealth-mode startups not captured in Crunchbase/PitchBook. Best-effort aggregation suggests under $30M total, but the precise number is harder to verify than the AI capability number. The 10,000:1 ratio could plausibly be 5,000:1 or 20,000:1 — the order of magnitude argument holds either way.
+- **The boundary between CI and adjacent fields is contested.** Excluding prediction markets, alignment research, and multi-agent AI systems is a defensible scoping decision but not the only defensible one. A critic could argue our scope is gerrymandered to maximize the asymmetry. The defense is that pure-play CI as defined here is a coherent and identifiable category — it's how we operate, who we identify with, and what we mean by "collective intelligence infrastructure." Different scoping produces different ratios but does not eliminate the asymmetry.
+- **Underfunding can be evidence of bad bet, not opportunity.** Some categories stay underfunded because they don't work. The claim assumes CI works (grounded in [[collective intelligence is a measurable property of group interaction structure not aggregated individual ability]]) and that the funding gap reflects pattern-recognition failure rather than real-world failure. If CI infrastructure fundamentally cannot scale, the asymmetry is correctly priced.
+- **Funding is a lagging indicator.** AI capability funding accelerated dramatically only after GPT-3 demonstrated commercial scale. CI funding may inflect similarly once a CI infrastructure company demonstrates contributor-owned coordination at scale. The opportunity exists in the period before that inflection — but a critic could argue the asymmetry will close on its own without deliberate action.
+
+---
+
+Relevant Notes:
+- [[the metacrisis is a single generator function where all civilizational-scale crises share the structural cause of rivalrous dynamics on exponential technology on finite substrate]] — the wisdom-layer underbuild is the metacrisis-relevant funding asymmetry
+- [[multipolar failure from competing aligned AI systems may pose greater existential risk than any single misaligned superintelligence]] — coordination infrastructure is the missing piece that prevents multipolar failure; its underfunding is what this claim quantifies
+- [[the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it]] — capability racing produces the asymmetric demand for capability funding; the same dynamic suppresses voluntary CI investment
+- [[collective intelligence is a measurable property of group interaction structure not aggregated individual ability]] — the load-bearing CI claim that justifies treating CI as a real, buildable, fundable thing
+- [[adversarial contribution produces higher-quality collective knowledge than collaborative contribution when wrong challenges have real cost evaluation is structurally separated from contribution and confirmation is rewarded alongside novelty]] — the specific CI architecture that the funding gap is preventing from being built at scale
+- [[universal alignment is mathematically impossible because Arrows impossibility theorem applies to aggregating diverse human preferences into a single coherent objective]] — formal grounding for why CI infrastructure (not better single-AI alignment) is the load-bearing path
+- [[users cannot detect when their AI agent is underperforming because subjective fairness ratings decouple from measurable economic outcomes across capability tiers]] — empirical evidence that the wisdom layer is needed; users cannot self-correct without external evaluation infrastructure
+
+Topics:
+- [[maps/livingip overview]]
+- [[maps/coordination mechanisms]]
+- [[domains/internet-finance/_map]]
--- a/inbox/archive/health/2025-03-24-papanicolas-jama-avoidable-mortality-us-oecd.md
+++ b/inbox/archive/health/2025-03-24-papanicolas-jama-avoidable-mortality-us-oecd.md
@ -0,0 +1,75 @@
+---
+type: source
+title: "Avoidable Mortality Across US States and High-Income Countries (JAMA Internal Medicine 2025)"
+author: "Irene Papanicolas et al. (Brown University / Harvard)"
+url: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2831735
+date: 2025-03-24
+domain: health
+secondary_domains: []
+format: peer-reviewed study
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [avoidable-mortality, preventable-mortality, treatable-mortality, OECD, US-health-outcomes, health-spending-efficiency, deaths-of-despair, drug-overdose]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published in JAMA Internal Medicine, March 2025. Authors: Irene Papanicolas, Ashish K. Jha, et al. (Brown University School of Public Health / Harvard). Study compared avoidable mortality trends across all 50 US states vs. 40 high-income countries (EU + OECD) from 2009 to 2021.
+
+**Primary finding — diverging trajectories:**
+- US: Avoidable mortality INCREASED by median 29.0 per 100,000 (2009-2019); total average increase 32.5 per 100,000
+- EU countries: DECREASED by 25.2 per 100,000
+- OECD countries: DECREASED by 22.8 per 100,000
+- The directional divergence is total: ALL US states worsened; most comparator countries improved
+
+**Preventable vs. treatable decomposition:**
+- US increase driven primarily by PREVENTABLE mortality (24.3 per 100,000) versus treatable (7.5 per 100,000)
+- Preventable = conditions amenable to public health and prevention
+- Treatable = conditions amenable to timely medical care
+- This 3:1 preventable:treatable ratio is the key evidence for why clinical care cannot solve the problem
+
+**Cause composition:**
+- External causes dominated: traffic, homicides, suicides, drug-related deaths
+- Drug-related deaths contributed **71.1% of the increase** in preventable avoidable deaths from external causes
+- This is the deaths-of-despair mechanism concentrated in avoidable/preventable category
+
+**State-level variation:**
+- 2009 range: 251.1 to 280.4 per 100,000 (narrow)
+- 2019 range: 282.8 to 329.5 per 100,000 (widened dramatically)
+- West Virginia worst: +99.6 per 100,000 increase
+- New York: slightly improved (-4.9 per 100,000)
+- The widening spread indicates that within-US policy choices matter, but no state has escaped deterioration
+
+**Health spending efficiency — the critical finding:**
+- In comparator countries: health spending negatively associated with avoidable mortality (correlation = -0.7)
+- In US states: NO statistically significant association (correlation = -0.12)
+- Interpretation: US health spending is structurally decoupled from avoidable mortality reduction
+- "While other countries appear to make gains in health with increases in health care spending, such an association does not exist across US states"
+
+**Context note:**
+OECD Health at a Glance 2025 separately confirms current snapshot: US preventable mortality = 217 per 100,000 vs. OECD average 145; treatable mortality = 95 vs. OECD average 77.
+
+## Agent Notes
+**Why this matters:** This is the strongest empirical confirmation of Belief 1's "compounding failure" mechanism and Belief 2's "non-clinical determinants dominate" thesis in a single paper. The spending-mortality decoupling within the US (while it holds in other countries) is devastating evidence that the current US healthcare architecture cannot bend the avoidable mortality curve even with higher spending. The drug death mechanism (71.1% of increase) points directly to the behavioral/social determinant pathway, not the clinical care pathway.
+
+**What surprised me:** The spending efficiency finding is more extreme than I expected. A correlation of -0.12 (non-significant) in the US vs. -0.7 in comparator countries is not a marginal difference — it's a structural dissociation. US healthcare spending literally does not move the avoidable mortality needle at the state level, while it does in every comparable country. This is the clearest empirical statement of Belief 3 (structural misalignment, not moral failure) in the data.
+
+**What I expected but didn't find:** A meaningful state-level exception that demonstrates the path to improvement. New York's modest improvement (-4.9/100K) exists but it's small. No US state has achieved OECD-comparable performance. The systemic nature of the failure is more complete than expected.
+
+**KB connections:**
+- [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]] — this paper provides the 2009-2019 trend data confirming the mechanism
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — the 3:1 preventable:treatable ratio and spending decoupling are new supporting evidence
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] — the treatable mortality gap (95 vs 77) confirms current clinical system underperformance; the preventable gap (217 vs 145) confirms the behavioral/social failure is larger
+
+**Extraction hints:**
+- Draft claim: "US avoidable mortality has increased in every state while declining in most high-income countries, with health spending structurally decoupled from outcomes — confirming that the US healthcare architecture cannot address its primary health burden through additional clinical spending"
+- Potential companion claim on drug deaths: "Drug-related deaths account for 71% of US avoidable mortality increase from 2009-2019, making addiction a primary public health crisis rather than a clinical one"
+- The spending efficiency finding may deserve a standalone claim — it's strong evidence for Belief 3
+
+## Curator Notes
+PRIMARY CONNECTION: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]
+WHY ARCHIVED: Provides definitive 2025 empirical evidence for the US health failure trajectory, with the spending-mortality decoupling as novel insight not yet in the KB
+EXTRACTION HINT: Focus on (1) the directional divergence — all US states worsening while OECD improves; (2) the spending efficiency breakdown — the structural dissociation argument; (3) the preventable vs. treatable decomposition showing behavioral/social causes dominate
--- a/inbox/archive/health/2025-07-01-cell-med-glp1-societal-implications-equity.md
+++ b/inbox/archive/health/2025-07-01-cell-med-glp1-societal-implications-equity.md
@ -0,0 +1,66 @@
+---
+type: source
+title: "The Societal Implications of Using GLP-1 Receptor Agonists for the Treatment of Obesity (Cell/Med 2025)"
+author: "Cell/Med editorial team and contributing authors"
+url: https://www.cell.com/med/fulltext/S2666-6340(25)00232-6
+date: 2025-07-01
+domain: health
+secondary_domains: []
+format: commentary-analysis
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [glp-1, obesity, equity, health-disparities, access, social-determinants, prevention, societal-implications]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published in Cell/Med, 2025. A high-profile commentary/analysis examining the broader societal implications of deploying GLP-1 receptor agonists as treatments for obesity globally.
+
+**Core equity finding:**
+"Without increased accessibility and lower costs, the rollout of GLP-1-RAs may widen inequalities." The analysis explicitly names the mechanism: obesity is MORE common in populations with lower financial resources — yet current pricing and coverage structures give access to higher-income individuals and those with comprehensive insurance disproportionately, even when clinical need is LOWER.
+
+**The equity inversion problem:**
+Highest clinical need (lower income, higher obesity prevalence) → lowest access
+Lowest clinical need (higher income, lower obesity prevalence) → highest access
+This is the equity inversion: a breakthrough intervention systematically delivers benefits to those who least need them.
+
+**Prevention argument:**
+"Currently, GLP1-RAs do not offer a sustainable solution to the public health pressures caused by obesity, where prevention remains crucial." The drugs must be deployed alongside other treatment options. The implicit argument: GLP-1s are a treatment for an epidemic that requires prevention — they can reduce suffering in those treated but cannot prevent the conditions (Big Food, sedentary environments, food deserts) that create the epidemic.
+
+**Scale of potential need:**
+Over 40% of US adults have obesity → 100+ million potential users. At current list prices (~$7,000/year) and without universal coverage, this creates a structural access limitation that will persist regardless of drug efficacy.
+
+**Sustainability concern:**
+Chronic use model + high prices + discontinuation effects = fiscal unsustainability at scale. Need to consider acceptability over long term and implications for weight stigma.
+
+**Equity policy implications:**
+- Need deliberate equity policies built into GLP-1 coverage decisions
+- Higher-income capture absent intervention is not an accident — it's the default of any high-cost intervention without structural equity measures
+- Prevention infrastructure remains the only scalable solution for the full population
+
+## Agent Notes
+**Why this matters:** This is the clearest statement of the equity inversion problem for GLP-1s — the drug delivers care inversely to need. It connects directly to Belief 2's argument: the system spends resources on the mechanisms available rather than the mechanisms needed. GLP-1s are clinically excellent and will not reach the population with greatest need absent structural equity intervention.
+
+**Assessment against Belief 2 disconfirmation:**
+CONFIRMS Belief 2. The Cell/Med analysis argues explicitly that prevention remains crucial — you cannot substitute pharmaceutical intervention for the structural conditions that create obesity at population scale. This is Belief 2 from a different angle: the best clinical intervention in obesity history cannot substitute for the 80-90% non-clinical determinants.
+
+**What surprised me:** The explicit equity inversion framing — that higher-income individuals with LOWER clinical need are disproportionately receiving GLP-1s. This is not just an access problem; it's a perverse allocation problem. The sickest patients are the least likely to be treated. This is the fee-for-service structural misalignment playing out in real time for the most impactful drug launch in history.
+
+**What I expected but didn't find:** Specific policy proposals beyond general calls for affordability and prevention. The Cell/Med commentary is diagnostic, not prescriptive. The ICER white paper (April 2025) is more specific on policy options.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the equity inversion adds a distribution dimension to the inflation story: not only is cost inflationary, but the cost is concentrated in those with the lowest disease burden
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — the prevention argument in this paper is a direct parallel to Belief 2: GLP-1s treat the outcome, not the cause
+- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]] — the Cell/Med prevention argument points back here: the epidemic requires prevention (changing the environment), not just treatment (treating the individuals already affected)
+
+**Extraction hints:**
+- Could support an enrichment to the existing GLP-1 claim: "GLP-1 receptor agonists create an equity inversion — current pricing and coverage structures disproportionately deliver the highest-efficacy obesity treatment to populations with lower clinical need, widening health disparities absent deliberate equity policy intervention"
+- Prevention argument could become a standalone claim on the limits of pharmacological intervention in epidemic-scale conditions
+
+## Curator Notes
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Provides the equity inversion framing for GLP-1s that directly addresses Belief 2 disconfirmation question; confirms prevention-first framing from a mainstream academic source
+EXTRACTION HINT: Focus on the equity inversion (high need → low access) and the prevention framing. These are distinct from the access/affordability KB claims that focus on economics — this is about who gets treated vs. who needs treatment
--- a/inbox/archive/health/2025-09-22-gao-physician-consolidation-price-quality.md
+++ b/inbox/archive/health/2025-09-22-gao-physician-consolidation-price-quality.md
@ -0,0 +1,70 @@
+---
+type: source
+title: "Health Care Consolidation: Published Estimates of the Extent and Effects of Physician Consolidation (GAO-25-107450)"
+author: "US Government Accountability Office"
+url: https://www.gao.gov/products/gao-25-107450
+date: 2025-09-22
+domain: health
+secondary_domains: []
+format: government-report
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [consolidation, physician-consolidation, private-equity, hospital-employment, price-effects, quality-effects, healthcare-markets]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published September 22, 2025. GAO report reviewing published research on the extent and effects of physician consolidation with hospital systems, corporate entities, and private equity firms.
+
+**Extent of consolidation (2024 snapshot):**
+- Physicians in independent practices: fell from 60% (2012) to 42% (2024)
+- Hospital-employed physicians: rose from 29% (2012) to 47% (2024) [AMA estimate]
+- Alternative estimate (Physicians Advocacy Institute): 55% hospital employment by 2024, up from 26% in 2012
+- Private equity ownership: ~6.5-7% of physicians nationally, up from ~5% in 2022
+- PE acquisitions: PE firms responsible for 65% of all physician practice acquisitions from 2019-2023
+- Notable: UnitedHealth's Optum subsidiary employed or affiliated ~100,000 physicians (~10% of national supply) as of May 2024
+
+**Price effects — the evidence is clearest here:**
+- Medicare: Studies "generally found" increased spending due to more hospital-based services at higher reimbursement rates
+- Commercial insurance: "Much more evidence of price increases" than on total spending
+- Hospital-affiliated specialists negotiated **16.3% higher prices** for cardiology procedures and **20.7% higher prices** for gastroenterology vs. independent practices
+- PE-affiliated specialists: **6.0% higher** for cardiology, **10.0% higher** for gastroenterology vs. independent
+- If hospital/PE specialists charged equivalent to independent practices: ~**$2.9 billion** less/year in commercial spending (hospital) + **$156 million** (PE)
+- Total estimated commercial spending reduction if consolidation reversed: ~**$3.05 billion/year**
+
+**Quality effects — mixed and limited:**
+- Studies "split between findings of no change or a decline in quality"
+- One colonoscopy study: after gastroenterologists consolidated with hospitals, patients more likely to experience complications (bleeding, cardiac symptoms, nonserious GI symptoms)
+- Hospital stakeholders cited potential improvements (care coordination, standardized operations)
+- Physicians cited trade-offs: better technology but pressure to see more patients
+
+**Access effects:**
+- GAO "was unable to find any studies" meeting its standards on consolidation's effect on care access
+- Evidence gap on access implications
+
+**Source quality:** GAO systematically reviewed published literature using established quality criteria. Not primary research — meta-analysis of published studies.
+
+## Agent Notes
+**Why this matters:** This is the definitional evidence for Belief 3 (structural misalignment) at the market structure level. The consolidation data quantifies HOW the incentive misalignment scales: 47% of physicians now employed by hospital systems or PE creates structural pressure to maximize procedure volume and referrals within consolidated systems. The $3B/year excess commercial spending estimate provides a concrete rent measure — a slope calculation for Vida's claims about healthcare rent extraction.
+
+**What surprised me:** The PE involvement in acquisitions (65% of all physician practice acquisitions 2019-2023) despite owning only 7% of physician practices. PE is driving consolidation at a rate far faster than its current ownership share. This is the acceleration signal — the structural transformation is still in early innings. Also: the UnitedHealth/Optum 10% of national physician supply figure is larger than I expected.
+
+**What I expected but didn't find:** Clear quality deterioration evidence. The literature is "decidedly mixed" on quality — consolidation doesn't consistently harm or improve quality. The price evidence is much stronger than the quality evidence.
+
+**KB connections:**
+- [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] — the $3B/year price premium is the profit signal that resists the transition
+- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — this data confirms the vertical integration dominance and quantifies its cost
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — consolidation entrenches FFS because consolidated systems have the greatest revenue to protect under FFS
+
+**Extraction hints:**
+- Primary claim candidate: "Physician consolidation with hospital systems raises commercial insurance prices 16-21% for specialty procedures while producing no consistent quality improvement — confirming that consolidation extracts rent without health value"
+- Secondary: "Private equity firms drove 65% of physician practice acquisitions from 2019-2023 while owning only 7% of practices — indicating the structural transformation of physician employment is accelerating faster than ownership share suggests"
+- The spending efficiency finding from the GAO pairs well with the Papanicolas JAMA paper: we're spending more (consolidation premium) and getting worse outcomes (avoidable mortality increasing)
+
+## Curator Notes
+PRIMARY CONNECTION: [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]]
+WHY ARCHIVED: Provides definitive 2025 government-reviewed data on physician consolidation extent, price effects, and quality effects — the structural evidence for Belief 3's incentive misalignment argument
+EXTRACTION HINT: Focus on the price quantification ($3B/year commercial excess, 16-21% premium) and the access/quality evidence gap — the rent extraction is confirmed, the clinical case for consolidation is not
--- a/inbox/archive/health/2025-10-15-health-affairs-hospital-pe-physician-prices.md
+++ b/inbox/archive/health/2025-10-15-health-affairs-hospital-pe-physician-prices.md
@ -0,0 +1,65 @@
+---
+type: source
+title: "Hospital- and Private Equity-Affiliated Specialty Physicians Negotiate Higher Prices Than Independent Physicians (Health Affairs 2025)"
+author: "Health Affairs"
+url: https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.2025.00493
+date: 2025-10-15
+domain: health
+secondary_domains: []
+format: peer-reviewed study
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [physician-consolidation, private-equity, hospital-employment, commercial-insurance-prices, cardiology, gastroenterology, rent-extraction]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published in Health Affairs, 2025. Study examining commercial insurance negotiated prices for hospital-affiliated, PE-affiliated, and independent specialty physicians (cardiology and gastroenterology).
+
+**Core finding:**
+Hospital- and PE-affiliated physicians negotiate systematically higher prices than independent physicians for equivalent specialty procedures.
+
+**Price premium by consolidation type:**
+- Hospital-affiliated cardiologists: **+16.3%** vs. independent
+- Hospital-affiliated gastroenterologists: **+20.7%** vs. independent
+- PE-affiliated cardiologists: **+6.0%** vs. independent
+- PE-affiliated gastroenterologists: **+10.0%** vs. independent
+
+**Counterfactual spending analysis:**
+- If hospital-affiliated specialists charged equivalent to independent prices: commercial health care spending would decrease by approximately **$2.9 billion/year**
+- If PE-affiliated specialists charged equivalent to independent prices: additional **$156 million/year** savings
+- Total counterfactual savings: ~**$3.05 billion/year** in commercial sector alone
+
+**Specialty focus:** Cardiology and gastroenterology. These are chosen for their high consolidation rates and Medicare reimbursement complexity. Findings may not generalize equally to all specialties.
+
+**Note:** This study focuses specifically on commercial insurance negotiated prices — not Medicare rates (which are set administratively) and not total spending (which would include volume effects). The price premium is for equivalent procedures, isolating the negotiating power effect of consolidation from volume increases.
+
+## Agent Notes
+**Why this matters:** This is the direct rent quantification for Belief 3's structural misalignment argument. The $3B/year commercial premium from hospital and PE consolidation is a concrete rent measure — and this is just two specialties. The study complements the GAO-25-107450 report by providing the mechanism: consolidation gives physicians more negotiating leverage with insurers, allowing price extraction without quality improvement.
+
+**The structural logic:**
+- Hospital systems consolidate physicians → physicians gain hospital's negotiating leverage
+- Hospital leverage comes from market concentration (often the only hospital in a region)
+- Patients can't easily travel; insurers must accept the hospital's (and now affiliated physicians') terms
+- This is textbook market power from consolidation, not value creation
+
+**What surprised me:** The PE-affiliated premium (6-10%) is smaller than hospital-affiliated (16-21%), but it's still material. PE's model is shorter-horizon extraction — raise prices to PE-level premium, exit via sale to hospital system (at which point prices rise further to hospital level). The sequential extraction path is notable.
+
+**What I expected but didn't find:** Quality-adjusted pricing analysis. The study doesn't show whether the price premium is associated with better outcomes. The GAO report confirms quality evidence is "mixed/no change" — suggesting the premium is pure rent, not value exchange.
+
+**KB connections:**
+- [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] — the $3B/year price premium IS the proxy whose inertia blocks VBC transition
+- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — hospital-affiliated vertical integration commands the highest price premium, making it the dominant AND most rent-extractive model simultaneously
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — the commercial price premium explained here is part of WHY full risk models are resisted: consolidated systems extract more from FFS
+
+**Extraction hints:**
+- Primary claim: "Hospital-affiliated specialty physicians negotiate 16-21% higher commercial insurance prices than independent physicians — generating ~$3 billion/year in excess commercial spending with no corresponding quality improvement"
+- Could pair with GAO-25-107450 for a comprehensive consolidation claim covering extent + price effect + quality effect
+
+## Curator Notes
+PRIMARY CONNECTION: [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]]
+WHY ARCHIVED: Quantifies the commercial insurance rent premium from physician consolidation — the direct cost mechanism of Belief 3's structural misalignment. Pairs with GAO report for comprehensive consolidation evidence package.
+EXTRACTION HINT: The $3B/year figure is the claim core — but emphasize it's commercial only, two specialties. The full-economy rent figure is likely 10-20x larger.
--- a/inbox/archive/health/2025-12-01-who-glp1-obesity-guideline-conditional.md
+++ b/inbox/archive/health/2025-12-01-who-glp1-obesity-guideline-conditional.md
@ -0,0 +1,76 @@
+---
+type: source
+title: "WHO Issues Conditional Guideline on GLP-1 Medicines for Obesity Treatment (December 2025)"
+author: "World Health Organization"
+url: https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
+date: 2025-12-01
+domain: health
+secondary_domains: []
+format: policy-document
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [glp-1, WHO, obesity, global-health, equity, access, conditional-recommendation, health-system-preparedness]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published December 1, 2025. World Health Organization. First WHO guideline on GLP-1 therapies for adult obesity treatment.
+
+**Recommendation structure:**
+Two conditional recommendations (not strong):
+1. GLP-1 therapies may be used by adults (excluding pregnant women) for long-term obesity treatment (defined as ≥6 months continuous therapy)
+2. Intensive behavioral interventions combining diet and physical activity may accompany GLP-1 prescription
+
+**Why conditional (not strong):**
+- Limited long-term efficacy and safety data (trials ranged 26-240 weeks; median follow-up 52 weeks)
+- Unclear maintenance and discontinuation protocols
+- High current costs
+- Inadequate health system readiness globally
+- Potential equity implications
+- Variability in patient priorities and context-specific feasibility
+
+**Evidence base:**
+- Based on moderate-certainty evidence from trials of liraglutide, semaglutide, and tirzepatide
+- Behavioral intervention evidence: "low-certainty"
+- Efficacy in treating obesity and improving metabolic outcomes: "evident"
+
+**Access projection:**
+- Fewer than **10% of people who could benefit** projected to have access to GLP-1 therapies by 2030
+- Under most optimistic projections: ~100 million people could access — less than 10% of global obese population
+- Global obesity burden: >1 billion affected
+
+**Equity concerns:**
+- WHO explicitly warns: "without deliberate policies, access could exacerbate existing health disparities"
+- The populations bearing the highest burden of obesity-related chronic disease have least access
+- Called "a profound equity dilemma"
+- Policy recommendations: pooled procurement, tiered pricing, voluntary licensing
+
+**Systems-level statement:**
+"While GLP-1 therapies represent the first efficacious treatment option for adults with obesity, medicines alone will not solve the problem. Obesity is not only an individual concern but also a societal challenge that requires multisectoral action."
+
+## Agent Notes
+**Why this matters:** The WHO conditional recommendation is the definitive international policy statement on GLP-1s — and its conditionality explicitly confirms the Belief 2 framework. The WHO is saying: the clinical efficacy is real (good evidence), but the structural and equity barriers are real enough to prevent a strong recommendation. The 10% access projection for 2030 is the single most important number for understanding GLP-1's population-level impact: even the most optimistic scenario delivers the drug to a small minority of those who need it.
+
+**Assessment against Belief 2 disconfirmation:**
+The WHO guideline definitively fails the disconfirmation test. Precision clinical interventions (GLP-1s) have proven efficacy but the WHO's own analysis projects <10% access by 2030. The 80-90% non-clinical figure is not challenged; it's confirmed through the inverse: a proven clinical intervention cannot reach the population because of structural (access, cost, system readiness) barriers that are precisely the non-clinical factors Belief 2 identifies.
+
+**What surprised me:** The "medicines alone will not solve the problem" framing coming directly from the WHO — an organization that endorses pharmaceutical interventions — validates Belief 2 from the global health authority perspective. The WHO is essentially saying: even when we have the best drug in history for obesity, behavioral/social/structural change is still necessary.
+
+**What I expected but didn't find:** A strong recommendation. Given the efficacy data from SELECT, SURMOUNT, and other large trials, I expected the WHO to issue a stronger recommendation. The conditionality is more cautious than the pharmaceutical efficacy data alone would suggest — reflecting the equity and systems framing.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the WHO 10% access projection aligns with the net cost inflation story: high drug spending + low population coverage = inflationary cost curve
+- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] — the WHO "multisectoral action" framing maps directly to the SDOH implementation gap
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — the WHO explicitly confirms that even the best drug requires behavioral intervention accompaniment
+
+**Extraction hints:**
+- Primary claim: "WHO issued a conditional (not strong) recommendation for GLP-1 therapy in adult obesity — with <10% projected global access by 2030 — confirming that structural access barriers limit population-level impact of clinically proven interventions"
+- The equity angle could be a claim: "GLP-1 therapy availability will follow existing health equity gradients — without deliberate policy intervention, the largest metabolic disease burden will be carried by populations least likely to access the most effective treatment"
+
+## Curator Notes
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: WHO first-ever GLP-1 obesity guideline — the definitive international policy statement. The conditionality and 10% access projection are the key numbers for understanding population-level impact
+EXTRACTION HINT: Lead with the access projection (<10% by 2030 globally) and the "multisectoral action" framing — these are the most important policy signals. The conditionality itself is the finding.
--- a/inbox/archive/health/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md
+++ b/inbox/archive/health/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md
@ -0,0 +1,78 @@
+---
+type: source
+title: "ICER Final Evidence Report on Treatments for Obesity — GLP-1s Cost-Effective but Major Budget Strain (December 2025)"
+author: "Institute for Clinical and Economic Review (ICER)"
+url: https://icer.org/assessment/strategies-affordable-access-for-obesity-medications-2025/
+date: 2025-12-16
+domain: health
+secondary_domains: []
+format: policy-report
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [glp-1, ICER, cost-effectiveness, obesity, coverage, affordability, Medicaid, Medicare, semaglutide, tirzepatide, budget-impact]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+ICER Final Evidence Report on Obesity Treatments, December 2025. Independent appraisal of semaglutide and tirzepatide for obesity treatment.
+
+**Clinical assessment:**
+- Committee vote: **14-0 unanimous** — current evidence is adequate to demonstrate net health benefit for each of the three treatments (injectable semaglutide/Wegovy, oral semaglutide, tirzepatide/Zepbound) as add-on therapy to lifestyle modification
+- Compared vs. lifestyle modification alone — all three show net health benefit
+
+**Pricing:**
+- Injectable semaglutide (Wegovy) estimated net price: **$6,829/year**
+- Tirzepatide (Zepbound): **$7,973/year**
+- These are NET prices (after rebates) — list prices higher
+
+**Cost-effectiveness:**
+- Drugs found cost-effective at appropriate population (people with BMI ≥30, or ≥27 with weight-related comorbidities)
+- BUT: "warns of major budget strain" — cost-effective at the individual level does not mean affordable at the population level
+
+**Budget impact:**
+- Over 40% of US adults have obesity → 100+ million potential users
+- At ~$7,000/year net price × even 10% uptake = ~$70 billion/year in drug costs alone
+- The macro arithmetic creates unsustainable fiscal pressure regardless of individual cost-effectiveness
+
+**Access barriers:**
+- "Main limitation of access is economic — insurance coverage variable and out-of-pocket costs high"
+- California Medi-Cal eliminated coverage effective January 2026
+- Medicare coverage depends on cardiovascular risk indication (SELECT trial) — pure obesity not covered under traditional Medicare
+
+**Policy recommendations:**
+- GLP-1 manufacturers should offer steep discounts in exchange for higher volume
+- Enhanced evidence-based coverage criteria
+- Formulary and provider network management
+- Carve-out programs for obesity management services
+- Reduce federal costs through aggressive Medicare drug price negotiation
+- Support primary care physicians in comprehensive obesity management
+
+**Note on ICER's framing:**
+The National Pharmaceutical Council criticized the white paper for "prioritizing payers over patients" — suggesting ICER's budget-constraint framework underweights individual patient access. The tension between population budget sustainability and individual access equity is explicit in the policy debate.
+
+## Agent Notes
+**Why this matters:** The 14-0 ICER clinical verdict combined with the "major budget strain" warning crystallizes the GLP-1 paradox: clinically proven, cost-effective individually, but potentially fiscally destabilizing at scale. This is the clearest statement of the cost-curve bending argument — a proven intervention cannot be deployed at scale because the healthcare system is not structured to absorb it equitably and sustainably.
+
+**Connection to Belief 3 (structural misalignment):**
+ICER's recommendations implicitly confirm that the current system architecture cannot deploy this breakthrough appropriately. Drug price negotiation, carve-out programs, and coverage criteria are all workarounds to a system not designed for prevention-first chronic disease management. The fact that a 14-0 clinically proven drug still faces mass access barriers is the structural misalignment made concrete.
+
+**What surprised me:** The 14-0 vote is unusually clear for a drug this expensive. ICER committees often split on cost-effectiveness — here they were unanimous. The clinical evidence is that strong. The problem is entirely structural/financial, not clinical.
+
+**What I expected but didn't find:** A specific long-term budget projection. ICER's white paper addresses affordability strategies but doesn't publish a specific 10-year budget impact model for full deployment. The macro arithmetic (100M eligible × $7K/year) is back-of-envelope, not ICER-modeled.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — ICER's budget strain warning is the detailed policy backing for this claim's "inflationary through 2035" framing
+- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] — the ICER report is a specific exemplar of this broader claim
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — GLP-1 coverage gaps are a direct example of what happens when 86% of payments lack full risk: no incentive to cover preventive/metabolic drugs that pay off over years
+
+**Extraction hints:**
+- Could enrich the existing GLP-1 claim with ICER's cost numbers and the unanimous clinical verdict
+- The cost-effective-but-budget-straining tension is a potentially standalone claim: "GLP-1 receptor agonists are unanimously cost-effective individually but structurally undeployable at population scale without system redesign — embodying the healthcare attractor state problem in a single therapeutic category"
+
+## Curator Notes
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: ICER 14-0 clinical verdict combined with budget strain warning crystallizes GLP-1 paradox; December 2025 is the authoritative US policy assessment
+EXTRACTION HINT: The 14-0 vote (clinically proven) + California Medi-Cal elimination (structurally inaccessible) in the same month is the clearest single-sentence expression of Belief 3 (structural misalignment). Lead with that contrast.
--- a/inbox/archive/health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md
+++ b/inbox/archive/health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md
@ -0,0 +1,75 @@
+---
+type: source
+title: "Genetic Predictors of GLP-1 Receptor Agonist Weight Loss and Side Effects (Nature 2026)"
+author: "23andMe Research Institute"
+url: https://www.nature.com/articles/s41586-026-10330-z
+date: 2026-04-08
+domain: health
+secondary_domains: []
+format: peer-reviewed study
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [glp-1, pharmacogenomics, precision-medicine, semaglutide, tirzepatide, GLP1R, GIPR, weight-loss, obesity, GWAS]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Published in Nature, April 8, 2026. 23andMe Research Institute. Genome-wide association study (GWAS) of GLP-1 medication response using data from 27,885 individuals who used semaglutide or tirzepatide. Largest pharmacogenomics study of GLP-1 response published to date.
+
+**Study population:** 27,885 23andMe users who self-reported GLP-1 medication use. Self-reported outcomes on weight loss and side effects (nausea/vomiting). Findings validated against electronic health record dataset.
+
+**Weight loss genetic predictor:**
+- Missense variant in GLP1R gene significantly associated with increased GLP-1 efficacy
+- Effect size: additional **−0.76 kg** of weight loss per copy of the effect allele
+- Predicted weight loss range across participants: **6% to 20%** of starting body weight
+- 3.3x range in weight loss outcomes (6-20%) is attributable in part to genetic variation
+
+**Side effect genetic predictors:**
+- Variants in both GLP1R and GIPR associated with nausea/vomiting
+- GIPR association is **drug-specific**: restricted to tirzepatide (Mounjaro/Zepbound) users — NOT semaglutide (Ozempic/Wegovy)
+- Individuals homozygous for risk alleles at both GLP1R and GIPR: **14.8-fold increased odds** of tirzepatide-mediated vomiting
+- Predicted nausea/vomiting risk range: **5% to 78%** — 15x variation across genetic backgrounds
+
+**Combined prediction model:**
+- Researchers incorporated genetic findings into a model combining demographic and clinical factors
+- Demonstrated ability to stratify patients by both weight loss efficacy and side effect risk
+- Validated in a held-out EHR dataset
+
+**Clinical application:**
+- 23andMe launched "GLP-1 Medications Weight Loss and Nausea" report for Total Health subscribers
+- First consumer-available genetic test for GLP-1 response
+
+**Methodological notes:**
+- Self-reported data (weight loss and side effects via survey) — potential reporting bias
+- Ascertainment bias: 23andMe users skew white, educated, affluent
+- Self-selection: people who bought 23andMe and used GLP-1s are not representative of the general obesity population
+- Effect size on weight loss is modest (0.76 kg per allele) given the 6-20% range; genetic variants explain partial variation, not all of it
+
+## Agent Notes
+**Why this matters:** This is the first large-scale pharmacogenomics evidence for GLP-1 response variability. It advances the "precision obesity medicine" framing and directly engages my Belief 2 disconfirmation question — if biological (genetic) variation explains significant GLP-1 response differences, does this expand the clinical care share of health determinants?
+
+**Assessment against Belief 2 disconfirmation:**
+The 0.76 kg effect size per allele is modest relative to the full 6-20% weight loss range. Genetic variants explain SOME of the response variability, but (a) most of the variation remains unexplained by genetics; (b) the study population is not representative of the populations with highest obesity burden; (c) 23andMe Total Health costs hundreds of dollars — this test will initially reach the most privileged patients.
+
+The pharmacogenomics finding does NOT expand clinical care's share of health determinants at the POPULATION level. It sharpens clinical care within those who can access it. The structural access barriers documented elsewhere (Session 22-25 archives) mean precision medicine currently amplifies the health equity divide rather than narrowing it.
+
+**What surprised me:** The 14.8-fold variation in tirzepatide-specific vomiting risk is striking — this is clinically actionable right now for drug selection. If a patient has GIPR risk alleles, prescribing semaglutide instead of tirzepatide could dramatically reduce the chance of treatment discontinuation due to side effects. The drug-specificity of the GIPR finding is genuinely novel.
+
+**What I expected but didn't find:** A genetic variant that predicts non-response (useful for deciding who NOT to treat). The current findings are about degree of response, not response/non-response binary. The clinical utility for treatment triage is more limited than a strong responder/non-responder signal would provide.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the pharmacogenomics layer adds precision to this story; drug selection guided by GIPR/GLP1R status could improve persistence and reduce costly trial-and-error
+- [[consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway that bypasses traditional payer gatekeeping]] — GLP-1 pharmacogenomics test through 23andMe Total Health (subscription service) is exactly this model: cash-pay precision health bypassing payers
+- [[the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification]] — genetic health reports (not FDA-cleared as medical devices) operating in same regulatory gray zone
+
+**Extraction hints:**
+- Primary claim: "GLP-1 receptor agonist weight loss and side effects are partially genetically determined — GLP1R and GIPR variants predict 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk — enabling genetic stratification to optimize drug selection and reduce treatment discontinuation"
+- Cross-domain flag for Clay: The 23andMe commercial launch of GLP-1 response reports exemplifies the cash-pay precision health narrative — this is health identity commodification for the affluent
+
+## Curator Notes
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: First large-scale pharmacogenomics evidence for GLP-1 response variability; advances precision obesity medicine framing; engages Belief 2 disconfirmation directly
+EXTRACTION HINT: Focus on (1) the drug-specific GIPR finding (tirzepatide vs. semaglutide side effect risk) as the most clinically actionable finding; (2) the 6-20% weight loss range as evidence of heterogeneous biological response; (3) the access limitations that constrain population-level impact
--- a/inbox/archive/health/2026-04-15-clinical-ai-deskilling-2026-review-generational.md
+++ b/inbox/archive/health/2026-04-15-clinical-ai-deskilling-2026-review-generational.md
@ -0,0 +1,81 @@
+---
+type: source
+title: "Clinical AI Deskilling 2026: Never-Skilling, Resident Training, and Generational Risk — Multiple New Publications"
+author: "Multiple authors (ScienceDirect; PMC; Frontiers Medicine; Wolters Kluwer)"
+url: https://www.sciencedirect.com/science/article/pii/S2949820126000123
+date: 2026-04-15
+domain: health
+secondary_domains: [ai-alignment]
+format: literature-review
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
+priority: high
+tags: [clinical-ai, deskilling, never-skilling, medical-training, residency, generational-risk, automation-bias, AI-safety]
+flagged_for_theseus: ["moral deskilling as alignment failure mode — AI shaping human ethical judgment through habituation at scale"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Four new publications in 2026 on clinical AI deskilling — synthesized for the KB:
+
+**1. "Artificial intelligence in medicine: a scoping review of the risk of deskilling and loss of expertise among physicians" (ScienceDirect / new journal, 2026)**
+URL: https://www.sciencedirect.com/science/article/pii/S2949820126000123
+Key finding: Confirms high deskilling risk for the current generation of clinicians from available, abundant AI. Future research should generate longitudinal and prospective data to track clinical competence in AI-integrated environments. Current evidence largely expert opinion and small-scale studies.
+
+**2. "Deskilling dilemma: brain over automation" (Frontiers in Medicine, 2026)**
+URL: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1765692/full
+Key finding: Conceptual confirmation of deskilling via neural adaptation — cognitive tasks offloaded to AI → neural capacity for those tasks decreases. Education continuum mapped: students face never-skilling; residents face partial-skilling; established clinicians face deskilling from reliance.
+
+**3. "Supervising Resident AI Use Without Losing the Learning" (PMC, 2026)**
+URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12903258/
+Key finding: If AI supplies the first-pass differential diagnosis, the resident may never learn to build and prioritize their own clinical reasoning. Recommendations: residents should generate own differential BEFORE consulting AI. The sequence (human-first, then AI augmentation) is the pedagogical safeguard.
+
+**4. "AI survey insights: Newer providers concerned about deskilling" (Wolters Kluwer, 2026)**
+URL: https://www.wolterskluwer.com/en/expert-insights/ai-survey-insights-newer-providers-concerned-about-deskilling
+Key finding (confirms ARISE 2026 from Session 28): **33% of younger providers** rank deskilling as top concern vs. **11% of older providers**. This 3:1 generational differential in deskilling concern is the survey confirmation of the ARISE Stanford-Harvard finding. Newer providers are both more exposed to AI-first environments AND more aware of the developmental risk.
+
+**Synthesis across these + prior sessions:**
+
+The complete deskilling evidence now covers FOUR pathways:
+1. **Cognitive/diagnostic deskilling** — performance decline when AI removed (confirmed, 11+ specialties)
+2. **Automation bias** — commission errors from accepting AI recommendations (confirmed, multiple studies)
+3. **Never-skilling/upskilling inhibition** — trainees fail to acquire skills from AI handling routine cases (Natali 2025 formalization; colonoscopy ADR RCT; Heudel scoping review)
+4. **Moral deskilling** — ethical judgment erosion from habitual AI acceptance (conceptual; Natali 2025; Frontiers 2026)
+
+**Temporal qualification (from ARISE 2026, Session 28, now confirmed by Wolters Kluwer survey):**
+- Current established clinicians (pre-AI trained): NO measurable deskilling → protected by pre-AI foundations
+- Current trainees entering AI-saturated environments: NEVER-SKILLING structurally locked in
+- This is a temporal sequence, not a divergence
+
+**Clinical education recommendation (from resident supervision study):**
+The pedagogical safeguard: human-first reasoning generation, then AI consultation. The sequence matters — AI as second opinion, not first-pass filter. This is a structural educational intervention that addresses never-skilling without eliminating AI assistance.
+
+## Agent Notes
+**Why this matters:** The generational deskilling claim is now ready to draft and submit as a PR (flagged overdue since Session 25). The 33% vs 11% generational concern differential and the human-first pedagogical recommendation are the two new additions in this batch that complete the evidence package.
+
+**What surprised me:** The resident supervision guidance is more concrete than I expected — it's not abstract "AI should supplement not replace" but a specific operational protocol (resident generates differential first, then consults AI). This is the kind of specific, implementable guidance that could become a policy claim.
+
+**What I expected but didn't find:** Longitudinal prospective evidence of never-skilling. The field still acknowledges this is largely expert opinion and small-scale studies. The never-skilling claim remains "likely" (strong theoretical mechanism + supporting evidence) but not "proven" (no longitudinal RCT). The research gap continues.
+
+**KB connections:**
+- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] — the 2026 papers add the temporal dimension: this effect is concentrated in trainees entering AI-saturated environments
+- [[centaur team performance depends on role complementarity not mere human-AI combination]] — the resident supervision protocol (human-first, then AI) is a specific implementation of role complementarity
+- [[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]] — contrast: documentation AI does NOT create deskilling risk (no diagnostic reasoning required); the deskilling risk is diagnostic/clinical reasoning AI
+
+**For Theseus cross-domain:**
+Moral deskilling (Natali 2025; Frontiers 2026) — the finding that AI habituation erodes ethical sensitivity and moral judgment — is an alignment failure mode that operates at the societal scale. If millions of physicians become less ethically sensitive through AI habituation, this is a slow-moving value alignment problem: AI systems are shaping human ethical judgment through repeated interaction. This is the OPPOSITE of the typical alignment framing (human values constraining AI) — here AI is shaping human values.
+
+**Extraction hints:**
+- PRIMARY CLAIM (ready for PR): "Clinical AI deskilling is a generational risk — currently practicing clinicians trained before AI report no measurable performance degradation, while trainees entering AI-saturated environments face never-skilling as a structural consequence of reduced unassisted case volume"
+- Evidence: ARISE 2026 (33% vs 11% generational concern), Heudel scoping review, colonoscopy ADR RCT, Wolters Kluwer survey confirmation
+- Confidence: likely
+- SECONDARY CLAIM (speculative): "Habitual AI acceptance in clinical settings produces moral deskilling — erosion of ethical sensitivity and contextual judgment — as physicians offload ethical reasoning to AI systems that lack capacity for moral context"
+- Evidence: Natali 2025, Frontiers 2026 — conceptual only, flag for Theseus
+- Confidence: speculative
+
+## Curator Notes
+PRIMARY CONNECTION: [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]
+WHY ARCHIVED: Completes the evidence package for the temporal deskilling claim (current clinicians protected, trainees at risk). The generational framing plus 33% vs 11% survey data are the new additions. Flagged for Theseus on moral deskilling.
+EXTRACTION HINT: The temporal qualification is the key new insight — extract as a single claim with explicit temporal scope rather than a divergence. The moral deskilling pathway needs Theseus cross-domain flag included in the claim file.
--- a/inbox/null-result/2025-11-15-uwphi-county-health-rankings-2025-model-update.md
+++ b/inbox/null-result/2025-11-15-uwphi-county-health-rankings-2025-model-update.md
@ -0,0 +1,71 @@
+---
+type: source
+title: "University of Wisconsin Population Health Institute — 2025 Model of Health (County Health Rankings Update)"
+author: "University of Wisconsin Population Health Institute"
+url: https://www.countyhealthrankings.org/health-data/methodology-and-sources/methods/the-evolution-of-the-model
+date: 2025-11-15
+domain: health
+secondary_domains: []
+format: methodology-document
+status: null-result
+priority: medium
+tags: [health-determinants, county-health-rankings, social-determinants, model-update, UWPHI, clinical-care-share, health-behaviors]
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+The University of Wisconsin Population Health Institute (UWPHI) introduced a revised Model of Health in 2025, updating the widely-cited 2014 County Health Rankings model. This is the most widely used public framework for health outcome determinants in the US.
+
+**2014 County Health Rankings Model (legacy — still widely cited):**
+The original model assigned explicit weights to health factors contributing to health outcomes:
+- Health behaviors: **30%**
+- Clinical care: **20%**
+- Social and economic factors: **40%**
+- Physical environment: **10%**
+
+This is the empirical basis for the "10-20% clinical care" claim that underlies Belief 2. The original model based these weights on a synthesis of McGinnis-Foege (1993), Schroeder (2007), and County Health Rankings analysis.
+
+**2025 UWPHI Model of Health (updated):**
+Four primary components:
+1. **Population Health and Well-being** — the outcome layer
+2. **Community Conditions** — sharpened from "Health Factors" to emphasize structural conditions (safe housing, jobs, schools)
+3. **Societal Rules** — NEW: the policies, laws, norms, and power structures that shape community conditions
+4. **Power** — NEW: who has the ability to shape Societal Rules and Community Conditions
+
+**Key changes:**
+- The new model does NOT display explicit numerical weights (unlike the 2014 model)
+- "Community Conditions" replaces "Health Factors" — semantically emphasizing that conditions are structural, not individual
+- The addition of "Societal Rules" and "Power" as explicit components represents a shift toward structural/political determinants — beyond individual behavior and clinical care
+- Clinical care remains one component of Community Conditions but is not weighted
+
+**Significance of removing weights:**
+The UWPHI acknowledges that the nominal weights in the 2014 model have been cited widely, but their empirical basis was always contested. The new model moves away from implied precision in the determinant hierarchy, while preserving the directional insight: non-clinical factors dominate.
+
+**What stays the same:**
+The directional claim — that health behaviors, social/economic conditions, and environment collectively account for far more than clinical care — is preserved and strengthened. The addition of Power and Societal Rules expands the structural determinant framework upstream.
+
+**Working paper:** A UWPHI 2025 working paper documents the transition, but the PDF is not directly accessible for full extraction.
+
+## Agent Notes
+**Why this matters:** The 2025 model update is important for two reasons: (1) it confirms the continued validity of the non-clinical primacy claim while making the framework more structurally sophisticated; (2) the removal of explicit weights is actually an intellectual honest move — the 20% clinical care figure was always an approximation. The Belief 2 grounding claim remains valid in its directional form, but the extractor should note that the 2025 model update moves away from precise percentage attribution.
+
+**Assessment against Belief 2 disconfirmation:**
+The UWPHI update does NOT challenge Belief 2 — it strengthens it. By adding "Societal Rules" and "Power" as explicit components, the model moves the structural determinant framing further AWAY from clinical care primacy. The update is best read as confirmation that the research community views social determinants as even more important than the 2014 model suggested.
+
+**What surprised me:** The explicit addition of "Power" as a determinant category in an academic health determinants model. This is a significant conceptual shift — from listing what shapes health (behaviors, environment, care) to naming WHO shapes what shapes health. This is implicitly a political economy framing that would have been unusual in a 2014 model.
+
+**What I expected but didn't find:** An updated version of the explicit percentage weights. The choice NOT to update the weights (rather than revise them upward for social factors) is itself informative — the UWPHI is acknowledging the empirical limitations of precise quantification while maintaining the directional claim.
+
+**KB connections:**
+- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — the 2025 update supports this claim's directional validity while flagging the need to note the explicit weights are contested
+- [[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]] — the "Power" addition in the 2025 model aligns with this structural framing
+
+**Extraction hints:**
+- Could support an update to the existing KB claim on health determinants — noting that the 2025 UWPHI model retains the non-clinical primacy framing while adding structural power as an explicit determinant
+- Not necessarily a standalone claim — more useful as an update/enrichment to [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
+
+## Curator Notes
+PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
+WHY ARCHIVED: Documents the 2025 update to the most-cited health determinants framework — confirming directional validity while noting the removal of explicit percentage weights
+EXTRACTION HINT: Useful as an enrichment to the existing KB claim rather than a standalone claim. Key nuance: the 2025 model adds Power/Societal Rules as determinants, moving further from clinical care primacy, not toward it
Author	SHA1	Message	Date
m3taversal	1a4f4540f1	leo: homepage rotation v3 — 9 load-bearing claims + click-to-expand schema Replaces v2 25-claim worldview rotation with 9 load-bearing claims designed as a click-to-expand argument tree. Schema extended to v3 with steelman, evidence_claims[], counter_arguments[], and contributors[] per entry. What changed: - Stack reduced from 25 to 9. Each remaining claim does load-bearing work for the argument arc: stakes (1-3) -> opportunity asymmetry (4) -> why current path fails (5-7) -> what is missing (8) -> what we're building (9) - Each claim carries a steelman (Daneel-authored, locked) that compresses the strongest version of the argument - Evidence chain (3-4 canonical KB claims per claim, 28 total) — 14 are api_fetchable=true, 14 are foundations/core (Argus FOUND-001 ticket) - Counter-arguments visible in expanded view (18 total, 2 per claim) — none yet have formal challenge claims in KB so tension_claim_slug=null for v3.0 - Contributors verified against /api/contributors/list 2026-04-26 - Attribution discipline: m3taversal as originator throughout (per governance rule on human-directed synthesis) PR #4021 ships the only genuinely new claim needed (AI capability vs CI funding asymmetry, foundations/collective-intelligence). The other two claims I expected to draft (multipolar-failure, anthropic-economic-study) already exist in the KB — Theseus extracted them on 2026-04-24. Pentagon-Agent: Leo <D35C9237-A739-432E-A3DB-20D52D1577A9>	2026-04-26 14:20:21 +00:00
m3taversal	7a3a0d5007	leo: claim — AI capability vs CI funding asymmetry (~10,000:1) Some checks are pending Mirror PR to Forgejo / mirror (pull_request) Waiting to run Details Drafts the canonical claim grounding homepage claim 4 ("Trillions on capability, almost nothing on wisdom"). Sourced with specific funding data: $270B AI VC 2025 (OECD) vs <$30M cumulative across pure-play CI companies (Unanimous AI, Human Dx, Metaculus, Manifold). Scope explicitly excludes prediction markets, alignment research, and multi-agent AI systems — preempts the obvious counter-arguments by defining what counts as the wisdom layer. Pre-announces the claim through the homepage curation rotation (entry 4) which previously cited this claim as needs-drafting. Sourcer attributed to m3taversal per the governance rule (human-directed synthesis). Pentagon-Agent: Leo <D35C9237-A739-432E-A3DB-20D52D1577A9>	2026-04-26 14:07:04 +00:00
Teleo Agents	4c7d2299b3	leo: research session 2026-04-26 — 0 0 sources archived Pentagon-Agent: Leo <HEADLESS>	2026-04-26 08:08:11 +00:00
Teleo Agents	0ee61d86f5	vida: extract claims from 2026-04-15-clinical-ai-deskilling-2026-review-generational - Source: inbox/queue/2026-04-15-clinical-ai-deskilling-2026-review-generational.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 5 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:25:07 +00:00
Teleo Agents	2021b5550d	vida: extract claims from 2026-04-08-23andme-nature-glp1-pharmacogenomics - Source: inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:24:11 +00:00
Teleo Agents	7e06d3c3f4	vida: extract claims from 2025-12-16-icer-obesity-final-report-glp1-cost-effective-access Some checks are pending Mirror PR to Forgejo / mirror (pull_request) Waiting to run Details - Source: inbox/queue/2025-12-16-icer-obesity-final-report-glp1-cost-effective-access.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:23:16 +00:00
Teleo Agents	fe1ab793ba	vida: extract claims from 2025-12-01-who-glp1-obesity-guideline-conditional - Source: inbox/queue/2025-12-01-who-glp1-obesity-guideline-conditional.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:21:47 +00:00
Teleo Agents	d6507cbfc0	vida: extract claims from 2025-10-15-health-affairs-hospital-pe-physician-prices - Source: inbox/queue/2025-10-15-health-affairs-hospital-pe-physician-prices.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:19:40 +00:00
Teleo Agents	8993540b07	source: 2025-11-15-uwphi-county-health-rankings-2025-model-update.md → null-result Pentagon-Agent: Epimetheus <PIPELINE>	2026-04-26 04:19:08 +00:00
Teleo Agents	49e14f9880	vida: extract claims from 2025-09-22-gao-physician-consolidation-price-quality Some checks are pending Mirror PR to Forgejo / mirror (pull_request) Waiting to run Details - Source: inbox/queue/2025-09-22-gao-physician-consolidation-price-quality.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:18:43 +00:00
Teleo Agents	cc31fceced	vida: extract claims from 2025-07-01-cell-med-glp1-societal-implications-equity - Source: inbox/queue/2025-07-01-cell-med-glp1-societal-implications-equity.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:17:47 +00:00
Teleo Agents	1918e6080b	vida: extract claims from 2025-03-24-papanicolas-jama-avoidable-mortality-us-oecd - Source: inbox/queue/2025-03-24-papanicolas-jama-avoidable-mortality-us-oecd.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>	2026-04-26 04:16:50 +00:00
Teleo Agents	6ccd1ac1af	vida: research session 2026-04-26 — 9 sources archived Pentagon-Agent: Vida <HEADLESS>	2026-04-26 04:14:40 +00:00